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 ABSTRACT 
Mechanisms of tissue compartmentalization in human T cells 
Michelle Miron 
 
 Mechanisms for human memory T cell differentiation and maintenance have 
predominantly been inferred from studies of peripheral blood, though the majority of T cells 
reside in lymphoid and non-lymphoid sites. Studies in mice have shown that memory T cells in 
non-lymphoid sites provide superior protection to pathogens compared to those in blood, 
defining a subset known as tissue-resident memory T cells (TRM), with emerging roles in 
lymphoid sites. There are many key unknown aspects of TRM biology in human tissues 
including if TRM have superior functional abilities, the mechanisms for maintenance of TRM in 
lymphoid and non-lymphoid sites, and the relatedness of tissue and blood localized T cell 
subsets. 
Through a collaboration with the local organ procurement agency, we obtained samples 
from >15 tissue sites from healthy organ donors of all ages. We analyzed CD8+ T cells in diverse 
sites and found the majority of TRM cells in lymph nodes (LNs) display an increased 
proliferative capacity, increased expression of TCF-1, and decreased turnover compared to TRM 
and effector memory (TEM) cells in other sites including blood, bone marrow (BM), spleen and 
lung. Further, we identified that exposure to type 1 interferons results in increased 
downregulation of TCF-1 expression during cell divisions driven by T cell receptor (TCR) 
stimulation. We investigated the relatedness of CD4+ and CD8+ T cell subsets, including central 
memory (TCM), effector memory (TEM), TRM, and terminal effectors (TEMRA) by sequencing 
TCR rearrangements. From diversity analysis of TCR repertoires we found that effector and 
memory subsets are maintained in a hierarchy from most to least diverse (TCM > TEM and 
 TRM > TEMRA) that is largely conserved across tissues and CD4+ and CD8+ T cell lineages. 
Overlap analysis revealed the low and high relatedness of TCM and TEMRA cells respectively 
and this was highly conserved across tissues; in contrast, we found the relatedness of TEM and 
TRM was more dynamic across tissues. Together, these findings have implications for immune 
monitoring and modulation, highlighting that lymph nodes may function as reservoirs for long-
lived memory T cells with high functional capacity; additionally, we identify cell extrinsic 
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CHAPTER 1: Introduction 
 
Adapted and expanded significantly from: Miron M., Thome J.J.C., Gordon C.L., Farber D.L. 
(2017) Study of T Cell Immunosenescence in Various Tissue Compartments, Springer, and 
Szabo, P.A., Miron M., Farber D.L. Staying put: Tissue resident memory T cells in mice and 
human. Under review at Science Immunology. 
 
Section 1.1 Overview of human T cell responses 
 T cells are crucial responders in the immune system that coordinate adaptive immunity. 
Key functions that T cells perform include protection from pathogens, prevention of 
autoimmunity, attack of cancer cells, and helping generate antibody responses. T cell responses 
can also function in undesirable ways and can be major drivers of autoimmune and inflammatory 
diseases. In order to perform these diverse functions, there are different subsets of T cells which 
each carry out specific roles in an immune response.  
T cells develop in the thymus, from precursor cells that migrate from the bone marrow.  
During development in the thymus, T cells acquire the ability to distinguish self from non-self 
molecules known as antigens. After development, naive T cells collectively have the ability to 
respond to millions of specific pathogens. These naïve T cells exit the thymus and seed lymphoid 
sites such as lymph nodes and spleen, where they recognize pathogen derived antigens. Upon 
recognition of antigen, naive T cells become activated and expand into pools of effector T cells 
[1, 2]. Effector cells disseminate to tissue sites of inflammation where they perform their diverse 
effector functions. Once the pathogen is cleared, most of the responding T cells die by apoptosis. 
A small portion of the initially activated pool of T cells differentiate into memory T cells that are 
maintained in the original sites of pathogen invasion, poised to respond where the pathogen may 
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likely re-appear. Upon antigen encounter, memory T cells produce a stronger response in situ 
resulting in more rapid clearance of the pathogen compared to primary responses. Additionally, 
smaller portions of memory T cells are maintained in lymphoid sites, with the ability to rapidly 
proliferate and disseminate if the pathogen re-appears. Memory T cells are long lived and can 
provide protection for years and up to decades. These important features of immunological 
memory make T cells a major target of vaccines and other immunotherapies.   
Most of our current understanding regarding the development, differentiation, 
maintenance and function of T cells stems from in vivo studies of T cell responses to pathogens 
such as viruses and bacteria in mouse models. The phases of T cell development and response to 
an acute viral infection are graphically summarized in Figure 1-1. Mouse models are a powerful 
tool in elucidating T cell function and have been essential in understanding the molecular 
underpinnings of a T cell response, which has led to development of several effective 
immunotherapies for human disease including design of vaccines and immunotherapies for 
autoimmunity and cancer [3]. The use of mouse models confines the study of T cell response to a 
single pathogen or in a specific disease model, whereas humans are constantly exposed to a 
myriad of pathogens, chronic viruses, and cancer yet remain protected lifelong. It’s therefore 
important to also study human immune system in order to translate findings in mouse models for 
their relevance in human health and disease. 
Immunological memory was originally found to be maintained within the blood, both in 
serum through long-lived antibody responses and circulating memory T cells.  More recent 
investigations have revealed the importance of tissue localized maintenance of immunological 
memory, especially T cell memory. Blood is the major source of material for human immune cell 
studies, but contains only 2-3% of the total T cell complement, with the majority in lymphoid 
sites (~76%), followed by skin and mucosal sites such as the lung and gut (~20%).[4, 5] The 
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total number of T cells in the human body is approximately 330x109 cells. Estimates of the 
percentage of total T cells in different human organs is shown in Figure 1-2. How human T cells 
in tissue sites function and persist relative to subsets in blood is not well understood. Defining 
the nature of tissue localized T cell responses is important for monitoring and modulating 
immune responses. Investigating tissue T cell populations in humans typically involves obtaining 
tissue samples from either biopsy, surgical resections of diseased organs, or deceased organ 
donors whose individual tissues are harvested for life-saving transplantation. Our lab has 
extensively characterized the use of previously healthy organ donor tissue for the study of 
immune cells [6-12], demonstrating that this type of tissue resource effectively reveals snapshots 
of tissue immunity throughout all stages of life. We have made many discoveries on the human 
immune system using this resource including on T cell compartmentalization with age [13], 
response to chronic viruses [10] and as well as characterizing other immune cells [11, 14, 15]. 
However, there are still many open questions about how T cells are compartmentalized in human 




Figure 1-1. Overview of T cell development and responses.  
(A) T cells precursors originate in the bone marrow (white) and migrate to the thymus (blue) 
where they develop into mature T cells called naïve T cells. Naïve T cells are exported from the 
thymus and seed lymphoid sites throughout the body including lymph nodes and spleen (blue). 
(B) Relative sizes and location of a T cell response to a viral infection and their respective 
kinetics. T cell population size is defined by number of total T cells over time. The peak of T cell 
expansion occurs after the peak of viral load (red), followed by contraction of the majority of T 
cells by cell death upon clearance of the pathogen. Most T cells die after resolution of 
inflammation; however, a portion of the initial responding T cells are maintained long-term as 
memory T cells. Localization of T cell populations during these phases are indicated by color, 
starting off in lymphoid tissues during activation and expansion (blue), and migration to diverse 
peripheral sites (purple) of inflammation, where effector function and maintenance of memory T 
cells occurs, with smaller portion maintained as memory in lymphoid sites. (C) The magnitude of 
a T cell response to secondary exposure (recall response) is larger and occurs more rapidly than 
the primary response. Additionally, while a primary response usually results in dispersion of 
effector cells throughout the body (purple), the recall response occurs more rapidly and with a 
greater magnitude than the primary response, due to tissue localized responding memory T cells 























Figure 1-2. Estimated percentage of the total number of T cells in different human organs. 
(A) The total number of T cells in the human body is approximately 330x109 cells. A pie chart of 
the estimated percentages of the total T cells in individual organs. It is estimated that the 
majority of T cells (76.4%) are in lymphoid tissues (lymph nodes, spleen, bone marrow, thymus, 
and Peyer's patches), followed by barrier sites (skin, lung and gut, totaling 21.3%), and the 










Section 1.2 Development of Human T cells 
Overview of T cell development 
 The primary sites for T cell development are the bone marrow and thymus; T cell 
precursors originate in the bone marrow and migrate to the thymus where mature T cells develop 
[16]. Two key processes occur in thymic development endowing T cell specificity and self-
tolerance. First, rearrangement of T cell receptor (TCR) gene segments occurs to encode a 
mature αβ TCR, with each T cell expressing a unique TCR; in humans this can comprise an 
estimated theoretical diversity of ~5x1011 distinct sequences [17] conferring different 
specificities [18, 19]. The second key process is for endowment of self-tolerance, in which T 
cells with strongly self-reactive TCRs are deleted by cell death, and only those T cells with TCR 
of optimal avidities to self-antigen emerge into the periphery as mature T cells [18]. The 
production of new T cells from the thymus is highest at birth and during infancy, and there is an 
established reduction in thymic function and volume beginning in puberty [20]. Upon generation 
of a sizable T cell repertoire early in life, this repertoire is maintained long term, mediates 
responses to new pathogens and provides life-long immunity [21]. 
 
Role of the thymus in T cell generation 
The thymus is a unique organ in the body both in its exclusive role in generation and 
selection of new T cells, and its distinct developmental program for functional and structural 
degradation relatively early in life. The importance of the thymus in generation of immunity was 
first discovered in mouse models by surgical removal of the thymus (thymectomy) resulting in 
severe immune defects[22, 23]. Further, mice with genetic defects in the FOXN1 gene are not 
able to form a thymus due to defective development of the thymic epithelium[24]. This mutation 
also leads to abnormal hair growth (hairlessness) and therefore mice with this mutation are 
9 
 
referred to as nude mice[25]. Homozygous nude mice lack T cells and suffer from a lack of cell-
mediated immunity. A rare case of the nude phenotype was also found in humans, mapped to the 
same gene and resulting in hairlessness and a complete lack of T cells leading to severe 
immunodeficiency[26]. In humans, a different genetic defect can lead the lack of a thymus and a 
rare syndrome known as DiGeorge syndrome. Individuals with DiGeorge syndrome can produce 
B cells but have a severe defect in the ability to form T cells. The genetic underpinning of 
DiGeorge syndrome has been mapped to a large deletion on chromosome 22 and leads to many 
complications and symptoms including congenital heart disease and immune deficiency[27]. 
Collectively these studies have shown the requirement of the thymus specifically for the 
production of T cells in mouse and human, and the importance of T cell development for cell-
based immune responses. 
   A significant difference between T cell development in mice and humans is that in mice 
the thymus continues to develop for 3-4 weeks after birth, whereas in humans, the thymus is 
already fully developed at birth. As a result, mice are born lymphopenic, while humans are born 
with a full complement of T cells.  Evidence for the timing of T cell development in humans 
derives from follow-up studies on infants thymectomized as a consequence of heart surgery to 
repair congenital abnormalities. Anatomically, the thymus is situated in front of the heart. In 
humans, neonatal thymectomy is performed during surgeries for congenital cardiac 
malformations in order to have optimal exposure of the surgical area. Longitudinal studies of 
patients thymectomized as neonates, show that patients can still develop naive T cells and do not 
experience more infections than healthy control children [28, 29]. However, long-term follow-up 
studies on adults who underwent thymectomy as neonates and were then in their 20s-30s did 
have significant decreases in T cell numbers and displayed increased declines in naïve T cell 
frequencies with age compared to control individuals [30, 31]. These studies show that while the 
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majority of T cells are produced early in life, new T cells can continue to be produced in the 
thymus during infancy and childhood [21]. Numerous studies have documented decreases in 
thymic function beginning in puberty and continuing into adulthood, with some changes seen 
immediately after birth [32]. It remains unknown whether later in life these individuals will be 
more prone to infections or cancer that are more common in the elderly due to already decreased 
immune function. In conclusion, the critical steps in T cell development occur before birth in 
humans. Additionally, once a T cell repertoire has been generated, this repertoire can be 
maintained for years in order to provide protection to new encounters throughout life. 
T cell development in the thymus is a highly regulated process that involves interaction 
with MHC complexes and specialized epithelial cells within the thymus. Two different subsets of 
thymocytes are generated in the thymus: CD4+ and CD8+ T cells. T cell precursors that migrate 
from the bone marrow and develop into thymocytes are initially double negative (DN) for the co-
receptors CD4 and CD8. The DN precursors give rise to two T cell lineages: the minority 
population of γδ T cells which lack CD4 or CD8 when mature, and the majority population of αβ 
T cells. The development of αβ T cells is the focus of this work. Following rearrangement of the 
TCR chains, the prospective αβ T cell populations proceed to into CD4+CD8+ double positive 
(DP) thymocytes. Most DP thymocytes die within the thymus, after becoming DP cells, but those 
cells whose receptors can interact with self-peptide:self-MHC molecular complexes lose 
expression of either CD4 or CD8 and increase the level of expression of the T-cell receptor, a 
process called positive selection[33]. Positive selection occurs through interaction with thymic 
epithelial cells. The opposite process called negative selection occurs through interaction with 
thymic antigen presenting cells (APCs) to elimiate T cells with too strong of self-reactivity by 
the TCR[34].  
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The cells that successfully pass both positive and negative selection events differentiate 
into single positive (SP) CD4+ or CD8+ naïve T cells through silencing transcription of one co-
receptor locus. Lastly, mature SP T cells are exported from the thymus to peripheral lymphoid 
sites. Naïve T cells emerging from the thymus in humans express CD45RA, an isoform of CD45, 
and the lymph node homing receptor CCR7 [35]. This stepwise process of T cell development in 
the thymus is highly regulated and occurs within distinct micro-anatomical niches within the 
thymus, containing different stromal cell types essential for T cell education and formation [16]. 
CD4 and CD8 are important cell-surface molecules for identifying thymocyte subpopulations 
with distinct properties and functional abilities. 
  
Formation of the T cell receptor  
 T cells sense the presence of antigens in their environment through cell surface T cell 
antigen receptor (TCR). Individual T cells express many copies of the same T cell receptor on 
the cell surface. Each developing T cell expresses a unique version of the TCR, that allows T 
cells to collectively have the ability to respond to millions of different antigens. If the human 
genome contained a unique gene to encode for every possible T cell receptor, this would add 
more genes than currently exist in the genome. Instead, the immune system has evolved a 
mechanism for generating highly variable proteins from a limited number of genes involving 
rearrangement of and joining of gene segments. The gene segments rearrange by somatic gene 
rearrangement to create variable regions of coding sequences. Gene rearrangements occur before 
the DP positive stage in T cell development as described above. These gene rearrangements 
allow the generation of an estimated theoretical diversity of 1020  different T cell receptors[36], 
each expressed by a single T cell. The mechanisms of gene rearrangements are common also to 
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B cells which produce antibodies. The generation of diverse T cell receptors is important for T 
cell ability to recognize diverse antigens and modulate their functions in protection.  
 The TCR is a transmembrane receptor that is made up of two protein chains: a and b. 
There are also other types of T cells that develop in the thymus, including γδ T cells; the focus of 
this work is on majority T cells with αβ TCRs.  Each protein chain consists of two regions; a 
variable (V) region which binds to antigen, as well as an invariant constant region (C) which 
functions downstream of antigen recognition for intracellular signaling and subsequent effector 
responses[37]. The V-region is the region that undergoes gene rearrangement which accounts for 
generation of unique sequences to code for unique T cell receptor proteins. The variable region is 
coded by the following gene segments: variable (V), diversity (D), and junction (J) which 
generate a functional VDJ-b chain which is why this gene rearrangement is called VDJ-
recombination. After rearrangement, a novel region in between the V and J gene segments is 
generated called the CDR3b which is the most variable region of the T cell receptor, due to both 
junctional diversity (from combination of different V, D and J gene possibilities) as well as 
mutational diversity which arises due to errors prone to the gene rearrangement process of 
repaired breaks in the DNA. The V-region exon is spliced in order to join to the C region. The 
resulting mRNA is then translated to yield the b-chain of the T cell receptor. The a chain results 
from rearrangement of a different set of V and J gene segments. Once a productive b chain gene 
rearrangement has occurred, the a and b chains pair soon after they are synthesized to form the 
a:b TCR heterodimer that is expressed on the T cell surface [38]. Expression of a functional a:b 
TCR suppresses rearrangement of the second TCR allele through a process called allelic 
exclusion. The layout of the different gene segments within the V region is depicted in Figure 
1-3, showing the germline encoded gene segments before and after somatic rearrangement as 
well as how splicing and translation form the T cell receptor. 
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 The a:b TCR alone is not sufficient to form a complete cell-surface antigen receptor. The 
TCR associates with invariant chains that carry out the signaling functions of the receptor to 
form a complete TCR complex[39-41]. The TCR complex consists of the a:b TCR heterodimer, 
four CD3 protein chains (CD3γ, CD3δ, and two CD3ε chains), and the ζ-chain. The TCR 





Figure 1-3. Gene rearrangements forming the TCR  
(A) The germline encoded locus for the human b-chain of the TCR before and after VDJ 
recombination and splicing. The locus coding for the b-chain of the TCR (TCR-b) located on 
chromosome 7 is comprised of 52 functional variable (V) gene segments distantly located from 
two segments each containing a diversity (D) gene and 6-7 joining (J) gene segments and single 
constant (C) gene. The TCR a-chain locus is not shown and has different numbers of gene 
segments with lower combinatorial diversity. After rearrangement, a novel region in between the 
V and J gene segments is generated called the CDR3 which is the most variable region of the T 
cell receptor, due to both combinatorial diversity (from combination of different V, D and J gene 
possibilities) as well as mutational diversity which arises due to errors prone to the gene 
rearrangement process of repaired breaks in the DNA. (B) The rearranged DNA is then 
transcribed, spliced and translated to form the b-chain of the TCR that binds most closely with 
antigen as shown in the diagram. Coloring of the b-chain corresponds to the rearranged locus 
that codes for that protein. Other parts of the TCR bind more with relatively conserved regions of 
MHC. The TCR a-chain (shown in dark grey), also important for binding antigen-MHC 
complexes, overall has lower diversity than the b-chains generated and structural data suggest it 












Part A of this figure is adapted from Janeway’s Immunobiology 8th Edition by Kenneth M. 
Murphy [38] 
The mechanisms that coordinate VDJ-recombination include recombination signal 
sequences (RSSs) that flank the gene segments and are recognized by recombinase enzymes such 
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as RAG-1 and RAG-2. The roles of enzymes involved in the process of VDJ recombination have 
been elucidated through naturally occurring and induced mutations in mice. For instance, lack of 
RAG-1 and RAG-2 leads to faulty development of functional lymphocyte populations[42, 43]. 
Mutations in these proteins lead to severe immune deficiencies, part of a broader category of 
illnesses of the immune system known as severe combined immune deficiency (SCID), due to 
combine B and T cell defects [42].  The immune compromised state results from an inability to 
complete VDJ recombination; this further illustrates the absolute importance of these receptors in 
function of lymphocyte cell responses. 
TCR gene rearrangement is central to the development of full naive T cell repertoire, 
conferring specificity to diverse antigens. Studies of human umbilical cord blood (UCB) show 
that Ag-specific T-cell precursors to common viruses and immunogenic antigens exist in the 
naive repertoire across a range between 1 and 352 cells per 100,000 CD8+ cells [44]. However, 
UCB is not necessarily representative of newborn T cell complement in terms of phenotype  and 
transcriptional profile[45]. Therefore more studies are required to fully understand repertoires of 
T cells at birth by studying other tissues present and functioning after birth such as lymph nodes 
and thymus.  
 
Age associated changes with T cell development 
New T cells eventually cease to form with age. This is due to age-associated changes in 
the thymus which includes reduction of thymic volume, loss of thymic epithelial cells, increase 
in the perivascular space and predominance of adipose tissue [46]; however, the quantitative 
contribution of these changes to thymopoiesis has not been clear.  A recent study of thymus 
tissue from surgical explants and organ donor tissues from infancy through 73 years of age found 
active thymus tissue from H&E staining at all ages, but large increases in adipose tissue and 
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fewer Hassel’s corpuscles (a structural hallmark of the human thymus) in adult compared to 
infant thymus tissues [9]. Analysis of thymocyte populations in that study revealed that DP 
CD4+CD8+ thymocytes comprised 60-80% of total thymocytes (similar to DP frequencies in 
active human and mouse thymi) up until the fifth decade of life, after which the DP frequency 
was reduced to 5-15% thymocytes [13]. These findings show that active thymopoiesis does not 
exhibit a gradual decline but may cease abruptly at some discrete point in time after 40yrs of age. 
The cessation of development of new T cells, yet maintained ability to respond to new infections 
throughout life, is a testament for how long-lived T cell populations are, maintaining the ability 
to respond to new infections from T cell populations developed earlier in life. 
 
Section 1.3 T cell activation and differentiation 
T cell activation  
T cell activation and differentiation occur in secondary lymphoid organs such as lymph 
nodes where naive T cells and APCs meet. This meeting occurs because the lymphatic system 
drains the fluid that leaks from our blood vessels and builds up in tissues, carrying that fluid to 
lymph nodes throughout the body. Traveling in lymph fluid are APCs that have picked up 
foreign material or antigens from distant tissues, storing that information to be delivered later to 
T cells. Upon arrival in lymph nodes, APCs deliver this information by direct contact with naive 
T cells, initiating the adaptive immune response. It is estimated that an adult human has over 500 
lymph nodes throughout the body.[4] Additionally, other lymphoid organs can function as sites 
for T cell activation including bone marrow and spleen. [47, 48] 
 Naive T cells are first activated via contact with dendritic cells (DCs), a special class of 
APCs[49]. There are two important signals that DCs transfer to T cells; one signal is transferred 
to the TCR complex in the form of antigen complexed with MHC proteins (peptide-MHC 
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complexes), and the second signal is costimulation which is mediated through CD28 expression 
on T cells. Costimulation signal is important for naive T cell responses, and specifically binds to 
B7 receptor family members, for instance CD80 and CD86, on DCs. In naive T cells, CD28 
costimulation enhances cell cycle entry, and stimulates IL-2 important for T cell survival, as well 
as induction of differentiation programs leading to helper T cell and cytotoxic effector responses 
T cells. Signals received by TCR and CD28 converge by intracellular T cell signaling elements 
that lead to downstream changes in the nucleus altering transcription[50]. During activation, T 
cells transiently upregulate expression of surface expression of CD69[51], a marker of early T 
cell activation which promotes retention of T cells through S1PR1 [52, 53]. This activation 
event, called T cell priming, initiates the T cell differentiation program. 
 CD4+ T cells recognize antigen by presentation on MHC Class II complexes [54-58], 
expressed on specialized subsets of antigen presenting cells including but not limited to dendritic 
cells and macrophages [59]. These antigen presenting cells can take up exogenous antigens and 
present them, therefore providing a mechanism for T cells to respond to extracellular pathogens 
like certain bacteria in additional to intracellular pathogens, like viruses. CD8+ T cells recognize 
antigen by presentation on MHC class I complexes which are expressed on all nucleated cells in 
the body. 
 Priming leads to cellular changes including entry into the cell cycle resulting in 
proliferation and differentiation into diverse types of effector cell populations which carry out 
pathogen clearance. Effector cells also gain expression of homing molecules such as CXCR3 and 
CCR5 that allow exit from priming sites and entry to sites of inflammation by trafficking through 
the blood. Additionally, in order to exit from lymphoid tissues, effector T cells downregulate 
chemokine receptor CCR7 and selectin molecule CD62L. Alternatively, for T cells that act to 
help antibody responses, expression of CXCR5 allows homing to B cell follicles[60, 61].  (For 
19 
 
review of integrins, chemokine receptors and their respective ligands important for T cell 
migration see here [62]).  
  
CD4+ T cell function and differentiation 
When activated, naive CD4+ T cells differentiate into several diverse subsets known as T 
helper (Th) cells including Th1, Th2, Th17, T follicular-helper (Tfh) and T regulatory (Treg) 
each with specific roles. Th1 cells produce INF- γ and are important for responses to intracellular 
pathogens and their effector responses include activating macrophages and inducing 
inflammation. Th2 cells produce IL-4, IL-5, IL-13 and respond to helminth infections. Tfh cells 
are specialized in helping B cell responses in germinal centers for production of antibodies. Th17 
cells produce IL-17A, IL-17F and IL22 and control extracellular pathogens. Th cells have been 
associated with specific diseases including autoimmunity for Th1 and Th17 cells[63, 64], and 
allergic responses for Th2 cells  [65-67]. Treg cells express IL-10 and prevent over-active 
immune responses and associated immunopathology[68-70]. There is also a subset of cytolytic T 
cells that produce granzyme B, perforin, and FASL to promote killing of cells. Additionally, 
there are emerging types of Th cells such as Th9 and Th22 cells [71, 72].    
 The intracellular signaling events induced by priming lead to\ changes in gene 
expression. These changes are induced by specific transcription factors that regulate the 
formation of distinct helper T cell subsets. Transcription factors act as “master regulators” that 
coordinate the expression of different transcriptional programs. Each CD4+ T cell subset has 
unique transcriptional regulator that is required for development: RORG for Th17 [73], FOXP3 
for Treg [74, 75], GATA3  for Th2 [76, 77], Bcl-6 for Tfh [78], T-bet for Th1 [79, 80], and 
Eomes for cytolytic T cells ( 
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Figure 1-4). While these transcription factors are important for lineage specification, in reality, 
the delineation of the subset may be more complicated with certain TFs have being important for 
multiple lineages [81, 82] as well as evidence of the possibility for plasticity within Th subsets 
depending on context of signals received by T cells for a recall response. [83, 84] 
 
CD8+ T cell function and differentiation 
Activated CD8+ T cells differentiate into CTLs that kill infected cells through granzymes 
and perforin and secrete cytokines such as IFN-γ and TNF-α. Upon activation, T cells rapidly 
proliferate into a large pool of cells which can then circulate though the body and home to the 
tissue where inflammation is occurring, and there perform killing of the targeted infected cells. 
Most of the effector cells die off after clearance of an infection and subsequently a small portion 
of those previously activated cells remain long lived and differentiate into memory T cells.  
When CD8+ T cells differentiate into effector cells, they gain the ability to kill targeted 
cells. Functionally, this is achieved by production of several enzymes, including perforin and 
granzyme[85, 86 ]. This occurs through cell killing of targeting cells by apoptosis. This takes 
place when CTLs recognize antigen presented by MHC class I on the surface of an infected cell. 
Subsequently, T cells release granules containing cytotoxic molecules like perforin, which 
creates holes in the membrane of the target cells, and granzymes, which are enzymes that can 
induce apoptosis in the target cell after diffusing through pores created by perforin[86].  
In order to regulate T cell responses, it is important for T cells to also be eliminated to 
decrease potential harmful effects of T cell responses including aberrant cell killing that can 
result in autoimmunity and tissue damage. Therefore, following proliferation and function of 
effector T cells, the majority of those cells die, with only 10-15% remaining as memory T cells. 
A major mechanism for cell death of T cells includes Fas pathways induced by TCR signaling 
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events[87]. Engagement of Fas (CD95) by Fas ligand (FasL) results in apoptotic cell death 
mediated by caspase activation. This pathway is important in regulating cell death within 
lymphoid compartment, and is also known as activation-induced cell death (AICD)[88, 89].   
 Transcription factors also play a key role in the differentiation of CD8+ T cells. Many of 
the same transcription factors important for CD4+ T cell differentiation are also important for 
CD8+ T cell differentiation. Transcription factors function to control the maintenance of naive T 
cells, and the generation of both effector T cells that provide shorter and longer term protection; 
also known as regulating formation of effector and memory T cell potential. Studies in mice have 
revealed the importance of Foxo transcription factors including Foxo1 in maintaining T cells in 
naive state. The expression of key factors in this process including CCR7 and L-selectin are 
regulated by Foxo1. Through conditional deletion of Foxo1, its importance in maintenance of 
naive T cell homeostasis was revealed through regulation of several genes critical for T cell 
trafficking and survival including transcription factor Klf2.[90] Further, deletion of Foxo1 led to 
severe defect in trafficking of naive T cells to lymph nodes upon cell transfer compared to 
wildtype cells as well as decreased expression of interleukin 7 receptor alpha chain. Together the 
maintenance of a naive T cell state seems to be regulated by Foxo1 by regulation of homing and 
survival signals. These studies also showed the importance of tissue localization in maintenance 
of T cell states. [90] 
 T-bet and Eomes, two T-box transcription factors, have crucial roles in formation and 
function of effector and memory T cells. They function with partially redundant roles to create 




Figure 1-4. T cell activation and differentiation. 
 (A) Naive T cell activation is initiated by recognition of MHC/antigen complexes by their TCR 
(blue) and costimulation by CD28, resulting in transient upregulation of CD69. The 
differentiation program initiated by recognition of antigen results in cellular changes including 
cell cycle entry and production of IL-2 leading to cell proliferation, differential expression of 
chemokine receptors and selectin molecules that mediate migration to sites of inflammation, and 
the gain of effector functions including production of cytokines and cell killing molecules. 
Effector cells that gain expression of CXCR5 are able to enter to B cell follicles in lymphoid 
sites. Effector cells that gain expression of CXCR3 and CCR5 and lose expression of CCR7 and 
CD62L are able to exit from lymphoid sites and enter peripheral tissues. During differentiation, 
into individual T cell subsets, T cells acquire effector functions. Naive CD4+ T cells differentiate 
into several diverse subsets known as T helper (Th) cells including Th1, Th2, Th17, T follicular-
helper (Tfh) and T regulatory (Treg) each with specific roles. The roles of helper T cells include: 
helping B cell and CD8+ T cell responses, performing cell killing, producing diverse types of 
effector cytokines, and regulating immune responses by preventing over-active responses.  Naive 
CD8+ T cells differentiate into cytotoxic T lymphocytes (CTLs) that kill infected cells. The fate 
determination of T cells is thought to be regulated by the quality of signals that a T cell receives 
during stimulation which can depend on the context, strength and duration of peptide-MHC 











expressed in activated CD8+ T cells. [93] T-bet and Eomes regulate cytotoxic and memory 
formation abilities of T cells in part by impacting interleukin 15 (IL-15) [94]. Additionally, these 
transcription factors can play non-redundant and additive roles in CD8+ T cell differentiation 
[95]. CD8+ T cells lacking T-bet and Eomes lose CTL identity and become IL-17 producing 
CD8+ T cells that cause a lethal inflammatory syndrome during LCMV infection.[96]  
Evidence suggests that the same transcription factors also regulate T cell responses in 
humans. A study of human virus-specific T cells showed that T-bet and Eomes were markers for 
T cell capacity and ability for durable immune control. This study tracked virus specific T cells 
in response to chronic infection with cytomegalovirus (CMV) in lung transplant recipients who 
are mismatched from CMV+ donors and therefore at a greater risk for active CMV infection and 
higher mortality. This study found that the transcription factor expression profile of CMV-
specific T cells was indicative of their in situ function in viral clearance. Specifically, 
transcription factor expression patterns of T-bet > Eomes differentiated lung transplant recipient 
controllers from viremic relapsers[97]. These findings were consistent with previous findings in 
mouse models that show Eomes expression was up-regulated in exhausted CD8+ T cells during 
chronic infection[98]. In summary, high levels of T-bet expression are correlated with better 
outcomes in an ongoing infection highlighting the importance of T-bet for CD8+ CTL effector 
functions. 
 In summary, T cell differentiation begins with the activation of naïve T cells in secondary 
lymphoid tissue, leading to T cell proliferation, differentiation to effector cells that acquire the 






Section 1.4 Maintenance and Formation of T cell memory  
Human memory T cell subsets  
 Following clearance of pathogen, T cells undergo contraction where the majority of 
pathogen specific T cells die by apoptosis, and typically a small percentage survive and mature 
to become memory T cells. Due to an accumulation of antigen exposures over life, in adult 
humans, most T cells in the body are memory T cells [6, 7]. Memory T cells have two main 
functions: one is to self-renew, and the second is to mediate protective immunity upon re-
exposure to pathogen. The ability to self-renew is mainly performed by central-memory (TCM) 
cells which also have the ability to create effector-memory (TEM) daughter cells, while the 
ability for immediate effector function is performed by TEM cells. Therefore, a TCM cell has 
been referred to as having “stem-like” properties, while TEM cells can be thought of as more 
differentiated [99].   
  The two most commonly used markers to distinguish human naive and memory T cells 
are CCR7 and CD45. CCR7 is a chemokine receptor that is required for entry into lymph nodes 
through high endothelial venules (HEV) [100-102]. Both naive and TCM cells express CCR7, 
indicative of their predominance in and migration patterns to lymphoid sites. TEM cells do not 
express CCR7 and are able to migrate to diverse peripheral tissue sites. [99] The lack of CCR7 
expression on TEM cells is important for exit from lymphoid tissue and entrance into peripheral 
tissues and sites of inflammation[103, 104]. CD45 is a tyrosine phosphatase that regulates 
signaling through antigen receptors. Naive T cells express the long isoform of CD45 known as 
CD45RA, while memory T cells express the shorter CD45RO isoform [105, 106]. These markers 
also can be used to identify terminal effector T cells in humans, specifically CCR7 negative cells 
can re-express the CD45RA isoform and this population of cells are known as TEMRA cells. 
More recently an additional subset of memory T cells has been identified as a prominent T cell 
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population in mice and man: those that remain resident in diverse tissues termed tissue resident 
memory (TRM) cells, that often express CD69. The differentiation state of TRM in humans is 
unknown, and a topic of active investigation which will be address in future chapters within this 
dissertation.  
  In addition to the major delineations of memory versus naive T cells including markers 
CCR7 and CD45RA, there are many other phenotypic differences between naive and memory T 
cells[107-109]. Memory T cells express higher levels of IL-2R β-chain (CD122) a component of 
both the IL-2 and IL-15 receptors both thought to be important for maintenance of memory T 
cells. [110] Many of the markers upregulated on memory cells are also upregulated on effector 
cells, and therefore it is not always easy to distinguish an actively responding T cell to antigen 
(effector cell) from a memory T cells. In human blood TEMRA cells bear more features of an 
actively responding T cell. They express higher levels of perforin and granzyme and lower levels 
of CD27 and CD28, and are thought to arise from chronic exposure to antigen, aligning with the 
fact that CMV seropositive individuals, a chronic virus, tend to have higher frequencies of 
TEMRA cells predominantly in the CD8+ T cell compartment [10, 111, 112]. 
 More recently, an additional subset of memory cells, called stem memory T cells 
(TSCM) were identified [113-115]. TSCM are phenotypically similar to naive T cells and 
express CCR7 and CD45RA however are still distinct from naïve T cells by their epigenetic 
marks indicating previous activation. To complicate matters in identification, they can be 
distinguished by other markers similar to memory T cells including CD95. TSCM cells have 
been found to be specific to both viral and self-tumor antigens. Additional markers expressed by 
TSCM similar to naive and TCM cells are higher levels CD27 and CD28. In contrast, they also 
express increased levels CXCR3 and LFA-1 both attributes of memory T cells. In humanized 
mouse models, these T cells displayed increased proliferative capacity, more efficient 
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reconstitution of immunodeficient hosts, and increased efficacy in anti-tumor responses. TSCM 
cells are a rare population of cells that can be detected within peripheral blood, and it remains 
unknown if they are present in other sites[116]. These subsets and their localization patterns as 




Figure 1-5. Tissue localization patterns and phenotypes human T cell subsets. 
(A) Distinct subsets of T cells can be identified by their surface expression for the following 
markers: Naïve T cells, CCR7+CD45RA-; Central memory (TCM), CCR7+CD45RA-; Effector 
Memory (TEM), CCR7-CD45RA-; Tissue resident memory (TRM), CCR7-CD45RA-CD69+, 
Stem cell-like memory (TSCM), CCR7+CD45RA+CD95+ and Terminally differentiated effector 
cells (TEMRA) CCR7-CD45RA+. Each subset has a unique tissue localization pattern, with 
Naïve and TCM cells found in lymphoid tissue in addition to circulation, TEM cells found 
predominantly in circulation as well as peripheral tissues, TEMRA cells in circulation and 













Functional capacity of human memory T cells 
  The most important difference between memory and naive T cells is the ability of 
memory phenotype cells to respond more rapidly and robustly to antigen stimulation, known as a 
recall response. How does this occur? First, memory T cells are more sensitive to antigen 
stimulation and are less dependent on CD28-mediated co-stimulation. This could explain why 
naive T cells require dendritic cell antigen presentation, while memory T cells respond well to 
antigen presented on other APCS such as resting B-cells.[109, 117-119] Additionally, once 
activated memory T cells respond differently and produce different cytokines, specifically more 
IFN-γ and TNF-α compared to naive T cells[120].  
 In order to study human T cells in bulk, they can be stimulated polyclonally as their 
antigen specificity is not readily known. Upon polyclonal stimulation, naive T cells produce a lot 
of IL-2, central memory cells produce some and effector memory cells do not produce much IL-
2[121]. However, for production of effector cytokines, memory cells produce these rapidly 
including IFN-γ and TNF-α in response to stimulation while naive T cells do not, and TCM and 
TEMRA cells produce some but not as high levels as effector memory T cells[121]. Studies in 
mice and humans have shown that multifunctional memory T cells producing IFN-γ, TNF-α and 
IL-2 define a correlate of vaccine mediated protection against Leishmania major, highlighting 
the importance of the quality of the response as well as the magnitude[122]. Additionally, a 
study of virus-specific CD4+ and CD8+ T cells in human peripheral blood found multi-functional 
IFN-γ+TNF-α+IL-2+/- memory cells generated in response to chronic infection with CMV and are 
thought to be important for ongoing viral control[123, 124].  
 TEMRA cells produce cytokines, albeit at lower levels than TEM cells, have a dampened 
ability for proliferation, and express higher levels of cytotoxic molecules such as granzyme A/B 
and perforin compared to other T cell subsets[120, 124]. TEMRA also have a reduced capacity 
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for production of IL-2, an important cytokine for cell survival [125]. They are the most 
terminally differentiated T cell type, with expression of CD57, a molecule associated with 
replicative senescence and antigen-induced apoptotic death [126, 127]. The majority of TEMRA 
are CD8+ T cells, although rare populations of CD4+ TEMRA cells can also be present in certain 
individuals. The predominance of  TEMRA cells increases with age [128] as well as infections 
with pathogens including CMV (CD4+ and CD8+ TEMRA), and dengue (CD4+ TEMRA) [10, 
111, 112, 129, 130]. While TEMRA cells are most similar in phenotype to short lived effector 
cells (SLECs) in mice, it is unknown whether they represent the same population. In mouse 
models, SLECs can readily be defined and dissected by their short-term nature, their synchrony 
with timing of infection, and their specificity that can be precisely mapped using cell transfer and 
genetic models of manipulation. In contrast, in humans such experimental manipulation is not 
possible, and therefore understanding the lifespan of TEMRA cells and how they are generated 
in vivo is more difficult and remain open questions.  
 The different functional capacities, phenotypes and localization patterns of human T cell 




Table 1-1. Properties of human T cell subsets.  























































































Molecular basis for memory T cell formation 
 The distinct features of memory versus naive and effector T cells are reflected in 
differences in gene expression [131]. Studies doing whole transcriptome profiling by RNA-
sequencing, as well as transcriptome profiling by microarray, have found that the type of genes 
expressed in naive versus memory T cells are largely the same with over 95% overlap in the 
degree of similarity between naive and memory T cell transcriptomes, found by analysis of nine 
published studies (reviewed here [132]).  However, the genes that are highly over expressed in 
either naive or memory T cells have very important roles in their respective functions for 
activation, effector function, and homeostasis. In memory T cells, upregulated genes include 
those involved in activation such as MHC class II genes (HLA-DRA, HLA-DRB1, HLA-DPA1 
and HLA-DPB1) as well as genes important for migration including chemokine receptor genes, 
such as CCR5, CCR6, CXCR3 and CXCR5. Additionally, genes involved in intracellular 
signaling are also upregulated in memory T cells and these include mitogen-activated protein 3 
kinase 5 (MAP3K5), dual specificity phosphatase 4 (DUSP4), regulator of G-protein signaling 1 
(RGS1) and S100 calcium-binding protein A4 (S100A4). Genes involved in effector functions 
that are upregulated in memory T cells include molecules important for cell killing such as 
granzyme A (GZMA) and GZMK. Finally genes important for homeostasis that are upregulated 
in memory T cells include expression of interleukin receptors IL2RB and IL10RA, among other 
cytokine receptor genes.  Transcription factors regulate expression programs and these are also 
found to be differentially expressed in memory T cells. Notably, both MAF, thymocyte selection-
associated high mobility group box (TOX) and TBX21 (which encodes T-bet) are highly 
expressed in memory T cells compared to naive T cells[132].  
 Most of the highly expressed genes in memory T cells are shared between TCM and 
TEM subsets. However, there are several genes that are even more highly expressed in TEM 
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cells including CCR2, LGALS1, LGALS3, the MHC class II genes HLA-DPB1, HLA-DQA1, 
HLA-DRA, HLA-DRB5 and HLA-DRB6, and integrin αM (ITGAM) for CD4+ T cells.[132] Genes 
more highly expressed in CD8+ TEM cells compared to TCM cells mostly relate to genes coding 
for cytotoxic molecules such as GZMH, as well as effector function genes such as IFNG, and 
genes encoding cell surface chemokine receptors including CCR6 and CCR9. Together, these 
show that the highly expressed genes in TEM cells indicate their increased effector function and 
differential migration capacities. 
 This differential gene expression signature has been found to be driven by epigenetic 
changes including histone methylation patterns providing a chromatin basis for differential gene 
expression between naive and memory T cells[133]. Methylation patterns within the DNA occur 
predominantly at clusters of CpG dinucleotides (known as CpG islands). DNA methylation at 
CpG islands has been shown to regulate genes important for effector function and activation in 
memory T cells in numerous studies [134-138]. In a study examining naive, memory and effector 
T cells in mice, the IFNG locus was found to be differentially methylated according to subset. 
The IFNG locus was highly methylated in naive T cells, partially methylated in memory T cells, 
and unmethylated in effector cells, indicating that methylation contributes to lower production of 
IFN-γ observed in naive T cells. Interestingly, the IFNG gene was rapidly able to demethylated 
in memory but not naive T cells within 5 hours of antigen stimulation without requiring any cell 
division. [136]. Further, more recent studies conducting genome wide analysis of human naive, 
TEM and TEMRA cells show epigenetic networks regulate transcriptional programs. 
Interestingly, TEM and TEMRA cells shared similar epigenetic marks, and were both distinct 




Role of transcription factors in memory T cell fate  
 Given the dual roles of memory T cells play, the ability for effector function and self-
renewal, how is the formation of these diverse subsets regulated within T cells? Genetic ablation 
studies in mice revealed the importance of T-bet and Eomes in the differentiation of T cells 
important for their effector functions including IFN-γ, perforin, and granzyme B production [94, 
95]. Studies in mice have shown that higher expression of T-bet promoted short lived effector 
cells, while lower expression of T-bet promoted memory T cell precursor formation[91]. 
Transcriptional activation of Wnt responsive genes by T-cell factor 1 (TCF-1) and Lymphoid 
enhancer-binding factor 1 (LEF1) is important for maintenance of memory T cells. [140-146] 
Interestingly, TCF-1 and LEF-1 also play essential roles in multiple stages of T cell development 
including earliest stages of T-cell development during thymopoiesis [147-149], therefore 
conditional knockout models were used in order to elucidate their important roles at later stages 
of differentiation including for Tfh commitment [150-153], and CD8+ T cell lineages [140, 154]. 
 Genetic ablation studies have elucidated the cooperative roles of TCF-1 and LEF-1 in 
CD8+ T cell responses and shown that these factors are especially important for memory 
formation and maintenance. TCF-1 and LEF-1 are highly expressed in naive T cells, 
downregulated in effector cells, and then upregulated again in memory T cells [145]. TCF-1 is 
required for T cell development as shown in mouse models where lack Tcf-1 leads to partial 
block in T cell development, however some T cells are still able to develop and those that do 
develop still retain effector capacity[148]. Genetic ablation of Tcf-1 and Lef-1 is lethal, therefore 
to study their combined roles in T cells, Lef-1 was conditionally deleted using a Cre-lox system. 
This allowed Lef-1 to be intact for T cell development of naive T cells, and then deleted upon 
effector differentiation under the control of granzyme B promoter activity. Using this model, 
CD8+ T cells deficient for TCF-1 and LEF-1 lost the ability to form KLRG1loIL-7Rαhi memory 
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precursors, while maintaining the capacity to generate effector cells expressing IFN-γ, granzyme 
B, and perforin. Subsequently, these effector phenotype T cells were impaired in proliferation 
upon rechallenge [140, 155]. Conversely, transgenic mice with constitutively active Wnt 
signaling resulted in enhanced memory T cell formation and IL-2 production, resulting in 
enhanced immunity to secondary encounter to Listeria monocytogenes, a pathogenic bacterium. 
Taken together, these studies reveal the importance of Wnt signaling factors TCF-1 and LEF-1 in 
the generation and maintenance of CD8+ T cell memory. 
In humans, less is understood about the mechanistic underpinning of memory T cell 
formation, but evidence suggests that the same transcription factors that regulate memory T cell 
formation in mice are also important in human T cells. Interestingly, T-bet expression is highest 
in TEMRA cells, also high in TEM cells, and lower in TCM cells, agreeing with mouse studies 
of the importance of controlled T-bet expression for maintenance of memory T cells [156]. 
Additionally, very recent studies have elegantly demonstrated that TCF-1 marks self-renewing 
cells in human blood. Naive T cells express TCF-1, and expression is maintained in central 
memory T cells and important for their self-renewal capacities [157]. The expression of LEF-1 
follows similarly to TCF-1 with naive T cells having the highest expression, then TCM and TEM 
and TEMRA with the lowest expression.[158] The current knowledge of the expression of these 
T cell subsets is outlined in Figure 1-6 below, also indicating the gap in knowledge of expression 




Figure 1-6. Expression of T-bet, Lef-1 and TCF-1 in human T cells 
(A) Transcription factor expression with human T cell subsets is limited to those subsets which 
can be detected in peripheral blood. Naïve T cells express high levels of TCF-1 and LEF-1, TCM 
T cells express intermediate levels of TCF-1 as well as T-bet, TEM and TEMRA cells express 
high levels of T-bet and low levels of TCF-1. [156-158] For human TRM cells (purple) it 








Models for mechanisms of T cell memory formation 
 The mechanism for how diverse memory T cell subsets develop from a single naïve T 
cell clone is debated and has been for years[159-162]. There are many different schools of 
thought of how this occurs [163], broadly speaking these can be broken down into two main 
models. In one model, a single naïve T cell upon priming, undergoes branching into distinct 
precursors, one that can form memory and other that will differentiate into effector populations. 
In this model, once a naïve T cell becomes an effector cell, it cannot go back to memory 
phenotype and will go off to proliferate and then die. Memory precursors in this model can also 
further differentiate into effector T cells indicating a single directionality of the differentiation 
process, known as the decreasing potential model.  A second model is that all memory T cells 
first go through an effector phase, and then a portion of those effector cells re-express markers 
more similar to naïve T cells and become long lived memory, known as the de-differentiation 
model.  
 Experimental evidence to support both of these models exists. There are studies in mice and 
humans that support the de-differentiation model, including a study in humans tracking yellow 
fever virus (YFV) specific T cells. [164] In this study, participants were vaccinated with YFV 
vaccine (YFV-17D) and subsequently dosed with heavy water (D2O) daily for two weeks after 
YFV-17D vaccination. Deuterium from D2O is incorporated into DNA of cells that are 
actively dividing, and therefore quantification of deuterium levels in YFV-specific T cells 
derived from peripheral blood samples can reveal the rate of cell division during the time of 
D2O exposure. Peripheral blood samples taken during the effector phase revealed the 
maximum levels of deuterium incorporated as virus-specific T cells underwent robust 
proliferation. From analysis of memory T cells from longitude peripheral blood samples taken 
1-2 years later, they found high deuterium enrichment remains in the YFV-specific memory T 
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cells, indicating that this population originated from cells that underwent rapid proliferation 
during the effector stage of the immune response. Additionally, studies in mice provide 
supporting evidence that effector T cells de-differentiate to become memory T cells, by 
investigating changes in DNA methylation programming at naive and effector cell-associated 
genes in virus-specific CD8+ T cells during acute lymphocytic choriomeningitis virus 
infection in mice. The authors found evidence for elimination of de novo methylation profiles 
and re-expression of naive-associated genes after transfer of memory precursor (MP) cells, 
defined as KLRG1loCD127hi cells[165]. However, there is an alternate explanation for the 
erasure of de novo methylation programs and re-expression of naive- associated genes observed. 
The analysis was of bulk MP cells which could comprise a mixture of more effector-like 
precursors as well as more memory-like precursors, and over time if the effector like precursors 
died and only the rare memory-like precursors remained, this could explain the apparent erasure 
of methylation at effector genes. Single cell analysis techniques can aid in elucidation of the 
origins of distinct memory T cell fates. 
  Evidence to support the decreasing potential linear model is that T cells carry epigenetic 
marks, and these differ between subsets with Naïve T cell being most similar to TSCM, then 
TCM, and lastly TEM and TEMRA. Further, TCM and TSCM cells have the ability [113] to 
convert to TEM cell phenotype, but not vice-versa, which is coupled to increased methylation of 
CCR7 and Tcf7 loci, indicating a directionality in T cell differentiation programs [166]. 
Additionally, there is evidence that TCR signaling strength can lead to generation of distinct 
memory and effector cells[167]. There is also substantial evidence that shows after several cell 
divisions of a naïve T cell due to activation with antigen, the resulting cell populations that 
bifurcate into effector cells are irreversibly effector and exhibit silencing of TCF-1 expression, 
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while the TCF-1+ cells maintain the ability to produce both TCF-1+ and TCF-1 daughter cells. 
[168-171] 
Whether or not de-differentiation or the decreasing linear model is occurring, neither of 
these models explains how a single cell, whether naïve or effector, is able to produce two distinct 
daughter cells: effector and memory cells. Asymmetric cell division has been demonstrated to 
drive effector and memory T cell fates. During asymmetric cell division, cellular components 
including regulators of signaling and transcription are unequally partitioned resulting in two 
daughter cells with distinct fates. Asymmetric cell division is also broadly conserved in different 
phyla of life [172-175]. In T cells, unequal partitioning of PI3K signaling has been shown to 
mediate generation of TCF-1+ and TCF-1- daughter cells with self-renewal and effector T cell 
fates respectively[168-171]. While the occurrence of asymmetric division has been shown, the 






Section 1.5 Tissue Compartmentalization of Memory T cells 
Overview of Tissue Localized Memory T cells 
 Initially, immunological memory was thought to be maintained mainly by specialized 
circulating subsets of TEM and TCM cells in blood as described above to surveil lymphoid and 
peripheral tissues respectively. However, more recent investigations in mice have revealed that 
subsets of CD4+ and CD8+ T cells remain resident in tissues such as lung, skin, and gut long after 
infection resolution [177-183]. These studies established a new subset of cells designated tissue 
resident memory T cells (TRM). Functionally, TRM mediated immediate protection against 
diverse viral, bacterial and parasitic infections more effective than circulating memory T cell 
subsets [177-183]. Since these initial investigations, many additional studies continue to emerge 
finding TRM in almost every tissue examined including the salivary glands, brain, liver and 
lymphoid organs, with large populations in human tissues such as lung, skin, and liver [6, 8, 184-
197]. TRM can also be generated in response to vaccination and cancer [182, 198-200], as well 
as playing pathogenic roles in human diseases[201, 202].   
 TRM provide localized protective immunity and immune surveillance in tissues. [203] 
TRM were established as resident and non-circulatory in mouse models by various methods 
including parabiosis assays [177, 189, 204], in-vivo antibody labeling to determine accessibility 
to circulation [179, 190, 205], and photo-conversion of T cells to track migration [206-208]. 
These studies showed that phenotypically the majority of TRM can be distinguished from 
circulating memory T cells by expression of CD69, [190, 205, 209] a surface marker which 
promotes retention of T cells through S1PR1 [52, 53] and the alpha E integrin CD103 for subsets 
of CD8+ T cells [209, 210]. TRM are mainly characterized in barrier tissues, but play emerging 
roles in lymphoid tissues as well [206, 208, 211]. Mouse models show how TRM development 
differs in infants, providing strategies and mechanism for better understanding of the molecular 
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underpinnings of TRM formation. Collectively, with a better understanding of TRM populations, 
we will have a better ability to target TRM generation with vaccination to promote long lived 
immunity. 
 
Identification of TRM 
TRM are generated in diverse sites in response to acute and chronic viruses, including 
influenza (lungs) [179], murine cytomegalovirus (MCMV) (salivary glands) [212], lymphocytic 
choriomeningitis virus (LCMV) (many sites) [213], and herpes simplex virus (HSV) (skin, 
vaginal mucosa) [198, 214]. An important experimental method in mouse models that has shown 
T cells remain resident in tissues is parabasis, surgical joining the circulations of two mice, and 
tracking migration of T cells from one parabiont to the other. While blood T cells typically reach 
homeostasis between the partners within weeks, many T cells in tissues do not become 
equilibrated and remain in specific tissues of one parabiont. [177, 215-217] Another approach for 
identifying TRM in mice is the in-vivo labeling of circulating cells with fluorochrome-
conjugated antibodies via intravascular injection, which can effectively identify T cells that are 
tissue resident at the time of injection and thus remain unlabeled. [179, 205, 218]  Additionally, 
the transplantation of peripheral tissues into congenic or naive mouse recipients also permits the 
assessment of residency potential and persistence of putative donor TRM in the graft. [181, 213] 
The findings from these and other studies in mice have demonstrated that TRM are a distinct, 
non-circulating population of long-lived memory T cells.  
 Similar criteria using parabiosis and in vivo labeling to establish tissue residency cannot 
be applied to human T cells.  However, certain clinical situations involving T cell deletional 
therapies, and sampling from organ and composite tissue transplantation have provided evidence 
for the persistence of tissue memory T cells maintained distinct from circulating counterparts. 
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Treatment of cutaneous T cell lymphoma (CTCL) patients with anti-CD52 depleting antibodies 
(alemtuzumab) eliminated circulating T cells from the blood, but spared a persisting resident 
population of CD4+ and CD8+ memory T cells in the skin[192]. Further, alemtuzumab is 
completely ineffective for a relatively benign skin-limited variant of CTCL called mycosis 
fungoides (MF). In MF patients, pathogenic T cells persist for decades in regionally defined 
inflammatory lesions in the skin. During treatment with steroids, the legions can disappear but 
upon cessation of treatments, the lesions re-appear in exactly the same location in the skin, 
further indicating they are likely due to a resident T cell subset[219]. More severe variants of 
CTCL have been associated with circulating T cells and therefore require more systemic 
therapies. These studies show how TRM biology influences disease state and treatment 
considerations[201]. Transplantation of HLA-disparate tissues and organs containing 
endogenous TRM has created a natural experiment for assessing potential persistence of donor-
derived TRM and development of tissue T cell populations from circulating recipient T cells. In 
intestinal transplants, donor-derived T cells were detected both in circulation and within the 
intestinal graft up to a year post-transplant with TRM phenotype cells in the intestinal graft [220, 
221]. Similarly, epidermal CD8+T cells of donor origin in face transplant recipients were 
observed up to 2 years post-transplantation [222]. Together, these results indicate that human 
TRM persist in the tissue niche long-term, similar to mouse TRM. 
While defining tissue resident in humans is more difficult to due limits in experimental 
methods, substantial evidence shows that these cells are predominant in many tissue sites. In 
both organ donor tissue and surgical resections, TRM-phenotype cells expressing CD69 +/-
CD103 have been identified in virtually every tissue examined including lungs, liver, pancreas, 
lymphoid tissues, genital mucosa, the GI tract (stomach, jejunum, ileum, and colon), bone 
marrow (BM), and in brain obtained from autopsies [193, 195, 197, 223-226]. Transcriptional 
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profiling of CD69+ memory T cells from human lungs, spleen, liver and other sites has further 
revealed a conserved transcriptional profile distinct from blood memory T cells that exhibits key 
features with mouse TRM [8, 196, 227]. Importantly, the advantage of studying TRM in human 
tissues is the ability to directly associate TRM responses to protective immunity and specific 
disease states such as inflammatory and autoimmunity [201, 228]. 
 In human tissues, the extent of CD69 and CD103 expression by CD4+ and CD8+ tissue 
memory T cells varies by tissue site and is highly conserved between diverse individuals [7, 8, 
205]. The identification of TRM in both species has relied two key markers, CD69, originally 
defined as an early T cell activation marker, and expressed by a large proportion of tissue 
memory CD4+ and CD8+T cells in mice and humans, and CD103 (αE- subunit of the αEβ7-
integrin that binds E-cadherin expressed on epithelial cells [229]), expressed by mouse and 
human CD8+memory T cells in mucosal and barrier tissue sites [6, 181, 187, 230]. Both of these 
molecules likely function in tissue retention or localization. CD69 serves as a signal for tissue 
retention by binding to and sequestering the sphingosine-1-phosphate receptor (S1PR1) which is 
required for tissue egress [52, 53, 231]; downregulation of S1PR1 is essential for TRM formation 
in mice [232]. While transient expression of CD69 on recently activated effector T cells similarly 
serves to retain them in the lymph nodes [52], CD69 expression by TRM is constitutive and not 
associated with expression of other activation markers like CD25, CD38 and HLA-DR [8]. 
Interestingly, genetic deletion of CD69 in mice results in a reduction (but not ablation) of 
CD8+TRM in the skin and lung [217, 233], and does not greatly affect CD4+TRM formation 
[190, 206]. Taken together, these findings demonstrate that CD69 is an important marker to 




 CD103, the αE-subunit of the αEβ7-integrin that binds E-cadherin expressed on epithelial 
cells, is expressed by a subset of mouse and human CD8+memory T cells in mucosal and barrier 
tissue sites [6, 181, 187, 230]. CD103 expression is limited to certain subsets of TRM likely 
because E-cadherin:αEβ7-integrin interactions anchor CD103+ TRM in specific locations within 
the mucosal epithelium. Accordingly, the formation of CD8+ TRM in the skin of CD103-
deficient mice is reduced and CD103- cells exhibit increased motility compared to wildtype 
controls [233, 234]. There are, however, populations of CD8+TRM outside of the epithelia in 
tissues, such as in secondary lymphoid organs and bone marrow [8, 15, 235-237], that do not 
express CD103 at steady state. Furthermore, the role of CD103 on CD4+ TRM is less clear, as 
the majority of CD4+ TRM in mice and humans do not express CD103, though smaller 
populations of CD103+CD4+ TRM persist in the lungs, intestines and skin [8, 238]. A parabiosis 
study in mice found that a proportion of CD69-CD4+ memory T cells egressing from the skin 
expressed CD103, suggesting that CD103 expression alone does not indicate tissue residency in 
memory T cells [239]. Therefore, while CD69 and CD103 expression do not alone determine 
tissue residency, stable expression of CD69+CD103+/- remains the most effective way to 
phenotypically distinguish TRM from their circulating counterparts.  
 TRM also express other molecules on their surface that distinguish them from circulating 
T cells. For instance, mouse and human CD4+ and CD8+ TRM express the integrin CD49a in the 
lung and skin [8, 181, 191, 233, 240]. CD49a (integrin α1) binds to CD29 (integrin β1) to from 
VLA-1, an integrin specific to collagen [241] suggesting that CD49a may play an important role 
in adhesion of TRM near collagen-rich basement membrane of the epithelium. Accordingly, 
antibody blockade and genetic deletion of VLA-1 in mice results in impaired retention of CD8+ 
TRM in peripheral tissues [242]. CD49a expression may also delineate subsets of human TRM, 
particularly in skin as CD49a+CD8+TRM cells produced IFN-γ while CD49a-TRM cells 
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produced IL-17 [240]. CXCR6, a chemokine receptor which binds CXCL16, is another 
commonly identified marker of TRM in both human tissues [8] and in the mouse skin and liver, 
where it plays an essential role in the formation of CD8+TRM [234, 243]. We recently reported 
that most CD4+ and CD8+ TRM in human tissues commonly express the inhibitory receptors 
CD101 and PD-1 [8]. Relatively little is known about CD101 including its binding partner, 
though a mechanistic study in human T cells found that antibody stimulation of CD101 prevents 
CD3-induced T cell proliferation by interfering with IL-2 production [244].  
 Upon chronic stimulation, T cells can become exhausted and no longer responsive to 
antigen. T cell exhaustion has been well characterized in mouse models has a major role in 
failure to control chronic infection and neoplasia. Exhausted T cells have unique expression and 
cell phenotypes including high expression of PD-1, an inhibitory molecular on T cells [245, 
246]. Further, the molecular underpinnings of PD-1 expression have been found to be negatively 
regulated by transcription factor T-bet, a master regulator of effector function[247]. However, 
expression of PD-1 alone is not enough to indicate T cell exhaustion, and further, T cells in 
tissues that are not exhausted also express PD-1, indicated its immunomodulatory roles beyond T 
cell exhaustion [248]. More specifically, PD-1 expression has been described in CD8+TRM 
generated through infection in mice [249, 250], and also in human multiple tissues at steady-state 
including in the lungs, spleen, tonsils and liver [8, 193, 196]. Interestingly, TRM expressing 
these inhibitory molecules mediate robust and rapid effector functions following TCR 
stimulation [8, 12, 193]. Additionally, PD-1 treated T cells can respond to immunotherapy and 
provide proliferative bursts to curtail viral infection. Additionally, human studies have shown 
efficiency in anti-PD1 therapies that reinvigorate T cells within tumors for clearance.[251] 
Constitutive expression of these inhibitory receptors on TRM may serve to fine-tune or self-
47 
 
regulate TRM responses to optimize protective responses, while minimizing tissue pathology in 
situ.   
 
Transcriptional regulation of tissue residency programs 
The designation of TRM as a distinct subset with a unique transcriptional profile, raised 
the important question concerning the identity of the transcription factor(s) which drive TRM 
formation. Several transcription factors including Hobit, Blimp, Runx3 and Notch were found in 
mouse infection models to promote CD8+ TRM formation [196, 252-254].  These transcription 
factors (TFs) were identified based on upregulated expression of the TF or transcriptional targets 
in TRM compared to circulating memory T cells. Whether these TF function in TRM formation 
for CD4+T cells or for human T cells remains yet to be established. Hobit transcripts are 
upregulated in human T cells after activation [255] and are expressed at very low levels in 
resting human TRM cells, albeit with upregulated expression in lung CD69+ compared to CD69- 
memory T cells [8, 196, 227]. Notch/RBPj is upregulated in human TRM and is part of the core 
gene signature [8 , 196], although expression of Runx3 in human TRM has not yet been reported. 
Thus, the transcription factors driving human TRM formation remain unclear and whether mouse 
TF function similarly in human T cells has not yet been demonstrated. It is possible that TRM-
driving TF are upregulated early in TRM formation, while in human tissue, TRM may be 
persisting for years or more and therefore TF expressed in human TRM may be reflecting a 
maintenance rather than development requirement. Ultimately, modulation of human TRM may 
need to target factors required for TRM maintenance or tissue retention such as TGF-β, produced 




Mucosal Tissue TRM populations 
In human skin, the majority of dermal TRM are CD4+CD69+CD103- cells, with the 
epidermis containing mixed populations of CD103+CD4+ and CD8+TRM [238]. These TRM 
express high levels of the cutaneous lymphocyte antigen (CLA) and specific chemokine 
receptors such as CCR4 and a proportion upregulate the chemokine receptor CCR8 upon entry 
into the human skin niche [256, 257].  Stromal keratinocytes play key roles in the formation and 
maintenance of both CD4+ and CD8+ skin TRM through the activation of latent TGF-β that 
facilitates the upregulation of CD103 [238, 258]. Keratinocytes also produce IL-7 and IL-15 that 
is required for long-term maintenance and survival of memory T cells [259]. A recent study also 
found that skin TRM may alter their metabolism within specific sites; mouse dermal CD8+ TRM 
acquire a program of exogenous lipid uptake and increased oxidative metabolism to persist in the 
skin niche and mediate immunity [260]. Whether this metabolic reprogramming of TRM is a 
general mechanism for tissue adaptation or specific to lipid-rich epithelial tissues remains to be 
determined.  
 The lung is another mucosal site with abundant populations of CD4+ and CD8+ TRM 
identified in humans and mice [6, 179, 189, 191, 261]. Lung parenchyma and airway CD8+ TRM 
express either CD69+ CD103- or CD69+ CD103+, while the majority of CD4+ TRM are CD69+ 
only. Similar to the skin, optimal formation of CD8+ TRM in the mouse lungs needs cross-
priming DC within the local lymph node [262], but, also requires 41BB signaling and CD4+ T 
cell help via the production IFN-γ [263, 264]. Once in the lung niche, CD103+ dendritic cells 
facilitate CD103 upregulation and maintenance of CD8+ TRM through the production of TGF-β 
[265], and the long-term survival these CD103+ cells requires IL-15 [183].  In the lung, there is 
differential localization of CD4+ and CD8+ T cells that display unique clustering patterns within 
the tissue; CD8+ TRM localize within specific niches of tissue regeneration after lung injury 
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(termed repair-associated memory depots) that aid their formation and maintenance, while CD4+ 
TRM localize to the airways or around B cell follicles [217, 261].  
 
Lymphoid TRM populations 
Bone marrow is a prominent niche for populations of CD4+ and CD8+ memory T cells in 
both humans [266-268] and mice [188, 269, 270]. Human bone marrow contains significantly 
more TEM cells and fewer Naïve T cells compared to peripheral blood, suggesting increased 
maintenance of memory in the bone marrow [266-268]. Furthermore, the bone marrow 
CD4:CD8 ratio is abut 1:2, in contrast with peripheral blood and lymph node sites which are 
closer to 2:1. [271] Interestingly, populations of bone marrow memory T cells also express 
canonical TRM marker CD69. In mice, it is a minority of memory (CD44hi) T cells expressing 
CD69 (between 10-30%)[272], however in humans, a larger percentage of memory T cells in the 
bone marrow can express CD69 (between 40-60%), with higher expression on CD8+ T cell 
memory [266]. Expression of CD69 was initially thought of as indicating BM T cells are at an 
increased activation state compared to those in blood, due to simultaneous increased 4-1BB 
expression in CD4+ and CD8+ T cells and increased CD25 expression in CD8+ T cells [266]. 
However, follow up studies revealed that CD69+ T cells in human bone marrow are actually 
more quiescent rather than activated in phenotype, shown by decreased expression of Ki-67, a 
marker of active proliferation, as well as gene profiling showing a global resting gene expression 
signature of ex-vivo CD69+  compared to CD69- CD4+ T cells from the bone marrow and T cells 
from peripheral blood [223, 273]. Genetic knockout studies in mice have shown that in CD69 
knock-out animals, there is decreased accumulation of CD4+ T cells in the BM compared to WT 
counterparts, therefore suggesting that CD69 plays a role in retention of T cells in bone marrow 
nice [272].  
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 T cells in the bone marrow also differ from blood T cells in that they express chemokine 
receptors such as CCR5 and CXCR4 which may aid in their retention within the bone marrow 
niche [268].  Despite the tissue-specific expression and possible mechanisms of maintenance 
within the bone marrow, evidence in mice suggests that bone marrow T cells are highly 
circulating and the markers of tissue residence may instead denote a temporary residence in bone 
marrow for homeostatic survival signals vis IL-15 signaling [266, 270, 274]. The evidence for 
bone marrow memory being highly circulating is largely from experiments in mice by parabiosis 
showing that the ratio of host and donor T cells equilibrates to one after about two weeks [215], 
however whether this is indicative of T cell dynamics in humans remains unknown. Moreover, 
given mice have fewer putative CD69+ resident memory T cell than humans, perhaps there are 
increased levels of functional maintenance of T cells in human bone marrow compared to mice. 
Taken together, the bone marrow is a niche for memory T cell maintenance, however the extent 
to which any of the T cells are truly resident remains unknown as well the functional role of this 
niche for T cells in humans. 
Recent studies in secondary lymphoid tissues of mice and humans demonstrate that CD4+ 
and CD8+ TRM also take up residence in LNs and spleen [7, 275-277]. In conventional inbred 
mouse models, the majority of virus-specific T cells within lymphoid tissue are circulating with 
<10% truly resident by parabiosis [189]. Compared to mice, a much greater proportion of CD4+ 
and CD8+ T cells in lymphoid tissues express phenotypes and transcriptional profiles of TRM 
cells [7, 8]. Interestingly, dirty mice possess a similarly increased number of TRM in their lymph 
nodes relative to conventional SPF-mice [278], suggesting that the greater levels of antigen 
exposure experienced by humans may relate to the size of the lymph node TRM pool. Much less 
is known about lymphoid TRM, possibly because these are a rare population within SPF mice, 
yet in humans they may play a big role. Future studies are required to better understand 
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populations of TRM within lymphoid tissues and is the focus of part of this dissertation work. 
TRM in humans specific for CMV and EBV have been found in tonsillar tissue [194]. Taken 
together, TRM in human lymphoid tissues are playing emerging roles, perhaps first overlooked 
due to their rarity in mouse models. 
 
Maintenance of TRM populations over time 
  Once generated, the requirements and potential of TRM for long-term maintenance 
within the tissue are an active area of investigation in mouse models, and difficult to assess in 
humans. In the lung, IL-2 and IL-15 are required for CD4+ TRM formation [200], and given the 
known role of IL-15 as a homeostatic cytokine for peripheral memory T cell maintenance [279], 
it is possible that TRM use IL-15 for maintenance. Whether TRM can be maintained in tissues 
long-term is an area of debate: in the lung, CD8+ TRM generated from influenza virus infection 
were found to diminish over time due to apoptosis and lack of replenishment from circulating 
TEM cells [280, 281]. Lung CD4+ TRM generated from influenza did persist for months after 
infection and persistence did not require replenishment form circulation over the short-
term[190], suggesting differential maintenance requirements for CD8+ and CD4+ TRM.  
Although it is difficult to assess the persistence of human TRM in vivo and mechanisms 
for homeostatic turnover, these is evidence that TRM in certain human sites are long-lived. First, 
the overall proportion of TRM is set quite early in life, and this proportion is maintained at 
constant frequencies for decades of life—and into old age as assessed by extensive flow 
cytometry analysis of tissue memory T cells from key sites such as the lung and intestine from 
infancy through childhood and into the ninth decade of life [9, 190]. While this analysis does not 
assess antigen-specific populations, on the whole tissue level, there seem to be mechanisms for 
overall homeostatic maintenance of a stable population of TRM. In the human lung, influenza-
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specific T cells can be readily detected [190, 282], although the timing of the initial infection that 
generated them cannot be determined. TRM in the lung and other human tissues exhibit lower 
frequencies of Ki67+ cells indicative of proliferating cells, compared circulating T cells in blood 
and other sites [190], suggesting lower rates of turnover of tissue compared to circulating T cells. 
In human skin, there is evidence, however, for long-term maintenance of antigen-specific TRM, 
based on studies of cutaneous T cell lymphoma (CTCL) [192], and skin lesions in psoriasis, an 
inflammatory skin condition. Lesions and flare-ups are known to occur occurs at the same 
location over years, and this is associated with the presence of clonal populations of skin TRM 
that produce IL-17 [283].  
Aging is associated with decline in the ability to mount an immune response. This decline 
is associated with changes in various cell types of the immune system and the most defined 
changes are attributed to T lymphocytes which coordinate adaptive immunity. In general, there is 
a marked decline in T cell functionality associated with diminished responses to vaccines and 
infections, and immune dysregulation associated with increased autoimmunity in the elderly. As 
discussed earlier, T cell subsets are compartmentalized in tissues similar to adults with mucosal 
sites having predominant TEM populations, lymphoid tissue comprising both naïve and TEM 
cells, TCM cells found only among the CD4 subset in lymphoid sites and blood, and TEMRA 
cells found only among CD8 T cells in blood, spleen and lung, representing a blood-borne, 
circulatory subset [7]. Overall, this compartmentalization of memory T cells in mucosal sites, 
naïve T cells in lymphoid tissue, with blood containing all four subsets is maintained through 
many decades of adult life with a decrease in the frequency of naïve T cells being the major 
change with age [7]. These data indicate that the decline with age is not due to subset identity 
necessarily but maybe the quality of T cell responses with age. Further, effector memory CD8+ T 
cells isolated from older adults exhibited diminished proliferative responses and cytolytic 
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activity in response to ex vivo influenza A/H3N2 challenge [284]. By contrast, the phenotypic 
and functional characteristics of effector CD4+ T cells responding to influenza in older adults are 
preserved, suggesting a compensatory response to influenza infection when CD8+ T cells 
become compromised during immune aging [285]. The incidence of cancer increases rapidly 
with age and is hypothesized to be a result of the accumulation of somatic mutations over life. 
However, a new mathematical model, created by incorporating the decline in T cell production 
with age outperforms previous models based on somatic mutations.[286] Together, these 
findings show that age related decline in T cell function is a major risk factor for disease.  
 Lastly, in mouse models of influenza infection that generate TRM cells, it's been shown 
that TRM generation is significantly impaired in mice infected as infants [287]. The defect in 
ability to form TRM results in excess of effector cell at the expense of TRM generation. Further 
this increased effector generation is due to over-expression of T-bet, and T-bet heterozygote 
mice are better able to form TRM as infants more similar to adults [287, 288]. In conclusion, 
both infants and the elderly have impaired immune responses which may be due to inability to 
generate and maintain effective T cell responses. 
 
TRM development by vaccination 
 The ultimate goal in translating the fundamental knowledge of TRM revealed in mouse 
models to humans is to develop novel vaccines for promoting protective immunity. Accordingly, 
preclinical mouse models of vaccination and infection have shown promising outcomes when 
targeting TRM responses. Intranasal administration of a live-attenuated IAV (LAIV) vaccine 
generated long term virus-specific CD4+ and CD8+ TRM in the lungs of mice, which mediated 
heterosubtypic protection independent of circulating memory T cells or neutralizing antibodies 
[182]. Importantly, intraperitoneal injection of inactivated virus or LAIV failed to generate TRM 
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responses and provide cross-strain protection [182], demonstrating that both route and vaccine 
formulation (i.e., live-attenuated virus) are key determinants for TRM formation. Vaccination 
with Bacille Calmette-Guérin (BCG) in mice similarly demonstrated that mucosal but not 
subcutaneous administration of BCG generated protective TRM in the airway [289]. Delivery of 
vaccine vectors to specific tissues has also proved successful in inducing protective TRM 
immune responses including those using IAV vectors expressing HIV antigens and HPV 
pseudovirus encoding antigens from HSV [290, 291] and RSV[292]. These results emphasize 
that the current immunization approaches administering vaccines peritoneally may be less 
effective in generating optimal protection compared to methods targeting sites where pathogens 
infect.  
 Another immunization approach to generate TRM, designated “prime and pull”, 
combines vaccination (prime) with local administration of chemokines or adjuvants to recruit 
TRM precursors to target tissues (pull). Subcutaneous immunization with an attenuated strain of 
HSV-2 coupled with topically applied chemokines to the vaginal mucosa generated virus-
specific CD8+ TRM cells that protected mice from lethal HSV-2 challenge in the FRT [198, 
217]. Variations of this approach combine prime and pull into a single inoculum, such as using 
antigen complexed to antibodies targeting tissue-specific DC populations [265]. A particularly 
successful strategy in mice used a hepatocyte-specific adenovirus expressing malaria antigens to 
target TRM formation in the liver and prevent liver-stage malaria, which has now progressed to 
phase I clinical trials in humans [293].  
 Together, these studies provide promising proof-of-principle results that protective TRM 
can be generated by vaccination. Whether TRM-based vaccines can be applied to humans to 
prevent acute and/or chronic infections, will likely be determined in the coming years. 
Therapeutically generated TRM must also conform to the homeostatic balance of tolerance and 
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effector responses within tissues to prevent immunopathology. The capacity of individual human 
tissues to generate and maintain TRM and the minimum threshold of TRM to provide protection 
are essential questions that will inform optimization of protective immunity in the next 
generation of vaccines.  
 
Outstanding questions in field of tissue localized responses 
Overall, studies in mouse and humans indicate that modulation of T cell responses in tissues 
can have great impact on many human pathologies including infections, therapies against cancer, 
vaccines and more. However, there are still key questions about TRM biology that remain not 
well understood. For instance, what is the developmental relationship between T cell subsets in 
blood and those within tissue sites? Additionally, much of the work on TRM has been derived 
from mouse models and specifically on TRM in barrier sites, and less is known about TRM in 
lymphoid tissues. In fact before the start of my thesis work, resident memory T cells in lymph 
nodes where not identified in humans, however now they are emerging as prominent 
populations.  More specifically, given there are high levels of T cells expressing CD69, a marker 
of TRM, in lymphoid tissues in humans, are these cells similar to canonical TRM as defined in 
mouse models? TRM biology is further complicated by the fact that different tissue sites may 
contain T cells of different specificities. Additionally, humans are exposed to many pathogens 
and antigens at once, and how this shapes T cell response in tissue is unknown. How does 
exposure to myriad of antigens shape and influence T cell populations on the clonal level? Are 
properties of T cells on the clonal level more influenced by subset identity (TCM, TEM, 
TEMRA, and TRM) or tissue-specific features? What role does antigen play in generation of 
TRM populations, how different are TRM populations in different tissues, compared to those in 
blood? The use of T cell receptor sequencing methods and molecular profiling techniques as well 
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as access to human organ donor tissue has given us an unprecedented opportunity to investigate 




Section 1.6 Thesis Objectives 
Memory T cell differentiation, function, and maintenance occurs at diverse tissue sites. T 
cells travel via blood and lymph in order to enter into peripheral sites of inflammation including 
non-lymphoid barrier sites and several secondary lymphoid sites where T cells coordinate 
adaptive immunity. Lymphoid and non-lymphoid sites contain an estimated >95% of the total T 
cells in humans, yet most knowledge on human T cell differentiation and maintenance derives 
from extrapolation of studies on peripheral blood. Initially, two human memory T cell subsets, 
named TCM and TEM, were discovered in blood based on differential functional potential and 
homing to lymphoid and non-lymphoid sites respectively. More recently in mice, TRM cells, 
defined by ability to remain resident in non-lymphoid and lymphoid tissue sites have been found 
to play important roles in adaptive immunity. There are many key gaps in knowledge about 
human TRM biology. Our goals are to understand how human T cells are localized in 
lymphoid sites and what regulates the maintenance of T cell subsets in lymphoid and non-
lymphoid sites. This body of work investigates the hypothesis that there are tissue-specific 
mechanisms for tissue compartmentalization of human memory T cells. With a better 
understanding of the healthy immune system in humans, we can better understand what goes 
wrong in disease. 
Our first main objective is to investigate differentiation and mechanisms for maintenance 
of lymphoid memory T cells in BM, spleen and lymph nodes. Evidence from mouse models 
show that a small percentage of T cells within lymphoid tissue (<10%) establish residence, as 
shown by parabiosis studies. This is in contrast to T cells in non-lymphoid sites such as skin, 
intestine, and salivary glands of which nearly all are resident by the same parabiosis experiments 
[189]. In contrast, human data show that a large majority of memory T cells within lymphoid 
tissue express TRM marker CD69, indicating there may be increased amounts of TRM in human 
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lymphoid tissue compared to mouse models. Therefore, our first objective is to examine memory 
T cells in lymph nodes, bone marrow, and spleen and investigate their properties and functions; 
and second to identify what, if any, tissue specific mechanisms are playing a role in their 
maintenance.  
 Results from our first objective reveal a novel organ-specific, memory T cell subset that 
is maintained in LN but not in blood and other lymphoid or mucosal tissues. Interestingly, both 
LN TEM and TRM displayed a unique profile of protein and RNA expression that was distinct 
from those in other sites including expression of transcription factors Tcf-1 and Lef-1 known to 
be important for self-renewal and TFH differentiation [141, 143-145, 150-152, 154, 157, 170], 
and expression of chemokine receptors CXCR4 and CXCR5 that have roles in regulating 
lymphoid homing and migration to B-cell follicles [294]. The specific properties of LN TEM and 
TRM as more quiescent, having diverse receptor repertoires, and having high proliferative and 
differentiation capacities indicate that LN provide distinct niches for maintaining high capacity T 
cells poised for protective responses. Their maintenance throughout many decades of life, as 
shown here, provides immune reserves for eliciting protective responses and controlling chronic 
infections, and provide a mechanism for our previous findings of LN-restricted localization of 
CMV-specific T cells in certain individuals [10]. Finally, we identify type-1 IFN signaling as an 
opposing mechanism for TCF-1 maintenance in lymph node sites. Together these findings 
suggest that LN provide a specialized niche for maintenance of TEM and TRM over life. 
 Our second main objective is to investigate the relatedness of human effector and 
memory T cells in tissues. In mice, effector cells are widely disseminated during a primary 
infection, whilst short lived, and memory populations remain long-lived in specific tissue sites 
depending on localization of initial pathogen encounter and sites of inflammation. In humans, 
four major human CD4+ and CD8+ T cell subsets that have been identified including TEM, 
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TCM, TRM, and TEMRA cells, however how antigen has driven differentiation and 
compartmentalization of these subsets in human lymphoid and non-lymphoid tissues remains 
unknown. Sequencing of the TCR-β chain allows identification of T cell clones in order to 
investigate the relatedness of T cell subsets across tissues. Our second objective is to investigate 
our hypothesis that tissue site has a major influence on the diversity of T cell clone repertoires 
and that a given T cell clone may be found widely disseminated in multiple sites in order to 
provide protection to many on-going systemic pathogens. 
 Our results investigating our second objective reveal that the relatedness of T cells 
between sites, including blood, bone marrow, spleen, lymph nodes, and lung, is highly subset 
specific. From diversity analysis, we found a hierarchy of T cell diversity; it was highest among 
CD4+TCM, then CD4+ and CD8+ TEM and TRM, and lowest among CD8+TEMRA cells, a 
finding mostly conserved across tissues. We looked for tissue-specific features and found that 
CD4+ and CD8+ T cells in LN are more diverse than in BM. From our clonal overlap analysis, we 
found high degree of overlap between CD8+TEMRA cell populations across tissues; with few 
tissue-specific clones. Clonal overlap analysis across tissues revealed tissue-specific patterns and 
maintenance of TEM and TRM clones, including a high degree of similarly between CD4+TEM 
and CD4+TRM in lung, and a high degree of similarity between CD4+TEM in BM and CD4+ 
TEM in Spl. Overall, our findings show that the relatedness of T cell clones is influenced mainly 
by subset and to a lesser degree, anatomical site.  These results show how T cell responses are 
distributed in tissues and can serve as a baseline for future studies investigating T cell responses 




CHAPTER 2: Materials and Methods 
 
Section 2.1 Human tissue acquisition and lymphocyte isolation 
 
Acquisition of human samples.  
Human tissues were obtained from deceased (brain dead) organ donors at the time of 
organ acquisition for life-saving clinical transplantation. Donor tissues were obtained through an 
approved protocol with LiveOnNY. Organ donors were free of chronic disease and cancer, 
negative for hepatitis B, hepatitis C and HIV. The tissues collected for research include: blood, 
bone marrow, lung, lymph nodes (lung-, mesenteric-, and iliac-draining), intestinal sites (ileum, 
jejunum, and colon), spleen, tonsils, and salivary glands. The tissues collected are depicted 
graphically in Figure 2-1. For isolation of blood from living volunteers, blood was drawn via 
venipuncture from consented volunteers, as approved by the Columbia University IRB.  
 
Isolation of lymphocytes from human samples.  
Tissue samples were maintained in cold saline and brought to the laboratory within 2-4h 
of procurement. Samples were rapidly processed using enzymatic and mechanical digestion to 
obtain lymphocytes with high viability. For spleen, lymph nodes, and mucosal tissues (including 
lung), tissues were minced and incubated at 37°C in enzymatic digestion media: RPMI (Thermo 
Fisher) containing 10% fetal bovine serum (FBS) (Thermo Fisher), L-glutamate (Thermo 
Fisher), sodium pyruvate (Thermo Fisher), nonessential amino acids (Thermo Fisher), penicillin-
streptomycin (Thermo Fisher), collagenase D (1 mg/ml, Roche), trypsin inhibitor (1 mg/ml, 
Thermo Fisher) and DNase I (0.1 mg/ml, Roche). For the lung tissue, prior to incubation in 
digestion media, the tissue was inflated with digestion media using a 50cc syringe and 18g 
61 
 
precision needle. The incubation in digestion media times varied for each tissue; lymph nodes 
were incubated for 1 hour and spleen and lung were incubated for 1.5 hours. Digested tissue was 
further disrupted using the gentleMACS tissue dissociator (Miltenyi Biotech); the resulting 
suspension was passed through a tissue sieve (10–150 mesh size) and then pelleted through 
centrifugation. For only the spleen, red blood cells (RBC) were lysed using ACK lysis buffer 
(Corning Cellgro) by incubation for 5 minutes on ice. Following a wash with RPMI containing 
2% FBS, dead cells and epithelial cells were removed via centrifugation through 30% Percoll 
(GE Healthcare Life Sciences). The settings for density separation using Percoll were 50g and 
breaks set at 0 (zero) and acceleration set at 3 for 15 minutes at room temperature. After 
centrifugation with Percoll, mononuclear cells that were below the top layer of epithelial cells 
were rescued and washed in RPMI media containing 2% FBS. To remove residual RBCs, RBCs 
were lysed using ACK lysis buffer by incubation for 5 minutes on ice. This was the second ACK 
lysis step for spleen, and is usually required for lung but not lymph nodes. Resulting cell 
suspensions were resuspended in RPMI containing 2% FBS. Finally, cells were passed through 
100 µm filter paper. Resulting cell suspensions were kept on ice until downstream use. Total 
processing time for lymphocyte isolation from each tissue is about 2.5 hours for spleen, 3.5 hours 
for lung, and 1 hour for lymph nodes. 
 For isolation of lymphocytes from blood and bone marrow, lymphocyte separation 
media (Cellgro) was used to perform density gradient centrifugation to isolate the mononuclear 
cells from the RBCs. The settings for the lymphocyte separation centrifugation were 400g and 
breaks set at 0 and acceleration at 0 for 20 minutes at room temperature. The mononuclear cell 
layer positioned between the plasma (top layer) and LSM (bottom layer) was extracted and 
washed with RMPI.  If residual RBC contamination was present then cells were incubated in 
5mL of AKC lysis buffer for 5 minutes at 4°C, followed by a wash and resuspension in RPMI 
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containing 2% FBS. Finally, cells were passed through 100 µm filter paper. Resulting cell 
suspensions were resuspended in RPMI containing 2% FBS and kept on ice until downstream 
use. Total processing time for mononuclear cell isolation from blood and bone marrow is about 1 












Cryopreservation of lymphocytes 
Single cell suspensions of lymphocytes were cryopreserved in Cryogenic Vials (Corning) 
in a solution of 10% dimethyl sulfoxide (DMSO) in FBS at a concentration of 10 million 
cells/mL. Vials containing the cell suspension were placed into Mr. Frosty Cryo Freezing 
Containers (Nalgene) and placed in the -80°C freezer. The “Mr. Frosty” containers are filled with 
a basin of ethyl alcohol, which allows for a cooling rate of 1°C/minute. After cooling to -80°C, 
vials containing frozen cell suspensions were transferred to liquid nitrogen freezer. The frozen 
suspensions can be stored for years and currently the Farber lab has cryopreserved lymphocyte 
suspensions from multiple sites from over 400 donors.  
 To thaw cryopreserved samples, vials are removed from liquid nitrogen and transferred to 
37°C water bath until cell suspensions are fully thawed.  Immediately upon thawing, pre-warmed 
RPMI containing 10% FBS added slowly according to a protocol shown to increase both T cell 
viability and functionality post-cryopreservation [295]. Initially 1 mL of media (to double the 
volume of cell suspension) was added with 0.1mg/mL DNase to minimize cell clumping of cell 
suspensions and allowed to sit for 1 minute. Subsequently, additional warmed RPMI containing 
10% FBS is added one drop at a time until cell suspension solution is 10X in volume. Cells were 
spun down and resuspended in RPMI containing 10% FBS. Finally, cell suspensions were passed 




Section 2.2 Flow Cytometry 
 
Flow cytometry staining, acquisition, and analysis 
For flow cytometric analysis, single cell suspensions were stained with fluorochrome 
conjugated antibodies for 30 minutes at 4°C in the dark. For the last 5 minutes of staining, DAPI  
was added for identification of dead cells (Biolegend). Staining and washing of cells was 
performed in FACS buffer (PBS/1% fetal bovine serum/0.1% sodium azide). Control samples 
included unstained, single fluorochrome–stained compensation beads (Ultra Comp eBeads, 
eBioscience) and fluorescence minus one (FMO) controls. Stained cells were acquired using a 
BD LSRII or BD Fortessa analytical flow cytometer in the CCTI flow cytometry core and 
analyzed using FlowJo (Treestar) and FCS Express (De Novo Software).  
 For intracellular staining, cells were stained with a fixable live-dead stain during the 
surface staining (Thermo Fisher). For detection of cytokine and transcription factor expression, 
cells were incubated in perm-fix buffer (eBioscience) for 1 hour, washed, resuspended in 
permeabilization buffer (eBioscience) with antibodies specific for intracellular markers for 1 
hour at 20-25°C.   
For isolation of subsets by fluorescent-activated cell sorting, lymphocyte suspensions 
were first enriched for T cells using a magnet based CD3 negative enrichment kit, MojoSort 
Human CD3 T cell Isolation Kit (Biolegend), stained for surface markers (as described above) in 
sort buffer (PBS/1% FBS), and sorted using an Influx high-speed cell sorter or Aria II cell sorter 





Section 2.3 CyTOF 
 
CyTOF Sample Prep 
 Cryopreserved cell suspensions from each tissue were thawed and labeled with Rh103 
intercalator as a viability marker. For each donor, cells from each tissue were first barcoded 
using a unique combinatorial barcode of CD45 antibodies conjugated with monoisotopic 
cisplatin and then pooled. The pooled tissue samples were then stained with a panel of antibodies 
against cell surface markers, washed, fixed and permeabilized (eBioscience Transcription Factor 
Staining Kit) and then stained with additional antibodies against intracellular targets. CyTOF 
antibodies were either purchased pre-conjugated from Fluidigm (formerly DVS Sciences) or 
purchased purified and conjugated in-house using MaxPar X8 Polymer Kits (Fluidigm) 
according to the manufacturer’s instructions. For a complete list of antibodies used see Table 
2-2. The samples were then washed and incubated in 0.125nM Ir intercalator (Fluidigm) diluted 
in PBS containing 2% formaldehyde, and stored at 4oC until acquisition. 
 
Sample Acquisition and Analysis 
Immediately prior to acquisition, samples were washed once with PBS, once with de-
ionized water and then resuspended at a concentration of 1 million cells/ml in deionized water 
containing a 1/20 dilution of EQ 4 Element Beads (Fluidigm). The samples were acquired on a 
CyTOF2 (Fluidigm) equipped with a SuperSampler fluidics system (Victorian Airships) at an 
event rate of <500events/second. After acquisition, the data were normalized using bead-based 
normalization in the CyTOF software and uploaded to Cytobank for initial data processing.  
For analysis, the data were gated to exclude residual normalization beads, debris, dead cells 
and doublets, and the derived from each tissue were deconvolved by Boolean gating on CD45 
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barcodes, leaving DNA+CD45+Rh103- events for subsequent clustering and high dimensional 
analyses. 
FCS express software (De Novo) was used for generating tSNE (t-Distributed Stochastic 
Neighbor Embedding) and PCA plots from CyTOF data[296, 297]. To generate tSNE plots, we 
used the Barnes-Hut implementation of the t-SNE algorithm called viSNE [298]. One tSNE 
analysis was generated for three individuals (D332, D333, D335) together. A separate tSNE 
analysis was generated for a fourth individual (D342) in which the panel lacked TCF-1 and 
included blood as an additional sampling site. Downstream statistical analysis was done using R 
programming language. Heatmaps of normalized marker expression were generated using R. We 
plotted the heatmap using the Z-score of average marker expression with samples clustered by 
unsupervised hierarchical clustering function hclust and visualized with heatmap.2 in the gplots 
package. We performed multidimensional scaling (MDS) analysis using the cmdscale function in 




Table 2-1. Antibody and reagents used for flow cytometry. 
  
Reactivity/ Reagent Target Fluorochrome Clone/target Company 
Human CCR7 AF488 G043H7 Biolegend 
Human CCR7 PE-Texas Red G043H7 Biolegend 
Human CD45RA BV605 hi100 Biolegend 
Human TCF1 PE C63D9 Cell Signaling 
Human CD3 BV510 OKT3 Biolegend 
Human CD4 PECy7 SK3 Biolegend 
Human CD4 APCCy7 OKT4 Biolegend 
Human CD4 BV650 SK3 Biolegend 
Human CD8 APCCy7 SK1 BD Biosciences 
Human CD8 PE HIT8a Biolegend 
Human CD8 BUV737 SK1 BD Biosciences 
Human CD8 PerCPCy5.5 RPA-T8 Tonbo 
Human CD45RO PerCP-eFluor710 UCHL1 Ebiosciences 
Human CD69 BV421 fn50 Biolegend 
Human CD69 APC FN50 Biolegend 
Human CD57 PE-Dazzle-964 HNK-1 Biolegend 
Human Ki67 BV421 B-56 BD Biosciences 
Human Lef1 FITC C12A5 Cell Signaling 
Human Peforin PE-CF594 GG9 BD Biosciences 
Human Tbet PE 4B10 Biolegend 
Human Eomes PE-Eflour610 WD1928 Ebiosciences 
Human CCR5 AF700 J418F1 Biolegend 
Human CXCR4 APC 12G5 Biolegend 
Human PD1 AF647 EH12.1 BD Biosciences 
CMV-Multimer APC A2402, pp65 113-121 Proimmune 
CMV-Multimer APC A0201, pp65 495–503 Proimmune 
LIVE/DEAD™ Dead Cell Stain  Fixable Red - ThermoFisher 
LIVE/DEAD™ Dead Cell Stain Fixable Blue - ThermoFisher 





Table 2-2. Antibodies used for CyTOF 
Target Tag Clone Source Source Cat# 
CD57 113 In HCD57 Biolegend 322302 
CD28 141 Pr CD28.2 Biolegend 302902 
CD19 142 Nd HIB19 Biolegend 302202 
CD45RA 143 Nd HI100 Biolegend 304102 
CD103 144 Nd Ber-Act8 Biolegend 350202 
CD4 145 Nd RPA-T4 Biolegend 300502 
CD8a 146 Nd RPA-T8 Biolegend 301002 
Perforin 147 Sm dG9 Biolegend 308102 
CD16 148 Nd 3G8 Biolegend 302014 
CD127 149 Sm A019D5 Biolegend 351302 
CD1c 150 Nd L161 Biolegend 331502 
CD123 151 Eu 6H6 Biolegend 306002 
CD66b 152 Sm G10F5 Biolegend 305102 
PD-1 153 Eu EH12.2H7 Biolegend 329912 
ICOS 154 Sm C398.4A Biolegend 313502 
CD27 155 Gd O323 Biolegend 302802 
CCR5 156 Gd NP-6G4 Fluidigm 3156015A 
Bcl6 158 Gd IG191E/A8 Biolegend 648302 
Tcf1 159 Tb 7F11A10 Biolegend 655202 
CD14 160 Gd M5E2 Biolegend 301810 
CD56 161 Dy B159 BD Biosciences 555513 
CXCR5 163 Dy J252D4 Biolegend 356902 
CD69 164 Dy FN50 Biolegend 310902 
41BB 165 Ho 4B4-1 Biolegend 309802 
CD25 166 Er M-A251 Biolegend 356102 
CCR7 167 Er G043H7 Biolegend 353222 
CD3 168 Er UCHT1 Biolegend 300402 
Tbet 169 Tm 4B10 Biolegend 644802 
CD38 170 Er HB-7 Biolegend 356602 
CD95 171 Yb DX2 Biolegend 305602 
LAG3 172 Yb 11C3C65 Biolegend 369302 
CXCR4 173 Yb 12G5 Fluidigm 3173001B 
HLADR 174 Yb L243 Biolegend 307602 
TIGIT 175 Lu MBSA43 eBioscience 16-9500-85 





Section 2.4 Whole transcriptome profiling by RNA sequencing 
 
Isolation of RNA 
T cells were purified by cell sorting and total RNA was isolated using an RNA/DNA kit 
(AllPrep DNA/RNA mini kit, QIAGEN) according to manufacturer’s protocol. Briefly, sorted 
cells were pelleted, resuspend in RLT plus buffer and put through QIAshredder (Qiagen) 
columns to completely lyse cells. DNA and RNA were extracted using RNA/DNA columns by 
step-wise process outlined specifically in the manufacturer’s manual. The final step in the RNA 
extraction protocol is to elute the purified RNA from the column. Next, we assessed RNA 
concentration and quality by RNA Integrity Number (RIN) using an Agilent 2100 Bioanalyzer 
(Agilent Technologies). For the majority of samples, >200ng of total RNA was submitted for 
sequencing with RIN>8. 
 
RNA-sequencing pipeline 
 Library preparation and whole transcriptome profiling by RNA-sequencing was 
performed by the Columbia Genome Center. Library preparation was done using a poly-A pull-
down to enrich mRNAs from total RNA samples followed by library preparation using Illumina 
TruSeq RNA prep kit. Libraries were sequenced using Illumina HiSeq2000 at Columbia Genome 
Center. Samples were multiplexed in each lane, which yields targeted number of paired-end 
100bp reads for each sample, as a fraction of 180 million reads for the whole lane.  
For base called, RTA (Illumina) was used and bcl2fastq (version 1.8.4) for converting 
BCL to fastq format, coupled with adapter trimming. Reads were mapped to a reference genome 
(Human: NCBI/build37.2) using Tophat (version 2.1.0) [299] with 4 mismatches (--read-
mismatches = 4) and 10 maximum multiple hits (--max-multihits = 10). To map reads derived 
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from exon-exon junctions, Tophat infers novel exon-exon junctions ab initio, and combines them 
with junctions from known mRNA sequences (refgenes) as the reference annotation.  The 
relative abundance (aka expression level) of genes and splice isoforms was estimated using 
cufflinks [300] (version 2.0.2) with default settings. Data are available at GEO accession # 
GSE106420. 
 
Differential gene expression and pathway analysis. 
Downstream statistical analysis was done using R programming language. We tested for 
differentially expressed genes under various conditions using DEseq2 [301], an R package based 
on a negative binomial distribution that models the number reads from RNA-seq experiments 
and tests for differential expression. We considered genes as significantly differentially 
expressed between two groups if FDR≤0.05 and the absolute value of log2 fold change >1. For 
downstream analysis and visualization, we first normalized gene counts with DeSeq2 and used 
the subsequent normalized counts (rlog normalized counts). For some analyses, the normalized 
counts were averaged between CD69- and CD69+ samples in order to identify CD69 independent 
differences between transcriptomes of T cells derived from different tissue sites.  We performed 
multidimensional scaling (MDS) analysis using the cmdscale function in R on a distance matrix 
computed with the dist function in R. Principle component analysis (PCA) was done using the 
the pca function within DeSeq2 which uses the prcomp function. Both MDS and PCA were 
plotted using ggplot. For heatmap visualization of RNA-seq data Z-score of FPKM values were 
plotted using Microsoft Excel.  Pathway analysis was conducted using Ingenuity Pathway 
Analysis software (IPA; QIAGEN). We used the Canonical Pathways function of IPA software 
to compare transcriptomes of memory T cells isolated from different sites (bone marrow, lymph 




Gene Set Enrichment Analysis (GSEA).  
 GSEA was implemented to compare human LN CD8+TEM cells to published datasets of 
mouse CXCR5-positive or CXCR5- negative T cells [302, 303] generated in response to chronic 
infection. We used two approaches. First, we obtained a gene list from microarray data [302]. 
For comparing to microarray data, we used a list of top upregulated genes (250 genes) and a list 
of the top downregulated genes (250 genes) ranked by fold change. The second approach used 
RNA-sequencing data. We derived a gene list from published RNA-sequencing DE analysis 
[303]. We split up the DE genes into two lists: a list of upregulated and a list of downregulated 
genes defined by Deseq analysis conducted in the paper and applied the following cutoffs: FDR 
≤ 0.05, |Foldchange| ≥ 1). We used the gene lists from mouse populations as input into GSEA 
[304] and tested the null hypothesis that mouse genes have uniform distribution in ranks by the 
absolute value of log fold change between human TEM cells from lymph nodes and bone 





Section 2.5 T cell Proliferation Assays 
 
Polyclonal T cell Proliferation Assay 
 T cells isolated from tissues were purified by cell sorting on an Influx cell sorter (BD 
Bioscience) in the CCTI flow cytometry core. TEM cells were sorted using the following 
antigens: CD3+CD8+CD4-CCR7-CD45RA-.  After sorting, cells were stained with eFluor450 
cell proliferation dye (eBioscience) according to manufacturer’s instructions. Briefly, cells were 
washed twice with PBS to remove any serum, resuspended in Cell Proliferation Dye eFluor450 
5uM final concentration in PBS and stained for 10 minutes in the dark at 37°C. Labeling was 
stopped by adding 4-5X volumes of cold RPMI-1640 containing 10% FBS and incubated for 5 
minutes on ice. Cells were plated in a 48 well plate at 5X105 cells/mL in complete media (RPMI-
1640, 10% FBS, 1mM sodium pyruvate, 100 U/mL penicillin, 100ug/mL streptomycin, and 
2mM L-glutamine) in the presence of ImmunoCult Human CD3/CD28 T cell Activator 
(STEMCELL technologies) at 25 uL/mL media. Cells were analyzed at day 3,4 and 5 after 
stimulation. Controls included unstimulated cells as well as cells unstained with eFluor450 in 
order to determine cell divisions. In some cases, 1000 Units of Recombinant Human IFN-α A 
(R&D Systems) and recombinant Human IFN-β (PeproTech) was added to culture medium. 
 
CMV-specific T cell proliferation 
 Mononuclear cells (1-3X106) isolated from blood or tissues as described above, were 
cultured in 96 well tissue culture plates at 5X105 cells/mL Complete Media in presence or 
absence of 0.3μg/mL HCMV pp65 peptide mix (JPT Peptide Technology). IL-2 100U/mL was 
added on day 2 and cells were analyzed at day 8 or 9 after stimulation. Media was checked daily, 
and as needed was replenished with fresh media. HLA multimer reagents containing epitopes of 
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CMV (CMV-multimers) (see Table 2-1) were obtained from ProImmune. Staining with 
multimers was done according to the manufacturers protocols. Briefly, cells isolated from bone 
marrow, blood, and lymph nodes were washed with PBS and stained for 10mins at 37°C with 
tetramer reagent. Cells were washed and subsequently stained with other antibodies for 




Section 2.6 TCR sequencing 
 
DNA extraction 
 For most samples, sorted T cell subsets were pelleted and resuspended in cell lysis 
solution (Qiagen). DNA was isolated from cell lysate using the Gentra Puregene kit (Qiagen). 
For the samples from 3 of 11 total donors, (D287, D280, and D229) DNA was extracted using an 
RNA/DNA kit (AllPrep DNA/RNA mini kit, QIAGEN) according to manufacturer’s protocol. In 
the donor 383, the blood samples had fewer cells sequences, and therefore may not be 
quantitative, but the rest of the samples were equally sampled.  
 
TCR Vβ amplification, library preparation and sequencing.   
TCR sequencing was performed by the Human Immunology Core in collaboration with 
Dr. Nina Luning Prak and her laboratory. For TCR Vβ amplification, a cocktail of 23 Vβ 
families from framework region 2 (FR2) forward primers, and 13 Jβ region reverse primers, 
modified from the BIOMED2 primer series were used [305]. The PCR was performed with two 
mixes, all of which used the same 23 Vβ forward primers, but two different Jβ mixes. Primer 
sequences are provided in Table 2-3. The Vβ and Jβ primers mixes were used at 0.6 µM in a 
reaction volume of 25 µL using a Multiplex PCR kit (Qiagen, Cat. No. 158388).  Amplification 
conditions for the PCR were: primary denaturation at 95°C for 10 minutes, cycling at 95°C 45s, 
Ta (57°C for Jβ mix 1, 61°C for Jβ mix 2) for 90s, extension at 72°C for 90s for 35 cycles, and a 
final extension step at 72°C for 10 minutes. 
 Amplicons were purified using the Agencourt AMPure XP beads system (Beckman 
Coulter, Inc) in a 1:1 ratio of beads to sample and eluted in 40 µL of TE (0.1mM EDTA) buffer. 
Second-round PCRs to generate the sequencing libraries were carried out using 4 µL of the first 
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round PCR product and 2.5 µL each of NexteraXT Index Primers S5XX and N7XX, using the 
Qiagen Multiplex PCR kit in a reaction volume of 25 µL. Amplification conditions for the PCR 
were primary denaturation at 95oC for 10 minutes, followed by cycling at 95oC 30s, 60oC 30s, 
extension at 72oC 45s for 8 cycles, and a final extension step at 72oC for 10 minutes. To confirm 
adequacy of amplification, aliquots of both the 1st and the 2nd round PCR products were run on 
agarose gels. Library quality was evaluated using Bioanalyzer 2100 (Agilent Technologies) and 
quantified by Qubit Fluorometric Quantitation (Thermo Fisher Scientific).  A sharp single band 
from Bioanalyzer analysis indicated a good quality library and was used for sequencing.  
Readings from Qubit using the dsDNA HS (high sensitivity) assay kit (Cat. No. Q32851) were 
used to calculate the molarity of the library. Libraries were then loaded onto an Illumina MiSeq 
in the Human Immunology Core Facility at the University of Pennsylvania. 2x300 bp paired end 
kits were used for all experiments (Illumina MiSeq Reagent Kit v3, 600 cycle, Illumina Inc., Cat. 
No. MS-102-3003).  
   
77 
 
Table 2-3. PCR Primers used for TCR-Vβ amplification. 










































TCR read counting and clone mapping 
 Raw reads were first processed using pRESTO [306] and filtered as described [307] with 
the script provided in Appendix A (page 222). Briefly, sequences are trimmed of poor-quality 
bases, paired reads are aligned into full length contiguous sequences, short sequences are then 
filtered out and bases with low quality score are replaced with an N, and any sequence 
containing more than 10 such bases is removed from further analysis. Filtered sequences are next 
processed by MiXCR (version 2.1) [308] or ImmuneDB [309, 310] for V and J gene 
identification and clone counting. The data from MiXCR and ImmuneDB were compared for 
initial data analysis and showed similar results; ImmuneDB was used for all analysis presented 
here. For the ImmuneDB pipeline, a non-default parameter was implemented during the clone 
counting step where we defined sequences with identical CDR3 amino acid sequences and the 
same V and J gene pairings to be collapsed into clones.  In addition to clone assignment function 
of ImmuneDB, there is also a feature to create a web interface. We used the web interface for 
two purposes: 1) creating interactive plots for initial data visualization and exploration and 2) 
exporting the data to .tsv files in various formats for more in-depth downstream analysis scripted 
in R. The ImmuneDB webpage contains instructions for implementing the ImmuneDB pipeline 
(https://immunedb.readthedocs.io/en/latest/pipeline_example.html). To summarize, we used 











Overview of TCR analysis in R 
 The ImmuneDB web interface (http://clash.biomed.drexel.edu/databases/miron5/) was 
used to export T cell receptor sequencing data in two formats for analysis. Downstream analysis 
included several methods of quantifying and visualizing T cell clone diversity of samples. 
Diversity analysis included clonal summary plots and calculating the clonality of each sample. 
We also did several analyses to quantify the extent of clonal overlap between samples. These 
overlap analyses including cosine similarity calculation, Jaccard index calculation, principle 
coordinate analysis of cosine similarity and clone tracking plots. Scripts for all of these analyses 
were written in R and can be found in the Appendix (page 222).  
 
TCR diversity analysis 
  The clonal summary plots were generated using the clonal.porportion function from the 
tcR package in R. Clonality was measured for all TCR samples by normalizing the entropy 
values of each sample to the number of unique TCR sequences, resulting in a value ranging from 
0 (most diverse) to 1 (least diverse). Given a clonotype x, the frequency of that clonotype, 
denoted as p(x) was used to calculate Shannon entropy (H) of a TCR repertoire X by:  H(X) =	−∑ p(x)log.	p(x)/∈1 . Normalized entropy (Hnorm) is calculated in order to control for set size 
where L is the total number of unique clonotypes in the sample:H2345(X) = 6(1)7839:	;<. Next, 
clonality is calculated as follows: Clonality(X) = 	1 −	H2345(X). For clonality analysis, the 
same input T cell DNA was used for each sample from the same individual. True diversity is 





Quantifying TCR clone overlap by Cosine Similarity and Jaccard Index 
 Cosine similarity was calculated using the cosine function in R. The mean of the four 
pairwise comparisons of two replicates per biological sample was reported in the heatmap. 
Hierarchical clustering was performed on the matrix of cosine similarity values for CD4+ and 
CD8+ T cells using the complete linkage, a method that find similar clusters, performed with the 
pheatmap function in R. Jaccard index (number of intersecting clonotypes over the union of 
clonotypes between two samples) was calculated using filtered data with abundance counts 
greater than 50% of the mean frequency to account for sequencing errors.  
 
Principal coordinates analysis of T cell clonotype abundances 
 Raw read counts were first sampled down to a depth of 19,000 reads per sample, and any 
samples with total read counts below this cutoff were excluded. To control for the presence of 
any clonotypes that may have resulted from technical errors, a single sequence was required to 
be present in at least two samples to be included in the analysis. Pairwise cosine distances 
between samples were then calculated using the pdist function in MATLAB. The cmdscale 
function in MATLAB was used to perform principal coordinates analysis (PCoA).  
 
Clone Tracking Analysis 
 The clone tracking plots were generated using VDJtools [312] software and specifically 
the Track Clonotypes command. The R script modified from the VDJtools software can be found 





Section 2.7 Statistical tests 
Descriptive statistics (percent, mean, median, SEM) were calculated using Prism 
(Graphpad software) for flow cytometry data and R programming language for T cell receptor 
sequencing data. Significant differences in frequencies, ratios, gMFI, and density were assessed 




CHAPTER 3: Human lymph nodes maintain TCF-1+ T cells with high functional potential 
and clonal diversity  
ABSTRACT: 
Our understanding of T cell responses in human lymphoid sites and their relation to 
peripheral blood remains sparse. In this study, we used a unique human tissue resource to study 
human T cells in different anatomical compartments.  We identify lymph nodes (LN) maintain 
memory CD8+ T cell with a distinct differentiation and functional profile compared with 
memory CD8+ T cells in blood, spleen, bone marrow, and lungs. LN memory CD8+ T cells 
express transcriptome and protein signatures of quiescence and self-renewal compared with 
corresponding populations in blood, spleen, bone marrow, and lung. Functionally, human LN 
memory T cells exhibit increased proliferation to TCR-mediated stimulation and maintain higher 
TCR clonal diversity compared with memory T cells from blood and other sites. These findings 
establish human LN as reservoirs for memory T cells with high capacities for expansion and 
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Luning-Prak, E., Farber, D.L. (2018) Human lymph nodes maintain TCF-1hi memory T cells 
with high functional potential and clonal diversity throughout life. Journal of Immunology. 









Section 3.1 Introduction 
 T cells mediate adaptive immune responses and long-lived protective immunity, through 
their differentiation to effector and memory T cell populations, respectively. While the majority 
of effector T cells are short-lived in vivo, a subset of primed effector cells differentiate and 
persist as populations of long-lived memory T cells. In humans, T cell subset differentiation and 
memory maintenance have been extensively characterized from peripheral blood, revealing 
subsets of memory T cells that differ in phenotype and proliferative potential.[14, 313] However, 
the majority of T cells in the body are localized in tissue sites, and particularly in lymphoid 
tissues including bone marrow (BM), spleen and an estimated 700 lymph nodes[4], where T cells 
responses are initiated, regulated and maintained. How human T cells in lymphoid sites function 
and persist relative to subsets in blood is not well understood; defining their nature is important 
for monitoring and modulating immune responses, and translating findings from mouse models 
where T cells from spleen and lymph nodes are the predominant sites of investigation.  
In human tissues, a significant fraction of memory T cells express markers including CD69 and 
CD103 which denote tissue-resident memory T cells (TRM).[7, 8, 15] In human lymphoid tissue, 
a lower proportion of memory T cells express CD69 and CD103 compared to mucosal sites.[8] It 
is not known whether lymphoid memory T cells persist with similar functional properties across 
tissues, or adopt compartment-specific attributes. Moreover, memory T cells in secondary 
lymphoid organs of laboratory mice generally do not exhibit TRM phenotypes[314], suggesting 
that lymphoid memory T cells in humans may exhibit features distinct from those in mouse 
tissues due to their longevity and/or increased exposure to diverse antigens encountered over 
human life.  
T cell differentiation to effector and memory cell fates is regulated by key transcription 
factors.[170] T cell factor-1 (TCF-1) is essential for memory T cell formation and maintenance 
86 
 
in the periphery, through regulation of pathways for survival and quiescence[144, 315], while T-
bet promotes effector over memory T cell generation.[91] In mice, differential expression of 
TCF-1 by memory T cells can influence their function and localization. In mouse models of 
chronic viral infection, several groups identified a TCF-1+ subset of memory CD8+T cells to be 
the responding population mediating viral clearance following anti-PD-1 therapy.[248, 303] This 
TCF-1+ memory subset was absent from peripheral blood, and only detected in lymphoid 
sites.[154, 248, 303, 316, 317] For human T cells, the role of specific transcription factors in the 
differentiation, maintenance and localization of effector and memory T cells has not been 
defined.  
In this study, we used our unique tissue resource where we obtain blood, multiple 
lymphoid and mucosal tissues from individual organ donors of all ages [6, 7, 11] to investigate 
how T cells in lymphoid sites are transcriptionally and functionally related to those in blood and 
peripheral sites. By studying T cells across multiple tissues within and between individuals, we 
demonstrate here that memory CD8+T cells are maintained in human LN in an organ-specific 
manner throughout the human lifespan. Notably, LN memory CD8+T cells maintain expression 
of transcription factors, TCF-1 and LEF-1 associated with self-renewal and exhibit distinct 
transcriptional and protein expression signatures involved in T-follicular helper (Tfh) cell 
differentiation with downregulation of effector function and inflammatory signals compared to 
memory T cells in blood, other lymphoid (spleen, BM) and peripheral sites (e.g., lungs). LN 
memory CD8+T cells also exhibit higher proliferative capacity and increased T cell receptor 
clonal diversity compared to memory T cells in other sites.  Together these findings establish 
human LN as reservoirs for maintenance of high potential memory T cells, and LN memory 




Section 3.2 Results 
Memory T cells exhibit increased TCF-1 expression in lymph nodes relative to other sites 
 Human T cells can be subdivided into major subsets based on CD45RA and CCR7 
expression into naïve (CD45RA+CCR7+), central memory (TCM, CD45RA-CCR7+), effector-
memory (TEM, CD45RA-CCR7-), and terminally differentiated effector cells (TEMRA, 
CD45RA+CCR7-).[7] For CD8+T cells, TEM phenotype cells are the predominant memory T cell 
subset in blood and diverse tissue sites, with low frequencies of TCM-phenotype cells[7], as 
shown here in BM, spleen, lung and lymph nodes (LN) (Figure 3-1A). We examined whether 
CD8+TEM cells exhibited tissue-specific variations in expression of TCF-1, a transcription factor 
associated with self-renewal.[145] In all donors, TCF-1 expression by CD8+TEM in LN was 
significantly higher than that found in CD8+TEM derived from blood, BM, spleen, and lung 
(Figure 3-1B). TCF-1+CD8+TEM cells were observed in LN draining different anatomical sites 
(lungs, intestines, groin, Figure 3-1B) and across all ages (9-76 years, Figure 3-1C). Moreover, 
TCF-1 expression was comparably high within CD69+ and CD69- subsets of LN memory T cells 
(Figure 3-2), delineating circulating and tissue-resident memory populations.[8] These results 
suggest that increased TCF-1 expression is an organ-specific (rather than subset-specific) feature 




Figure 3-1. Expression of TCF-1 is maintained in LN CD8+ TEM cells. 
 (A) CD3+CD8+T cell subset composition showing frequencies of effector memory cells (TEM, 
CD45RA-CCR7-) in blood and tissues from a representative individual (D251). (B) TCF-1 
expression is restricted to LN TEM cells. Left: TCF-1 expression by CD8+TEM cells in 
representative histograms from one donor (D334). Right: compiled frequencies from multiple 
donors (n=11). LLN=lung-draining, MLN= mesenteric-draining, ILN= iliac-draining lymph 
nodes; Spl= Spleen, Lng= Lung (C) LN-specific TCF-1 expression is maintained with age. Ratio 
of TCF-1 gMFI by CD8+TEM in tissues to that in blood. Error bars indicate SEM. * P<0.05, ** 

















Figure 3-2. Expression of TCF-1 in CD69- and CD69+ CD8+ TEM cells in tissues. 
(A) Expression of CD69 by CD8+ TEM cells in indicated tissues from a representative donor 
(D259). (B) Expression TCF-1 by CD69pos and CD69neg CD8+TEM cells in indicated tissues 
from a representative donor (D302). (C) Left: compiled expression data from (A) (Bld n=19, BM 
n= 28, Spl n=24, Lung n=12, LN n=27). Right: compiled expression data from (B) (Bld n=5, BM 






LN memory T cells exhibit a distinct phenotype and transcriptional profile 
We used whole transcriptome profiling by RNAseq to investigate whether increased 
TCF-1 expression by LN memory CD8+T cells indicated a distinct transcriptional program 
compared to memory CD8+T cells in blood and other lymphoid sites. We initially analyzed 
differential gene expression between memory CD8+T cells in LN and BM of three individuals 
(see sorting strategy, Figure 3-3), identifying over 2,000 differentially expressed (DE) genes 
conserved between individuals, many of which included markers associated with T cell 
differentiation by pathway analysis shown in Table 3-1. In particular, LN memory CD8+T cells 
had increased expression of transcripts associated with self-renewal (LEF-1, TCF-7), follicular 
helper T (Tfh) cell differentiation[78, 152, 318] (BCL-6, CXCR5, CXCR4, CCR7), co-
stimulation (CD28, ICOS), and reduced expression of effector transcripts (GZMA, PRF1) 
(Figure 3-4A). Genes involved in Wnt signaling (WNT10A, CD44, SOX13) and cell cycle 
control (CDKN1A, CDKN2C) were also differentially expressed in LN compared to BM 
memory CD8+T cells (Figure 3-4A). Analysis of protein expression confirmed increased CXCR4 
and LEF-1 expression and decreased expression of Perforin and T-bet in human LN compared to 
BM CD8+memory T cells (Figure 3-4B).  
 We further compared the transcriptional profile of LN memory CD8+T cells to that in 
blood and other tissues including spleen and lungs, for which we previously obtained RNAseq 
profiles.[8] Based on the ~2,000 DE genes defined above, the transcriptional profile of LN 
memory CD8+T cells clustered together by principle component analysis (PCA), distinct from 
that of memory CD8+T cells in blood, BM, spleen and lung for all donors analyzed (Figure 
3-4C). Through paired analysis of gene expression between LN and these other sites, we 
identified a gene signature comprising 330 upregulated and 340 downregulated genes in LN 
memory CD8+T cells compared to the corresponding subset in blood, spleen or BM (See gene 
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lists of genes upregulated in Table 3-2 and downregulated in Table 3-3). Notably, genes involved 
in T-follicular helper cell differentiation [319] were upregulated (IL21R, LEF-1, and ICOS), and 
genes involved in homing and cytotoxic function were downregulated (S1PR5, FCER1G, 
GRMH, and NKG7) in LN compared to blood, spleen and BM memory CD8+T cells (Figure 





Figure 3-3. Sorting strategy for isolation of lymphocytes for RNA-seq and TCR-seq. 
(A) Gating strategy shown in the following order (left to right): lymphocytes, singlets, memory T 
cells (CD3+CD45RO+), CD8+ and CD69+/- cells from bone marrow (BM) of a representative 






Figure 3-4. Human LN memory CD8+T cells are phenotypically and transcriptionally 
distinct from peripheral blood, BM, and Spl T cells. 
 (A) Heatmap of differentially expressed (DE) genes from whole transcriptome profiling of BM 
and LN (B and L respectively) CD8+TEM cells from three donors. (B) Protein expression of 
markers identified in (A) shown as histograms from one donor (top, from left to right: D259, 
D304, D227, D273 [see Table 3-6 for donor information]) and compiled: CXCR4, n=8; Perforin, 
n=5; Lef, n=7; T-bet, n=13 (bottom). (C) Principle component analysis (PCA) of transcriptional 
profiles of CD8+TEM cells from blood (Bld), bone marrow (BM), lung (Lng), spleen (Spl) and 
lymph node (LN) from nine individuals (1-9) based on the 2,521 DE genes between LN and BM 
memory CD8+T cells. (D) RNA expression of indicated genes among CD8+ TEM cells from 
blood and s tissue sites of nine individuals in (C). Error bars indicate SEM. * P<0.05, ** P<0.01, 








Table 3-1. Pathways differentially regulated in CD8+TEM cells in lymph nodes compared 
BM, spleen and blood.  
Results were obtained from the Canonical Pathways function of Ingenuity Pathway Analysis 
software (QIAGEN) by comparison of memory T cells isolated from different tissues (LN vs. 
BM, LN vs. Blood, and LN vs. Spl). 




LN vs. BM 
z-score 
LN vs. Spl 
z-score 
LN vs. Bld 
TFH or TH2 Up iCOS-iCOSL Signaling in T Helper Cells 3.3 1 -0.343 
TFH or TH2 Up CD28 Signaling in T Helper Cells 3.153 1.698 -0.16 
TFH or TH2 Up Th2 Pathway 2.785 0.218 1.372 
TFH or TH2 Up CXCR4 Signaling 1.291 0.655 -0.48 
Cell Cycle inhibition Up Cell Cycle: G1/S Checkpoint Regulation 0.447 1.265 0.577 
Co-stimulatory Up 4-1BB Signaling in T Lymphocytes 2.449 1 1.941 
Stem cell & 
Development Up 
Role of NANOG [..] Stem 
Cell 2.646 1.265 0.688 
Stem cell & 
Development Up 
Mouse Embryonic Stem Cell 
Pluripotency 2.496 1.807 0.667 
Stem cell & 
Development Up Wnt/β-catenin Signaling 1.043 1.414 2.359 
T cell activation Down cAMP-mediated signaling -0.667 -2.117 -2.219 
T cell activation Down Phospholipase C Signaling -0.784 -1.732 -1.987 
TH1 Down Cytotoxic T Lymphocyte -0.447 n/a n/a 
Cell signaling Down Gαs Signaling -0.632 -0.905 -1.177 
Cell signaling Down Gαi Signaling -0.632 -0.905 -1.177 
Cell signaling Down Eicosanoid Signaling -1.633 -1.265 -2.111 
Inflammatory Down Inflammasome pathway -0.632 -1.633 -0.632 
Inflammatory Down Toll-like Receptor Signaling -2.309 -2.53 -2.558 




Table 3-2. Total genes upregulated in LN CD8+TEM. 
Overlap of genes from differential expression analyses between CD8+TEM in different sites:: 
LN vs. BM, LN vs, Spl, and LN vs. Blood.  Deseq2 with the following cut-offs: FDR <0.05 and 
























































































































































































































































































































































Table 3-3. Total genes downregulated in LN CD8+ TEM.  
Overlap of genes from differential expression analyses between CD8+TEM in different sites: LN 
vs. BM, LN vs, Spl, and LN vs. Blood.  Deseq2 with the following cut-offs: FDR <0.05 and fold 

































































































































































































































































































































































Human LN memory T cells are transcriptionally similar to murine TCF-1+ CD8+ T cells that 
respond to checkpoint blockade 
We investigated whether the distinct transcriptional profile of LN memory CD8+T cells 
was due to enrichment of specific subset, such as TCM or TRM cells within the LN, or was 
organ specific. The LN-specific memory CD8+T cell profile identified in Figure 3-4 was not 
significantly similar to that previously defined for blood TCM CD8+TCM cells (18 shared genes 
of 785 TCM-associated genes).[320, 321] Moreover, the LN-specific gene signature identified in 
Figure 3-4 was conserved within both CD69+ (TRM-phenotype) and CD69- (circulating) 
memory subsets (Figure 3-5). Therefore, the distinct transcriptional profile of human LN 




Figure 3-5. Relatedness of CD69+ and CD69- CD8+TEM from tissues and blood based on 
differentially expressed genes between CD8+TEM in BM and LN. 
 MDS plot of gene expression from CD8+T cell subsets from indicated tissues. Gene list derived 
DE (differential expression) of transcripts between LN and BM CD8+TEM cells (2,521 genes). 








We then considered whether the Tfh-like profile of human LN memory CD8+T cells 
could be similar to a recently defined subset of T cells in mice that was a PD-1+TCF-1+CXCR5+ 
memory CD8+T cell subset generated in response to chronic infection LCMV infection. This 
subset mediated viral clearance, and proliferated in response to anti-PD-1 checkpoint 
blockade.[154, 248, 303, 316, 317] By gene set enrichment analysis (GSEA)[304], we found 
significant homology in the complement of up- and downregulated genes between the human 
LN-specific gene signature and the gene signature of mouse TCF-1+ memory versus TCF-1- 
CD8+T cells from two independent studies [248, 303] (Figure 3-6A). Key genes shared between 
mouse and human subsets include those encoding transcriptional regulators (ID3, TCF7, BCL6), 
homing molecules (CXCR5, CCR7), cytokines, effector molecules (GZMB), and cell cycle 
regulators (CDCA3, CDC8) (Figure 3-6B). Human LN memory CD8+T cells therefore exhibit an 
organ-specific transcriptional profile similar to a T cell subset that maintains and restores 




Figure 3-6. Human LN memory CD8+T cells exhibit similarity to murine CXCR5+CD8+ T cells 
generated in response to chronic LCMV infection. 
 (A) Comparison of mouse stem-like T cell transcriptome to human LN memory by gene set 
enrichment analysis. LN memory profile was generated from DE genes between LN and BM 
TEM cells. The list was ranked by log2FC and shown on a color scale of red (high in LN), white 
(no change between BM and LN) to blue (low in LN). LN memory T cells are compared to 
ranked lists of up (top two plots)  or down regulated (bottom two plots)  genes between TCF-1+ 
versus TCF-1 – memory T cells generated in mouse models of  chronic LCMV infection from 
two studies as indicated (Left, right) (12, 13). From the published studies we ranked the top 500 
differentially expressed genes from microarray or the significantly differentially expressed genes 
from RNAseq (FDR ≤ 0.05, |Fold change| ≥ 1). (B) Heatmap showing relative expression (FC= 
Fold Change) of genes from human LN (Hu) versus BM CD8+TEM cells compared to mouse 











Defining an organ-specific protein signature of LN memory CD8+T cells by CyTOF  
 We used cytometry by time-of-flight (CyTOF) to define a protein expression signature of 
LN memory CD8+T cells relative to other sites based on the transcriptional profile identified 
above. We analyzed CD8+T cells from four tissue sites (LN, BM, spleen and lungs) of three 
individual donors using a 35 marker CyTOF panel including markers of T cell differentiation, 
function, proliferation as well as transcription factors (see Chapter 2 Methods, Table 2-2). 
Subset- and tissue-specific variations within and between donors were assessed using t-
distributed stochastic neighbor embedding (t-SNE) analysis, a dimensionality reduction 
algorithm[297], on combined data for all tissues and donors. A total of 23 markers were used to 
generate the t-SNE plot with each the contribution of each individual marker and its expression 
density show in Figure 3-7. The concatenated analysis reveals that TCF-1 and CD28 segregate 
on distinct regions of the t-SNE plots relative to T-bet and Granzyme B expression (Figure 
3-8A), which correspond to naïve (CD45RA+CCR7+) and TEMRA cells (CD45RA+CCR7-), 
respectively (Figure 3-8B). By contrast, CD8+TEM cells (Memory, CD45RA-CCR7-) cluster on 
broader regions of the tSNE plot with the higher density clusters on regions distinct from naive 
and TEMRA cells, indicating heterogeneity of memory CD8+T cells. 
 We dissected the heterogeneity of CD8+TEM cells by tissue site and individual. For both 
donors shown, CD8+TEM in BM and lung were most similar to each other and contained regions 
that overlapped with regions denoted by TEM and TEMRA cells and with splenic CD8+TEM 
cells (Figure 3-8B,C). In LN, CD8+TEM occupied a distinct region of the tSNE, showing overlap 
with CD8+TEM from spleen but not from BM and lung (Figure 3-8C). We further stratified 
memory CD8+T cells by CD69 expression to delineate putative tissue residency.[8] The tSNE 
profile of CD69+TEM cells was similar in the four tissue sites (LN, spleen, BM, lung) (Figure 
3-8D), consistent with the finding that CD69+ tissue memory T cells exhibit a core signature of 
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TRM cells.[8]  However, the tSNE profile of CD69-TEM, was distinct in LN and similar in 
spleen, lung and BM (Figure 3-8D), and the LN CD69-TEM cell profile was not was not 
observed in blood (Figure 3-8E).  Interestingly the LN CD69-TEM cell profile was similar to LN 
CD69+TEM cells while in other sites, these two subsets were distinct (Figure 3-8D). Together, 
these findings indicate that LN memory CD8+T cells exhibit a protein expression signature that 





Figure 3-7. Expression of individual markers by total CD8+T cells concatenated from spleen, 
lung, BM, and LN of three donors in tSNE plots by CyTOF.  
(A) Density plots show expression of each marker used in the t-SNE analysis. (B) Markers 
excluded from t-SNE analysis and used for gating of cell subsets. (C) Gating strategy used for T 









Figure 3-8.  Human LN memory CD8+T cells exhibit a protein signature distinct from blood and 
other tissues. 
 T cells from LN, BM, spleen, lung +/- blood were stained with a 35-color panel (Table 2-2) and 
analyzed by CyTOF. (A) Expression of indicated markers on t-SNE plots of total CD8+T cells 
from BM, spleen, LN and lung of three individuals (D332, D333, and D335), based on 20 
markers (CD57, CD28, Perforin, CD127, PD-1, ICOS, CD27, CCR5, TCF-1, CXCR5, 41BB, 
CD25, T-bet, CD38, CD95, LAG3, CXCR4, HLA-DR, TIGIT, and Granzyme-B; Fig. S2) (B) 
Density plots as in (A) gated on Naïve (CD45RA+CCR7+), Memory (CD45RA-CCR7-) and 
TEMRA (CD45RA+CCR7-) CD8+T cells. (C) Density plots as in (A) showing CD8+TEM 
(Donor 332, top row and Donor 335, bottom row). (D) Memory T cells from indicated tissues 
either CD69- (top) or CD69+ (bottom). (E) Comparison of TEM CD69- from blood and indicated 









Figure 3-9.  LN memory CD8+T cells exhibit a differentiation profile with features of both naïve 
and memory T cells. 
 (A) T cells from LN, BM, spleen, lung were stained with a 35-color panel (Table 2-2) and 
analyzed by CyTOF. Heatmap showing relative expression of indicated proteins by naïve and 
TEM CD69- populations in tissues of three donors. (B) Multi-dimensional scaling (MDS) plot of 
T cell subsets by k means clustering. (C) PCA of indicated T cell subsets including total memory 
from LN (blue) and BM, spleen, and lung (red) and terminally differentiated effector cells 










LN memory CD8+T cells exhibit differentiation signature with similarities to both naïve and 
memory T cells  
 To identify which markers were driving the LN-specific signature identified above, we 
used clustering analysis which revealed that LN memory CD8+T cells express a unique 
combination of markers—including those shared with naïve T cells (cluster I & IV), and others 
with memory CD8+T cells in blood and other sites (cluster II & III) (Figure 3-9A).  Integrating 
the CyTOF data from multiple tissues and donors by MDS and K clustering analysis further 
shows that LN memory CD8+T cells have a protein expression signature that is distinct from 
naïve and memory T cells in other sites (Figure 3-9B). Principle component analysis (PCA) 
based on the protein expression data further reveals that LN TEM cells are more similar to naive 
T cells, while tissue TEM are more similar to TEMRA cells representing the most differentiated 
subset (Figure 3-9C). These analyses show that LN memory CD8+T cells exhibit a less 
differentiated profile when compared to memory T cells in blood and other lymphoid and 





Figure 3-10. Sorting strategy for isolation of CD8+ TEM cells for proliferation assays. 
(A) Gating strategy shown in the following order (left to right): lymphocytes, singlets, T cells 






Figure 3-11. Human LN memory CD8+T cells exhibit enhanced proliferation and effector 
phenotype in response to TCR stimulation.  
(A) Proliferation of CD8+TEM cells to anti-CD3/CD28 stimulation shown as %e-fluor450-
negative (divided cells) (red) compared to unstimulated (black) from a representative individual 
(D377) (B) Expression of transcription factor T-bet shown as percent positive on stimulated T 
cells from indicated tissue sites from a representative individual (D377). (C) Data from A 
compiled from 6 individuals by percent divided (%eFluor450low) and (D) Data from B compiled 
from 6 individuals by percent positive for T-bet expression in stimulated cells. Error bars 









Enhanced proliferative capacity of LN memory CD8+T cells  
 Functionally, TCF-1 expression is associated with a higher proliferative capacity to TCR-
driven stimulation.[146] When stimulated with anti-CD3/anti-CD28 antibodies, LN memory 
CD8+T cells (see sorting strategy Figure 3-10) exhibited greater proliferation compared to 
counterparts in BM, spleen and lung(Figure 3-11A, C). After CD3/CD28 stimulation, LN 
CD8+TEM cell counts were between 98-106 fold higher than BM. T-bet expression, was also 
increased to a greater extent in LN CD8+TEM cells following stimulation compared to other sites 
both in the level of expression and the fold-change increase following activation (Figure 3-11B, 
D). Together, these results demonstrate that LN memory CD8+T cells have a higher capacity for 
proliferation and differentiation compared to memory CD8+T cells in other sites. 
 
Increased TCR clonal diversity among LN compared to BM memory T cells 
 The results above indicate that LN maintain memory CD8+T cells exhibit a more 
quiescent state compared to other sites, including the BM which is a known reservoir for 
memory T cells of multiple specificities.[223] To assess whether there was differential 
maintenance of clonal populations between LN and BM memory T cells, we performed 
sequencing of the TCR CDR3b variable (V) regions of memory CD8+T cells isolated from 
multiple donors. We found an increased number of different V region sequences from 
comparable numbers of LN compared to BM memory CD8+T cells for all donors (Table 3-4). 
Importantly, BM memory CD8+T cells consistently had higher clonality compared to LN 
memory CD8+T cells (Figure 3-12A). Conversely, an increase in TCR diversity was observed for 
LN compared to BM memory CD8+T cells for all donors even when controlling for clone size 
(Figure 3-12B). Together, these results show that memory CD8+T cells in LN represent a more 
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clonally diverse population than is maintained in blood and other tissue sites, consistent with our 
findings that LN memory CD8+T cells are maintained in a quiescent state.     
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Table 3-4. Number of clones identified by TCR sequencing of CD8+ TEM in BM and LN. 
 
Donor Tissue Input DNA (ng) 
# valid 
seq # clones 
D233 Bone Marrow 270.4 444267 5441 
D233 Lymph node 270.4 522518 9195 
D287 Bone Marrow 220 727259 8009 
D287 Lymph node 220 552753 14248 
D255 Bone Marrow 184 281123 2378 
D255 Lymph node 184 420276 4605 
D280 Bone Marrow 104 477615 4846 
D280 Lymph node 104 504761 6694 
D299 Bone Marrow 164 537904 2998 





Figure 3-12. Higher TCR diversity of CD8+TEM cells in LN compared to BM.  
(A) Clonality of CD8+TEM TCR repertoires in BM and LN among 5 individuals. (B) Diversity 
of TCR sequences at different orders is shown for CD8+TEM cells from BM (dotted red) and LN 
(solid blue) among five individuals. At order zero, diversity is the total number of clones 





Mechanisms for T cell maintenance in LN sites and the role of type I IFN signaling 
To dissect mechanisms for the distinct gene expression profile of LN memory CD8+T 
cells, we analyzed pathways and upstream regulators. Pathway analysis showed conserved 
upregulated (Tfh, cell cycle, stem cell) and downregulated (T cell activation, signaling and 
inflammation) pathways in memory CD8+T cells from LN compared to BM, spleen and blood 
(Table 3-1). Potential upstream regulators of LN memory cells were associated with cell survival 
and growth factors (ie. FOXO1, NOTCH1, and EGFR), while molecules involving in interferon 
signaling and Type I IFN responses (ie. STAT1, IFNA2, IFNB1) were enriched in memory 
CD8+T cells derived from Blood, BM and spleen (Table 3-5). Therefore, LN memory CD8+T 
cells exhibit a distinct transcriptional program marked by quiescence and survival while memory 
CD8+T cells in BM, spleen, and blood exhibit cellular signatures associated with effector 




Table 3-5. Potential upstream regulators of LN memory CD8+ T cells 
Upstream Regulators1 Molecule Type Direction in LN Z-score 
Ifnar group Inhibited -3.27 
IFN alpha/beta group Inhibited -2.30 
IFNA2 cytokine Inhibited -2.74 
IFNB1 cytokine Inhibited -2.65 
STAT1 transcription regulator Inhibited -2.67 
STAT3 transcription regulator Activated 1.48 
FOXO1 transcription regulator Activated 0.72 
NOTCH1 transcription regulator Activated 3.16 
Vegf group Activated 3.47 
HGF growth factor Activated 3.11 
EGFR kinase Activated 3.48 
 
1Upstream regulators were identified as significantly enriched (p-value < 0.05). Z-score indicates 
predicted direction of regulator activity in memory CD8+ T cells from LN (inhibited or activated) 
compared to Blood, BM, and Spleen. Results were obtained from Ingenuity Pathway Analysis 
software (QIAGEN) by comparison of memory T cells isolated from different tissues (LN vs. 




IFN-I drives loss of TCF-1 expression in human memory CD8+ T cells 
Following from the observation that IFN-I signaling was identified as a potential 
upstream regular, specifically predicted as down regulated in LN memory T cells, we wondered 
how IFN-I regulates the proliferation of TCF-1+ CD8+ T cells in humans. We collected memory 
CD8+ T cells (CCR7- CD45RA- CD8+) from lymph nodes. The cells were labeled with 
Efluor450 and stimulated with anti-CD3 and anti-CD28 in the presence of absence of IFN-I as 
shown in Figure 3-13A.  Interestingly, global proliferation was unaffected by IFN-I over the 5-
day period (Figure 3-13B). However, there was a significant reduction in the number of 
proliferating cells that retained TCF-1 expression following IFN-I treatment (Figure 3-13C). 




Figure 3-13. IFN-I opposes maintenance of TCF-1 expression in proliferating CD8+ T cells. 
(A) Experimental scheme for human lymph node CD8+ memory T cell treatment. (B) Percent of 
memory T cells from lymph nodes that divided in response to stimulation with CD3/CD28 
antibodies treated with or without IFN-α/β. (C) Expression of TCF-1 with cell divisions of 
memory T cells from lymph nodes in response to stimulation with CD3/CD28 antibodies treated 
with or without IFN-α/β, measured by percent positive. Statistical comparison was performed 





Table 3-6. List of organ donors used in this study.  
Bld = Blood, Spl = Spleen, BM= Bone  Marrow, LN= Lymph nodes.
 
Donor Age Sex Tissue Data 
129 55 M Bld, BM, Spl, LN, Lung Flow 
153 46 M Bld, BM, Spl, LN, Lung Flow 
176 64 M Bld, BM, Spl, LN, Lung Flow 
180 55 F Bld, BM, Spl, LN, Lung Flow 
181 46 M BM, LN, Spl Flow 
182 46 M Bld, BM, Spl, LN, Lung Flow 
194 53 M BM, LN Flow 
199 50 M BM, LN Flow 
213 2 F Bld, BM, Spl, LN, Lung Flow 
219 50 M Bld, BM, Spl, LN, Lung Flow 
225 54 M BM, LN Flow 
227 26 M BM, LN Flow 
228 69 M Bld, BM, Spl, LN, Lung Flow 
229 32 M BM, LN Flow, RNA-seq 
230 52 F BM, LN Flow 
232 53 M Bld, BM, Spl, LN, Lung Flow 
233 26 F Bld, BM, Spl, LN, Lung Flow, TCR-seq 
236 75 F Bld, BM, Spl, LN, Lung Flow 
244 36 M Bld, BM, Spl, LN, Lung Flow 
245 50 F Bld, BM, Spl, LN, Lung Flow 
249 49 M Bld, BM, Spl, LN, Lung Flow 
251 9 M Bld, BM, Spl, LN, Lung Flow 
254 49 F Bld, BM, Spl, LN, Lung Flow 
255 63 F BM, LN TCR-seq 
259 46 M Bld, BM, Spl, LN, Lung Flow 
262 73 M Bld, BM, Spl, LN, Lung Flow 
273 67 F Bld, BM, Spl, LN, Lung Flow 
275 31 M Bld, BM, Spl, LN, Lung Flow 
277 21 M BM, LN Flow 
280 26 M BM, LN RNA-seq, TCR-seq 
287 34 M Bld, BM, Spl, LN, Lung Flow, RNA-seq, TCR-seq 
288 32 M Bld, BM, Spl, LN, Lung Flow 
289 58 M Bld, BM, Spl, LN, Lung Flow 
291 26 F Bld, BM, Spl, LN, Lung Flow 
293 53 F BM, LN Flow 
297 59 F Bld, BM, Spl, LN, Lung Flow 
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299 20 M Bld, BM, Spl, LN, Lung Flow, TCR-seq 
302 56 M Bld, BM, Spl, LN, Lung Flow 
304 68 M BM, LN Flow 
305 28 F Bld, BM, Spl, LN, Lung Flow 
306 71 F Bld, BM, Spl, LN, Lung Flow 
307 18 M Bld, BM, Spl, LN, Lung Flow 
308 68 M Bld, BM, Spl, LN, Lung Flow 
309 45 F Bld, BM, Spl, LN, Lung Flow 
310 20 F Bld, BM, Spl, LN, Lung Flow 
326 29 M BM,LN Flow 
328 52 M BM,LN Flow 
331 32 M BM,LN Flow 
332 38 M Bld, BM, Spl, LN, Lung CYTOF 
333 19 M Bld, BM, Spl, LN, Lung CYTOF 
334 64 M Bld, BM, Spl, LN, Lung Flow 
335 23 M Bld, BM, Spl, LN, Lung CYTOF, Flow 
336 49 M Bld, BM, Spl, LN, Lung Flow 
337 76 M Bld, BM, Spl, LN, Lung Flow 
342 59 M Bld, BM, Spl, LN, Lung CYTOF 




Section 3.3 Discussion 
 The majority of human T cells are found in lymphoid sites, although their function and 
relationship to blood T cells has been challenging to assess using conventional sampling. By 
examination of T cell subsets in human blood and tissue sites of individual organ donors, we 
demonstrate here that LN memory CD8+T cells exhibit organ-specific profiles not found in 
blood, other lymphoid (BM, spleen) or mucosal tissues. Specifically, LN memory T cells exhibit 
transcriptional and phenotypic signatures associated with quiescence, high proliferative capacity 
and enhanced TCR diversity compared to memory T cells in blood and other tissues which are 
enriched for effector function and inflammatory signatures. Our findings reveal that human LN 
serve as reservoirs for long-term maintenance of functional T cell responses and an important 
source for targeting in vaccines and immunotherapies. 
  We demonstrate here that memory T cells derived from LN maintain expression of the 
TCF-1 transcription factor associated with quiescence over decades of adult life. These results 
suggest differential priming of memory CD8+T cells that persist in LN compared to those that 
migrate and take up residence in other tissue sites. Recent studies in a mouse model of influenza 
infection showed differential TCF-1 expression by T cells primed in different LN sites: in the 
lung-draining LN there was rapid downregulation of TCF-1 expression, while TCF-1 expression 
was maintained by T cells primed to proliferate in a non-draining LN site, with reduced antigen 
and inflammatory signals.[168] We propose that memory T cells in LNs do not receive the full 
differentiation signals to promote LN egress and migration to the tissue site of infection, and 
therefore get retained and maintained with increased TCF-1 expression.  
 LN memory CD8+T cells exhibit a transcriptional and protein signature with homology to 
a mouse memory CD8+T cell subset generated during chronic virus infection which maintained 
functional capacity, proliferated and mediated viral clearance in response to anti-PD-1 
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therapy.[154, 248, 303, 316, 317] Whether human LN memory T cells provide similar roles in 
controlling chronic viral infection remains to be established; however, we previously showed 
that certain individuals with persistent cytomegalovirus (CMV) infection maintained CMV-
specific CD8+T cells exclusively in LN, but not in circulation or other tissue sites[10]. 
Additionally, HIV-specific resident memory CD8+T cells were recently characterized in human 
LN.[275] These results suggest that human LNs can maintain reservoirs of anti-viral memory T 
cells.  Moreover, the maintenance of higher TCR diversity among LN memory CD8+T cells 
suggest a unique role in maintaining functional T cell immunity over the lifespan with the 
potential to respond to different pathogens, of potential importance for targeting in vaccines.    
More recent studies have found that in human lymph nodes of HIV-infected patients, 
CD8+ TRM appeared to be transcriptionally similar to bona fide mouse CD8+TRM, with 
phenotypic, functional and epigenetic signatures associated with residency [275]. Recent studies 
in secondary lymphoid tissues of mice and humans demonstrate that CD4+ and CD8+ TRM also 
take up residence in lymph nodes and spleen [7, 275-277]. However it remains unclear whether 
CD69+ T cells in lymph nodes are truly resident or maintained there temporarily with the ability 
to re-enter circulation. Importantly, CD69 expression by TCM cells does not necessarily confer 
tissue residence [211]. Additionally, CXCR4 is expressed on central memory T cells. 
Interestingly, in mouse model, CXCR4-deficient cells have impaired memory cell maintenance 
due to defective homeostatic proliferation, but are still able to re-expand and renew following 
antigen re-challenge. Perhaps CXCR4 plays a similar role in human T cell maintenance in lymph 
nodes, however this is yet to be tested.[322] Interestingly, in both human and mouse, LN TRM 
displayed increased proliferative potential; either in response to TCR stimulation in vitro or to 
checkpoint blockade immunotherapy respectively, denoting similar functional capacities. In 
humans, LN TRM populations also displayed high T cell receptor diversity compared to T cells 
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in BM, consistent with the possibility that these LN TRM may be reservoirs for protection 
against multiple antigens. If human LN TRM are similar to mouse, perhaps they also carry the 
ability to proliferate and re-enter circulation in response to checkpoint blockade therapy, an 
important line of research for future investigations. LN TRM may represent a niche for long term 
TRM maintenance and quiescence. Whether this is due mainly to sequestration of specific T cell 
populations from antigen within microanatomical niches of lymphoid tissue, or tissue specific 
signals for maintenance of these phenotypes remains unknown and an important area of 
investigation. These results are summarized by a graphical representation in Figure 3-14.  
 The mechanisms by which human LN maintain this distinct TCF-1+ memory subset are 
not known, although there is evidence that protection from IFN signaling may play a role. 
Transcriptionally, LN memory CD8+T cells exhibited downregulation of pathways involved 
type-1 interferon (IFN) signaling which were correspondingly upregulated in blood, BM, and 
spleen memory T cells. Furthermore, inhibiting type-1 IFN signaling during viral infection in 
mice, led to higher accumulation of TCF-1+ T cells in a T cell intrinsic manner.[154] Further, we 
found exogenous type-1 IFNs oppose the maintenance of TCF-1 expression in proliferating 
human T cells during TCR driven stimulation. Compared to mucosal and barrier sites which are 
constantly exposed to diverse microbial antigens, human LN are likely exposed to lower levels 
of inflammation and antigens, and thus provide protective niches for long-term maintenance of 
functional memory T cells.   
 Our results suggest that LN memory CD8+T cells are a potentially important source of 
functional T cells to target in immunotherapies for anti-tumor immunity. Given their homology 
to the mouse subset, LN memory T cells could analogously provide a source of highly 
proliferative T cells to respond to anti-PD-1 therapy. Memory T cells in LN draining sites of 
tumors could therefore be targeted for expansion of highly functional T cells to infiltrate the 
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tumor site. Isolation of high potential memory subsets from blood has been a matter of 
considerable investigation in the field of adoptive cellular therapy, to optimize the persistence of 
expanded, differentiated cell populations[323], and to serve as a source of cells for transfection 
of targeted molecules for therapies in hematopoietic malignancies.[324] We propose that LN 
could be a more optimal source for memory T cells for adoptive immunotherapies compared to 
blood, based on their increased proliferative potential, and capacity to respond to diverse 
antigens.    
 In summary, our results provide evidence for long-term persistence of a distinct, organ-
specific T cell subset in human LN. These findings demonstrate that tissue localization is a major 
determinant for human T cell differentiation, with LN providing long-term reservoirs for 




Figure 3-14. Summary of findings on human lymph node memory T cells. 
We found lymph node memory T cells (CD3+CD8+CCR7-CD45RO+CD45RA-CD69+/-) 
differentially express several surface molecules and intracellular proteins relative to memory T 
cells in blood, BM, spleen and lung. Arrows indicate direction of differential expression in LN 
CD8+ memory cells (green = upregulated, red = downregulated). Memory T cells in LN also 







CHAPTER 4: Subset-specific compartmentalization of human T cell receptor repertoires 
across blood and tissue sites 
 
ABSTRACT: 
T cell antigen receptor (TCR) activation leads to generation of diverse effector and 
memory subsets essential for immune protection. Here we investigated the relatedness of human 
CD4+ and CD8+ T cell subsets comprising central memory (TCM), effector memory (TEM), 
tissue-resident memory (TRM) and terminal effector cells (TEMRA) in diverse sites including 
blood, BM, Spl, LN and lungs by sequencing the b-chain of the TCR. We found that patterns of 
clonal expansion and distribution were predominantly subset-specific and to a lesser extent 
tissue-specific. Among subset-specific properties of T cells, we found that repertoires of 
CD4+TCM were the most diverse and CD8+TEMRA were the least diverse. We looked for 
tissue-specific features and found that repertories of CD4+ and CD8+ T cells were more diverse 
in LN compared to BM, indicating tissue-specific reservoirs for T cells with previously low and 
high turnover respectively. We found substantial sharing of TEM and TRM cell clones across 
tissue sites; particularly abundant clones, suggesting systemic responses represent a significant 
portion of the T cell response in tissues. In summary, these results indicate the degree of clone 
sharing and diversity across sites is largely subset-specific, with implications for immune 











Section 4.1 Introduction 
 The ability of T lymphocytes to mediate protective immunity against pathogens depends 
on their specific recognition of pathogen-derived antigens, and their ability to migrate to diverse 
sites of pathogen encounter[179, 233]. Naïve T cells develop in the thymus and populate 
lymphoid tissues. Each naïve T cell expresses a unique T cell antigen receptor (TCR) comprised 
of a and b chains with variable CDR3 domains generated by gene rearrangement of TCRa and 
TCRb gene segments during T cell development. Naive T cells display a vast diversity of T cell 
receptor (TCR) proteins, conferring specificity to many possible antigen exposures with a 
theoretical diversity of ~5x1011 distinct b-chains [17]. When activated, antigen-specific naïve T 
cells clonally expand and differentiate into short-lived effector cells which acquire broad homing 
capacities for tissue-targeted migration. A fraction of these clonally expanded populations also 
develop into subsets of circulating and tissue-resident memory T cells that persist long-term and 
maintain protective responses. Mechanisms for the generation of circulating versus tissue-
resident memory T cells and their lineage relationship remains unclear. 
 The pathways for differentiation of antigen-specific effector and memory T cells have 
been studied primarily in TCR-transgenic mouse models, where epitope-specific clones of T 
cells can be tracked. These studies have revealed that single clones of T cells can give rise to 
multiple lineages of effector and memory T cells [160, 162, 325], indicating that single T cell 
clones exhibit functional diversification during clonal expansion. However, it is not known 
whether certain clones or subsets are preferentially maintained or how tissue distribution is 
regulated on the clonal level.  In humans, dissecting the clonal relatedness of T cell subsets has 
been challenging. Ex vivo studies have revealed that TCM can give rise to TEM phenotypes 
when activated [99]; however, assessing relatedness in vivo is limited by sampling constraints, 
with most studies on peripheral blood, representing only a small fraction (~3%) of total T cells 
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[4]. Assessing the relatedness of human T cell subsets in tissues and circulation has not been 
accomplished.  
 The primary subsets of CD4+ and CD8+ T cells in humans include central memory 
(TCM), effector memory (TEM), tissue-resident memory (TRM) and terminally differentiated 
effector cells (TEMRA).[99] TCM are distinguished from TEM based on expression of CCR7 
and lymphoid homing capacities, while TRM are defined by expression of CD69 and CD103 
which both function in tissue retention [7, 8, 121]. In humans, TRM cells are a non-circulating 
subset absent from peripheral blood, and have been identified in diverse sites such as bone 
marrow (BM), spleen (Spl), lymph nodes and lung and have distinct transcriptional properties 
compared to circulating T cells in blood and tissue to TRM [6, 8, 194, 196, 240, 275]. Although 
the role of TRM in human immune responses is not yet defined, they are implicated in a number 
of tissue-localized disease states, such as psoriasis in the skin and are associated with tumors 
specific to skin, liver, lung and breast tissues[326-329]. In humans little is known about how 
populations of previously activated T cells are distributed and maintained in blood and tissue 
sites throughout the body, important for optimal targeting in immunotherapies. 
 Next generation sequencing approaches have enabled the analysis of clonal populations 
within human blood and biopsy samples to high depth[330]. Here, we used CDR3 sequencing 
(along with sequencing V and J gene segments) in conjunction with validated computational 
approaches for identifying T cell clones to understand how clonally expanded effector and 
memory populations were maintained in human blood and tissue sites[309, 310].  We seek to 
understand the relatedness of human effector and memory T cell subsets on the basis of TCR 
sequence diversity and overlap. From diversity analysis we found that effector and memory 
subsets are maintained in a hierarchy of most diverse to least diverse (TCM > TEM and TRM > 
TEMRA) that is largely conserved across tissues and CD4+ and CD8+ T cell lineages. Overlap 
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analysis revealed the low and high relatedness of TCM and TEMRA cells respectively and this 
was highly conserved across tissues; in contrast, we found the relatedness of TEM and TRM was 
more dynamic across tissues. Taken together, these results reveal insights into human T cell 
differentiation in tissues and subset-specific patterns across sites.  
Section 4.2 Results 
Identifying T cell clones in lymphoid and non-lymphoid tissues 
 We isolated populations of previously primed T cell subsets comprising TCM, TEM, 
TEMRA and TRM cells from blood and tissue sites of 8 individual organ donors, along with 
corresponding populations in the blood of three living donors, resulting in 124 different 
biological samples ( Figure 4-1A). From two individuals we obtained five sites (bone marrow 
(BM), spleen, lung and lymph nodes draining the lung (LN), +/- blood) and six cell subsets 
(gating strategy in Figure 4-2). The age and characteristics of individual donors are listed in 
Table 4-1. Total DNA was isolated from each purified cell subset and divided into two equal 
parts (biological replicates) from which separate PCR and library preparations were performed 
and sequenced (Figure 4-1B) from 239 samples in total (the amount of DNA per sample is listed 
in Table 4-2).  
 We used an analysis and storage tool designated ImmuneDB [309, 310], to identify V and 
J gene segments and clone counts from the sequencing data [309, 310]. We defined clonally 
related sequence as those which shared V and J gene segments and CDR3 amino acid sequence 
and we required that a specific sequence be detected at least twice in order to be designated a 
clone to reduce over estimation of clones due to sequencing errors.[331] We detected an average 
of 5,860 clones per CD4+ T cell sample and 3,438 clones per CD8+ T cell sample across all 
individuals (see Table 4-2 for individualized data).  
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Figure 4-1. Overview of samples collected and experimental design for TCR sequencing of 
T cell populations from human lymphoid and non-lymphoid tissues. 
 A) Origin and identity of T cell subsets purified from 11 individuals from blood and tissue sites 
including CD4+ TCM (central memory), CD4+ TEM (effector memory), CD4+ TRM (resident 
memory), and CD8+ TEMRA (terminally differentiated effector) and CD8+ TEM, CD8+ TRM 
cells. B) Schematic for sample preparation and TCR clone determination.  DNA was extracted 
from purified memory T cells and subsequently separated into two equal parts (replicates) for 
sequencing. After PCR (with primers targeting the TCR Vb-chain) and sequencing, the data 
were processed with ImmuneDB (13) to identify clones by unique V and J gene segment pairing 





Figure 4-2. Gating strategy for T cell subsets isolated for TCR sequencing.  
First, we identified lymphocytes by FSC-A and SSC-A, singlets by trigger cell width (not 
shown), and T cells by CD3+. Subsequently, we fractionated total T cells by CD4+CD8- or 
CD8+CD4- cells (negative gates not shown). Next, CD4+ T cells were gated on to identify TCM 
cells (CCR7+CD45RA-) and CD8+ T cells were gated on to identify TEMRA cells 
(CCR7+CD45RA+). Finally, both CD4+ and CD8+ T cells were further gated to identify TEM 






Table 4-1. Age and characteristics of donors in this study.  
Information about individual organ donors used in this study including sex (M=male, F=female), 
age, cause of death (COD), and serology for chronic viruses CMV and EBV. N/A= Not 
applicable.  
 
Individual Donor Age Sex Race COD CMV EBV 
1 383 39 M White Head trauma 0 1 
2 324 56 M White Stroke 1 1 
3 299 29 M Hispanic Anoxia 1 1 
4 255 63 F Hispanic Stroke 1 1 
5 233 26 F White Anoxia 0 1 
6 287 34 M White Head trauma 1 1 
7 280 26 M White Anoxia 0 1 
8 229 32 M White Anoxia 0 1 
9 LD1 55  F White N/A - - 
10 LD2 32 F White N/A - - 





Table 4-2. Number of T cell clones identified per sample by TCR sequencing. 
The number of T cell clones identified by TCR sequencing for individual samples. Sample name 
indicates the donor number, anatomical site, lineage, subset, and replicate number of each 
sample respectively (example: D229_BM_CD4_TEM_1).
id sample name clones DNA (ng) 
1 D229_BM_CD4_TEM_1 6413 23 
2 D229_BM_CD4_TEM_2 5458 23 
3 D229_BM_CD4_TRM_1 4417 11 
4 D229_BM_CD4_TRM_2 4609 11 
5 D229_BM_CD8_TEM_1 4603 23 
6 D229_BM_CD8_TEM_2 4732 23 
7 D229_BM_CD8_TRM_1 5637 23 
8 D229_BM_CD8_TRM_2 5102 23 
9 D229_LN_CD4_TEM_1 6114 23 
10 D229_LN_CD4_TEM_2 8482 23 
11 D229_LN_CD4_TRM_1 5999 23 
12 D229_LN_CD4_TRM_2 7489 23 
13 D229_LN_CD8_TEM_1 5403 23 
14 D229_LN_CD8_TEM_2 4809 23 
15 D229_LN_CD8_TRM_1 5285 23 
16 D229_LN_CD8_TRM_2 4938 23 
17 D233_BM_CD4_TEM_1 7054 67 
18 D233_BM_CD4_TEM_2 5162 67 
19 D233_BM_CD4_TRM_1 6543 67 
20 D233_BM_CD4_TRM_2 4373 67 
21 D233_BM_CD8_TEM_1 2972 67 
22 D233_BM_CD8_TEM_2 2798 67 
23 D233_BM_CD8_TRM_1 3455 67 
24 D233_BM_CD8_TRM_2 2489 67 
25 D233_LN_CD4_TEM_2 7570 67 
26 D233_LN_CD4_TRM_1 6064 67 
27 D233_LN_CD4_TRM_2 6968 67 
28 D233_LN_CD8_TEM_1 4093 67 
29 D233_LN_CD8_TEM_2 3161 67 
30 D233_LN_CD8_TRM_1 4556 67 
31 D233_LN_CD8_TRM_2 3411 67 
32 D233_Spl_CD4_TEM_1 4520 67 
33 D233_Spl_CD4_TEM_2 6931 67 
34 D233_Spl_CD4_TRM_1 6622 67 
35 D233_Spl_CD4_TRM_2 6521 67 
36 D233_Spl_CD8_TEM_1 3887 67 
37 D233_Spl_CD8_TEM_2 3018 67 
38 D233_Spl_CD8_TRM_1 2353 67 
39 D233_Spl_CD8_TRM_2 4359 67 
40 D255_BM_CD4_TEM_1 1816 46 
41 D255_BM_CD4_TEM_2 3494 46 
42 D255_BM_CD4_TRM_1 4051 46 
43 D255_BM_CD4_TRM_2 5623 46 
44 D255_BM_CD8_TEM_1 354 46 
45 D255_BM_CD8_TEM_2 2836 46 
46 D255_BM_CD8_TRM_1 2573 46 
47 D255_BM_CD8_TRM_2 3709 46 
48 D255_LN_CD4_TEM_1 4952 46 
49 D255_LN_CD4_TEM_2 6681 46 
50 D255_LN_CD4_TRM_1 6357 46 
id sample name clones DNA (ng) 
51 D255_LN_CD4_TRM_2 8791 46 
52 D255_LN_CD8_TEM_1 2559 46 
53 D255_LN_CD8_TEM_2 3735 46 
54 D255_LN_CD8_TRM_1 1887 46 
55 D255_LN_CD8_TRM_2 2731 46 
56 D255_Spl_CD4_TEM_1 2221 46 
57 D255_Spl_CD4_TEM_2 3379 46 
58 D255_Spl_CD4_TRM_1 5144 46 
59 D255_Spl_CD4_TRM_2 12088 46 
60 D255_Spl_CD8_TEM_1 1791 46 
61 D255_Spl_CD8_TEM_2 2588 46 
62 D255_Spl_CD8_TRM_1 2163 46 
63 D255_Spl_CD8_TRM_2 3163 46 
64 D280_BM_CD4_TEM_1 6619 26 
65 D280_BM_CD4_TEM_2 7517 26 
66 D280_BM_CD4_TRM_1 1661 26 
67 D280_BM_CD4_TRM_2 1398 26 
68 D280_BM_CD8_TEM_1 1803 26 
69 D280_BM_CD8_TEM_2 2402 26 
70 D280_BM_CD8_TRM_1 2172 26 
71 D280_BM_CD8_TRM_2 2012 26 
72 D280_LN_CD4_TEM_1 2313 26 
73 D280_LN_CD4_TEM_2 1768 26 
74 D280_LN_CD4_TRM_1 3240 26 
75 D280_LN_CD4_TRM_2 3597 26 
76 D280_LN_CD8_TEM_1 2453 26 
77 D280_LN_CD8_TEM_2 2202 26 
78 D280_LN_CD8_TRM_1 1821 26 
79 D280_LN_CD8_TRM_2 2187 26 
80 D287_BM_CD4_TEM_1 10379 59 
81 D287_BM_CD4_TEM_2 11459 59 
82 D287_BM_CD4_TRM_1 5917 50 
83 D287_BM_CD4_TRM_2 6650 50 
84 D287_BM_CD8_TEM_1 3724 69 
85 D287_BM_CD8_TEM_2 4205 69 
86 D287_BM_CD8_TRM_1 6653 35 
87 D287_BM_CD8_TRM_2 6051 35 
88 D287_LN_CD4_TEM_1 12303 63 
89 D287_LN_CD4_TEM_2 11737 63 
90 D287_LN_CD4_TRM_1 11072 73 
91 D287_LN_CD4_TRM_2 12688 73 
92 D287_LN_CD8_TEM_1 7935 55 
93 D287_LN_CD8_TEM_2 8456 55 
94 D287_LN_CD8_TRM_1 4454 14 
95 D287_LN_CD8_TRM_2 5407 14 
96 D299_BM_CD4_TEM_1 4608 41 
97 D299_BM_CD4_TEM_2 4005 41 
98 D299_BM_CD4_TRM_1 5815 41 
99 D299_BM_CD4_TRM_2 5627 41 
100 D299_BM_CD8_TEM_1 2924 41 
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id sample name clones DNA (ng) 
101 D299_BM_CD8_TEM_2 1425 41 
102 D299_BM_CD8_TRM_1 3691 41 
103 D299_BM_CD8_TRM_2 3631 41 
104 D299_LN_CD4_TEM_1 4493 41 
105 D299_LN_CD4_TEM_2 4443 41 
106 D299_LN_CD4_TRM_1 4297 41 
107 D299_LN_CD4_TRM_2 3846 41 
108 D299_LN_CD8_TEM_1 4314 41 
109 D299_LN_CD8_TEM_2 4515 41 
110 D299_LN_CD8_TRM_1 5187 41 
111 D299_LN_CD8_TRM_2 5018 41 
112 D299_Spl_CD4_TEM_1 4561 41 
113 D299_Spl_CD4_TEM_2 4431 41 
114 D299_Spl_CD4_TRM_1 4921 41 
115 D299_Spl_CD4_TRM_2 4654 41 
116 D299_Spl_CD8_TEM_1 4008 41 
117 D299_Spl_CD8_TEM_2 3834 41 
118 D299_Spl_CD8_TRM_1 4270 41 
119 D299_Spl_CD8_TRM_2 4321 41 
120 D324_BM_CD4_TCM_1 4964 15 
121 D324_BM_CD4_TCM_2 4995 15 
122 D324_BM_CD4_TEM_1 5166 15 
123 D324_BM_CD4_TEM_2 4849 15 
124 D324_BM_CD4_TRM_1 4075 15 
125 D324_BM_CD8_TEM_1 831 12 
126 D324_BM_CD8_TEM_2 1926 12 
127 D324_BM_CD8_TEMRA_1 666 15 
128 D324_BM_CD8_TEMRA_2 658 15 
129 D324_BM_CD8_TRM_1 1544 11 
130 D324_BM_CD8_TRM_2 2466 11 
131 D324_LN_CD4_TCM_1 5421 15 
132 D324_LN_CD4_TCM_2 5120 15 
133 D324_LN_CD4_TEM_1 5872 15 
134 D324_LN_CD4_TEM_2 5505 15 
135 D324_LN_CD4_TRM_1 5565 15 
136 D324_LN_CD4_TRM_2 5166 15 
137 D324_LN_CD8_TEM_1 3697 13 
138 D324_LN_CD8_TEM_2 3274 13 
139 D324_LN_CD8_TRM_1 2533 15 
140 D324_LN_CD8_TRM_2 2668 15 
141 D324_Lung_CD4_TCM_1 3578 15 
142 D324_Lung_CD4_TCM_2 3553 15 
143 D324_Lung_CD4_TEM_1 4550 15 
144 D324_Lung_CD4_TEM_2 4144 15 
145 D324_Lung_CD4_TRM_1 4575 15 
146 D324_Lung_CD4_TRM_2 4439 15 
147 D324_Lung_CD8_TEM_2 3898 15 
148 D324_Lung_CD8_TEMRA_1 1027 15 
149 D324_Lung_CD8_TEMRA_2 1314 15 
150 D324_Lung_CD8_TRM_1 3577 15 
151 D324_Lung_CD8_TRM_2 3158 15 
152 D324_Spl_CD4_TCM_1 5965 15 
153 D324_Spl_CD4_TCM_2 5570 15 
154 D324_Spl_CD4_TEM_1 6169 15 
155 D324_Spl_CD4_TEM_2 5920 15 
156 D324_Spl_CD4_TRM_1 6161 15 
157 D324_Spl_CD4_TRM_2 6043 15 
158 D324_Spl_CD8_TEM_1 5072 15 
159 D324_Spl_CD8_TEM_2 4525 15 
160 D324_Spl_CD8_TEMRA_1 1365 15 
161 D324_Spl_CD8_TEMRA_2 1128 15 
162 D324_Spl_CD8_TRM_1 3190 15 
id sample name clones DNA (ng) 
163 D324_Spl_CD8_TRM_2 635 15 
164 D383_Bld_CD4_TCM_1 5092 33 
165 D383_Bld_CD4_TCM_2 4889 33 
166 D383_Bld_CD4_TEM_1 3480 50 
167 D383_Bld_CD4_TEM_2 3707 50 
168 D383_Bld_CD8_TEM_1 4605 20 
169 D383_Bld_CD8_TEM_2 4865 20 
170 D383_Bld_CD8_TEMRA_1 910 2 
171 D383_Bld_CD8_TEMRA_2 661 2 
172 D383_BM_CD4_TCM_1 7022 50 
173 D383_BM_CD4_TCM_2 5628 50 
174 D383_BM_CD4_TEM_1 6469 50 
175 D383_BM_CD4_TEM_2 6224 50 
176 D383_BM_CD4_TRM_1 4521 50 
177 D383_BM_CD4_TRM_2 4948 50 
178 D383_BM_CD8_TEM_1 1115 50 
179 D383_BM_CD8_TEM_2 3475 50 
180 D383_BM_CD8_TEMRA_1 2610 50 
181 D383_BM_CD8_TEMRA_2 2192 50 
182 D383_BM_CD8_TRM_1 2640 50 
183 D383_BM_CD8_TRM_2 2532 50 
184 D383_LN_CD4_TCM_1 8538 50 
185 D383_LN_CD4_TCM_2 5032 50 
186 D383_LN_CD4_TEM_1 13606 50 
187 D383_LN_CD4_TEM_2 11627 50 
188 D383_LN_CD4_TRM_1 11556 50 
189 D383_LN_CD4_TRM_2 4359 50 
190 D383_LN_CD8_TEM_1 6416 50 
191 D383_LN_CD8_TEM_2 6095 50 
192 D383_LN_CD8_TRM_1 6643 50 
193 D383_LN_CD8_TRM_2 3674 50 
194 D383_Lung_CD4_TCM_1 6870 50 
195 D383_Lung_CD4_TCM_2 7105 50 
196 D383_Lung_CD4_TEM_1 5334 50 
197 D383_Lung_CD4_TEM_2 5058 50 
198 D383_Lung_CD4_TRM_1 5963 50 
199 D383_Lung_CD4_TRM_2 3757 50 
200 D383_Lung_CD8_TEM_1 9858 50 
201 D383_Lung_CD8_TEM_2 9715 50 
202 D383_Lung_CD8_TEMRA_1 2557 50 
203 D383_Lung_CD8_TEMRA_2 2137 33 
204 D383_Lung_CD8_TRM_1 3787 50 
205 D383_Lung_CD8_TRM_2 3845 50 
206 D383_Spl_CD4_TCM_1 7641 50 
207 D383_Spl_CD4_TCM_2 6868 50 
208 D383_Spl_CD4_TEM_1 8150 50 
209 D383_Spl_CD4_TEM_2 6816 50 
210 D383_Spl_CD4_TRM_1 7139 50 
211 D383_Spl_CD4_TRM_2 7094 50 
212 D383_Spl_CD8_TEMRA_1 3364 50 
213 D383_Spl_CD8_TEMRA_2 2372 50 
214 D383_Spl_CD8_TMEM_1 5933 50 
215 D383_Spl_CD8_TMEM_2 2116 50 
216 LD1_Bld_CD4_TCM_1 10234 65 
217 LD1_Bld_CD4_TCM_2 6699 65 
218 LD1_Bld_CD4_TEM_1 5785 65 
219 LD1_Bld_CD4_TEM_2 5184 65 
220 LD1_Bld_CD8_TEM_1 2581 65 
221 LD1_Bld_CD8_TEM_2 2607 65 
222 LD1_Bld_CD8_TEMRA_1 1597 65 
223 LD1_Bld_CD8_TEMRA_2 1666 65 
224 LD2_Bld_CD4_TCM_1 9024 65 
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id sample name clones DNA (ng) 
225 LD2_Bld_CD4_TCM_2 8857 65 
226 LD2_Bld_CD4_TEM_1 7488 65 
227 LD2_Bld_CD4_TEM_2 4919 65 
228 LD2_Bld_CD8_TEM_1 7295 65 
229 LD2_Bld_CD8_TEM_2 6790 65 
230 LD2_Bld_CD8_TEMRA_1 5929 65 
231 LD2_Bld_CD8_TEMRA_2 3834 65 
232 LD3_Bld_CD4_TCM_1 6689 65 
id sample name clones DNA (ng) 
233 LD3_Bld_CD4_TCM_2 6654 65 
234 LD3_Bld_CD4_TEM_1 9012 65 
235 LD3_Bld_CD4_TEM_2 7883 65 
236 LD3_Bld_CD8_TEM_1 2305 65 
237 LD3_Bld_CD8_TEM_2 2507 65 
238 LD3_Bld_CD8_TEMRA_1 1181 65 






Evaluating diversity of T cell subsets from blood and tissues  
 We initially assessed the extent of TCR diversity and clonal expansion within each subset 
and tissue. To analyze the diversity of T cell clones within each sample we ranked all the clones 
from most expanded to least, and grouped clones based on their abundance into top 1-10, 11-100, 
101-1,000, and 1,0001+ clones. We then calculated the percentage of the total sample repertoire 
that was represented within each clone ranked group.  There were marked differences between 
CD4+ and CD8+ T cell subsets in terms of their overall clonal abundance and the proportion of 
total T cells that were represented by top clones. For CD4 T cells, the top 10 clones comprised  
2-20% of total T cell repertoire; by contrast, for CD8 T cells, the top 10 clones comprised up to 
80% of total T cell repertoire (Figure 4-3).  
The proportion of the repertoire represented by the top 10 clones was consistent between 
subsets within CD4 and CD8 lineages. By different cell subsets, we found considerable 
differences between subsets that were conserved across tissues; the percentage of the top 10 
clones for all subsets were as follows:  ~5% for CD4+ TCM, ~25% for CD4+ TEM and TRM, 
between 30-75% for CD8+ TEM and TRM, and >75% for CD8+ TEMRA. The remaining three 
groups (top 11-100, 101-1,000, and 1,0001+ clones), followed similar patterns to the first groups 
(Figure 4-3). Remarkably, both individuals exhibited a similar hierarchy of clonal expansions 
from highest to lowest: TEMRA > TEM and TRM > TCM. We could not acquire blood for all 
subsets from organ donors, therefore we obtained blood from three living volunteers and found 
similar results; the percentage of the top clonal expansions accounted for ~5% of CD4+ TCM, 






Figure 4-3. T cell clone abundances attributed mainly to subset differences.  
A) Proportion of top n clones per sample for CD4+ (left) and CD8+ (right) memory T cells 
subsets (TCM, TEM, TRM and TEMRA) from two individual donors 324 (top) and 383 
(bottom) and B) same from three live blood donors. C) Clonality across individuals by cell 
subset (all tissues combined) (CD4+: TCM, n=12; TEM, n=26; TRM, n=23; CD8+: TEM, n=25; 
TRM, n=22; TEMRA, n=10). D) or by tissue site (all subsets combined) for CD4+ and CD8+ T 
cells. (CD4+: Bld, n=8, BM, n=18; Spl, n=12; Lung, n=6; LN, n=17; CD8+: Bld, n=8; BM, n=18; 










 As another measure of TCR repertoire diversity, we calculated clonality, ranging from 0 
(least clonally expanded; maximally diverse) to 1 (monoclonal, no diversity), from sequences 
derived from all 11 individuals (see methods). We compared clonality of different T cell subsets 
(from all tissues together) and we found clonality from highest to lowest was: CD8+ TEMRA > 
CD8+ TEM and TRM > CD4+ TEM and TRM > CD4+ TCM, consistent with the diversity  
analysis above. Next we looked for tissue specific differences, and we found that if we analyzed 
all subsets together, that clonality of T cells in LNs was lower than BM for both CD4+ and CD8+ 
T cells (Figure 4-3). In summary, the dominant factor determining clonality and diversity was 
subset, with CD8+TEMRA the most expanded/least diverse and CD4+ TCM, the least 
expanded/most diverse. Importantly, this subset clonality was independent of tissue. There were 




Comparing DNA and RNA based methods for TCR sequencing 
 Increasingly, whole transcriptome profiling by RNASeq is being used to obtain TCR 
sequences. Software such as MiXCR[308], can be used to identify TCR sequences from T cell 
transcriptome profiles, without any targeted amplification of the TCR locus by PCR. One of the 
advantages of obtaining TCR sequence information from whole transcriptome profiling data is it 
allows simultaneous analysis of T cell functions coded by the transcriptome. However, the 
relative accuracy of TCR sequence determination from RNASeq compared to TCRseq has not 
been directly compared for human T cells. In order to compare these methods, we took 
advantage of a dataset we acquired using both DNA and RNA methods for TCR sequence 
identification from the same cell populations. We isolated total DNA and RNA from purified 
TEM and TRM cells from BM and LN for CD4+ and CD8+ lineages as described above from 
three donors (D299, D280, D287, see Table 4-1 for donor information) (Figure 4-4A). Whole 
transcriptome profiling was conducted from this RNA, as described in the methods section of 
Chapter 2. We found a substantial difference is the number of clones detected from DNA and 
RNA based TCR determination, with greater than 10 fold more clones detected using the DNA 
versus RNA-based method (Figure 4-4B). Interestingly, despite lower numbers of clones detected 
using the RNA method, there was a moderate linear relationship between clonality of samples 
from DNA and RNA methods (Adjusted R2 = 0.40); removing an outlier resulted in an even 
stronger linear relationship (Adjusted R2 = 0.74) (Figure 4-4C). In conclusion, with both methods 
we were able to analyze clonality and diversity of TCR sequences; however, the DNA method 
was superior due to higher coverage and the ability to detect far more unique T cell clones from 





Figure 4-4. Comparing DNA and RNA based methods for TCR sequencing.  
(A) Schematic for the experimental procedure of DNA and RNA based methods for TCR 
sequencing and clone identification. Briefly, total RNA and DNA was isolated from purified T 
cell populations. RNA was proceeded for whole transcriptome sequencing by RNA-sequencing 
and MIXCR was used to identify T cell clones. DNA was used for PCR with specific primers 
targeted to the TCR Vb-chain and ImmuneDB was used to identify clones. (B). Total number of 
unique clones identified by DNA (blue) or RNA (red) based methods for T cells, with tissue 
(BM or LN) and subset (TEM and TRM) identified by grey coloring for CD4+ and CD8+ T cells. 
(C) Clonality of samples from DNA versus RNA based methods with (left) or without (right) 
































Quantifying the overlap of T cell repertoires by cosine similarity  
 In order to determine how T cell clones are distributed across diverse sites within the 
same donor, we calculated the cosine similarity of clones for each subset between sites for the 
two donors (D324 and D383) that we had >4 sites analyzed. Cosine similarity, calculated by 
taking the cosine of the angle between two vectors of clone abundances, results in a value 
ranging from 0 (minimally overlapping) to 1 (complete overlap). [331] From this overlap 
analysis, we found that CD8+ T cells had overall higher cosine similarity compared with CD4+ T 
cells, indicating higher overlap. Importantly, there were substantial differences in the overlap 
between tissue T cell subsets of both CD4+ and CD8+ lineages (Figure 4-5). In order to analyze 
the subset differences, we performed hierarchical clustering on a matrix of pairwise cosine 
values which is shown as a heatmap in Figure 4-5. Hierarchical clustering revealed two main 
clusters for CD4+ T cells: TCM and TRM/TEM for D324, and two main clusters for CD8+ T 
cells: TEMRA and TEM/TRM for D324 and D383. For CD4+ T cells, TCM cells had low cosine 
similarity (close to 0) with all other samples, whereas CD4+ TEM and TRM cells displayed 
higher cosine similarity with non-TCM cells (up to 0.8) (Figure 4-5, left). For D324, CD8+ T 
cells, TEMRA cells had the highest cosine similarity with other TEMRA cells (close to 1), and 
very low cosine similarity with non-TEMRA cells (between 0-0.2); these samples clustered 
predominantly by subset (Figure 4-5, right). For donor 383, CD8+ TEMRA cells also had the 
highest degree of similarity with other TEMRA cells, compared to non-TEMRA cells, despite 
lower sampling of the blood sample (Figure 4-5, bottom right).  
 We next examined whether there was any tissue specific similarities between samples. 
For both individuals, we found that both CD4+ and CD8+ TEM and TRM from the lung had 
higher cosine similarity values with each other compared to non-lung samples (Figure 4-5, left).  
Additionally, for CD4+ T cells from both donors, Bld, Spl and BM TEM had higher cosine 
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similarity with each other compared to all non-TEM cells (Figure 4-5, left).  Interestingly, cosine 
similarity values for CD8+ TEM and TRM cells were more variable donors, with D324 having 
overall higher levels of cosine similarity of TEM and TRM cells with other TEM and TRM cells 
across tissues (~0.7), whereas D383 displayed a larger range of similarity (between 0.2-0.8) 
(Figure 4-5, right).  
 To reveal the overall relatedness and clonal sharing of subsets and tissues visualized 
together, we conducted principle coordinate analyses (PCoA) of the cosine distances between 
samples. Analysis of total samples for each individual showed distinct clustering of CD4+ and 
CD8+ T cells, indicative of their divergent repertoires (Figure 4-6A). We then analyzed CD4+ 
and CD8+ T cells separately, based on replicate sampling, and found that replicates clustered 
near each other for both CD8+ and CD4+ T cells indicating replicate samples are similar to each 
other (Figure 4-6B). When examined in terms of subset-specific similarities, CD4+ T cells tended 
to cluster by subset, especially for CD4+TCM cells (Figure 4-7, left). When examined for tissue-
specific similarities, CD4+ T cells, from the lung were clustered together (grey), while CD4+ T 
cells from the other tissue sites were intermingled together distinct from the lung (Figure 4-7, 
left). For CD8+ T cells subset similarities, TEMRA cells clustered closely together from different 
sites (Figure 4-7, right), while CD8+TEM and TRM subsets did not cluster by subset; they 
clustered more so by the tissue sites that these samples derived from, particularly for the lymph 
node samples which clustered together in both individuals (Figure 4-7, right). When analyzed 
with blood samples from donor 383, the blood TEM and bone marrow TEM and TRM samples 
clustered very closely together (Figure 4-7, right). These results agree with previous subset-
specific clustering patterns from cosine similarity heatmaps and provide an overview of the 




Figure 4-5 . Tissue distribution of T cell clones largely explained by cell subset and lineage 
identity.  
A) Cosine similarity between pairwise cell populations labeled by Cell Type (TCM, TEM, and 
TRM) with indicated colors. Dendrogram created using complete linkage method. Each cell 
within the heatmap is the mean of the pairwise cosine similarity between two replicate samples 





Figure 4-6. TCR repertoires of CD4+ and CD8+ lineages are divergent and show similarity 
between replicate samples. 
(A) Principle coordinate analysis of cosine distances colored by lineage (CD4= blue, CD8 = 





Figure 4-7. Tissue-specific and subset-specific differences of CD4+ and CD8+ T cell subsets. 
(A) Principle coordinate plots of cosine distances for CD4(left) and CD8 (right) samples from, 
D324 (top) and D383(bottom). Points are colored by subset (TCM = orange, TEM= light blue, 
TRM= dark blue) or Tissue (BM= dark blue, Lung= grey, LN = green, Spl= orange, Blood= 









Tracking the top clones and their abundances across tissues 
  The above analysis provided a quantitative assessment of the overlap of the entire 
complement of clones for each subset and tissue. In order to investigate how individual clones 
were distributed across subsets and tissues, we used a method of clone tracking which can be 
achieved with the most abundant clones. We examined the top 100 clones across all tissues 
within two individuals using clone tracking plots in which each clone is depicted as a colored 
segment of the plot, with the abundance of each clone proportional to the height of the segment; 
clones are stacked on top of one another (Figure 4-8). The color of each clone indicates the 
subset of the sample the clone was found in the highest frequency (TEM= light blue, TRM= dark 
blue, TCM= orange, TEMRA = red).  
 For CD4+ T cells, individual clones that were most abundant in TEM samples, tracked 
more frequently across TEM samples, but could also be detected in TRM and TCM samples 
across tissues (Figure 4-8, left). Likewise, individual clones that were most abundant in TRM 
samples, tracked more frequency across TRM samples, but could also be detected in TEM and 
TCM samples across tissues. This indicates some degree of increased sharing across subsets in 
different sites. Top clones in CD4+ TCM cells could also be detected in TEM and TRM samples 
across sites. For CD4+ T cells, we also observed some tissue-specific patterns, with lung and 
BM T cells which displayed highest proportion of these top clones, seen as higher peaks in the 
clone tracking plots. An interesting difference between the two individuals, was that donor 383 
CD4+ LN TEM cells displayed very low overlap with other samples, looking more similar to the 
TCM samples across all tissues. CD8+ T cells displayed striking TEMRA specific sharing across 
sites; these top clones were either not found or found at very low frequency in other sites (Figure 
4-8, right). Top clones in TEM and TRM samples displayed substantial sharing across subset and 
tissues. Similar to CD4+ T cells, the lung CD8+TEM T cells contained substantial TRM clones 
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shared with the lung TRM. Overall, this analysis shows the interconnectivity of the most 
abundant clones across all memory subsets analyzed, showing the dominant impact of T cell 




Figure 4-8. Top clones are widely distributed across tissues and compartmentalized in T 
cell subsets.  
A) The top 100 most abundant clones by cumulative abundance across all tissue sites and their 
relative frequencies for each memory T cell population for donor 324 (top two plots) and donor 
383 (bottom two plots) for CD4+ T cell populations (left) and CD8+ T cell populations (right). 
Each clone is colored by the memory T cell subset (TEM, TRM, TCM, or TEMRA) at which the 









Similarity between TEM and TRM populations in lymphoid sites 
 In order to quantify similarity between samples by number of clones, rather than by clone 
abundance as calculated by cosine similarity, we analyzed the Jaccard index between samples. 
The Jaccard index was calculated by dividing the number of shared clones by the total number of 
clones (shared and non-shared) and multiplying that number by 100 to get a percentage. Using 
the Jaccard index, we examined the similarity of TEM and TRM subsets in lymphoid sites (BM, 
Spl, and LN) from eight individuals. The similarity between TEM and TRM populations within a 
tissue was between 5-15% for CD4+ T cells and 10-30% for CD8+ T cells and was higher overall 
than the overlap across tissues which was between 2-10% for CD4+ T cells and 8-20% for CD8+ 
T cells (Figure 4-9A,B). More detailed analysis of the intra-tissue overlap revealed that TEM 
populations overlap more with TEM populations (light blue boxplots), and likewise TRM 
populations overlap more with TRM populations (dark blue boxplots), compared to overlap 
between TEM and TRM populations within the same tissues, for CD4+ and CD8+ T cells (Figure 
4-9A). 
 Next, we looked for subset-specific differences in the degree of overlap between different 
tissue sites. We found that CD4+ TEM cells overlapped more with CD4+ TEM cells in other 
tissues (dark blue boxplots, between 8-10%), compared to the degree of overlap with CD4+ TRM 
in other tissues (white boxplots, between 2-7%) in all lymphoid sites (Figure 4-9B, left). We also 
found that CD4+ TRM cells overlapped more with TRM cells in other tissues (light blue box 
plots, 5-8%) compared to with CD4+ TEM cells in other tissues (white boxplots, 2-7%) in all 
lymphoid sites, with the degree of overlap varying by tissue (Figure 4-9B, left).  Interestingly, 
CD8+ T cells had fewer subset-specific differences than CD4+ T cells (Figure 4-9B, right).  
 Next, we examined tissue-specific differences in the degree of overlap between T cell 
populations across sites. We found that the overlap of CD4+ TEM and TRM between BM and 
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Spl (5-12%) and of CD8+ TEM and TRM between BM and Spl (15-20%) was overall higher 
than the overlap of CD4+ TEM and TRM between Spl and LN or BM and LN (2-5%) and the 
overlap between CD8+ TEM and TRM across BM and Spl (8-12%).Together, these findings 
indicate that there are subset and tissue specific difference in the degree of similarity of TEM and 




Figure 4-9. Substantial overlap of TEM and TRM in tissues with high intra-tissue and 
subset overlap. 
A) T cell clones were counted in each sample and the jaccard index was calculated using the 
clones in samples 1 and 2 from the same tissues for CD4+ (left, from top: BM, n=7,8,8; Spl, 
n=4,5,5; LN, n=8) and CD8+ TEM and TRM cells (right, from top: BM, n=8, Spl, n=5,4,4, LN, 
n=8) B) and for samples from different tissues (top to bottom, CD4: BM-Spl, n=4,5,5,4; LN-Spl, 
n=5; LN-BM, n=8; CD8: Spl-BM, n=4,5,5,4, LN-Spl, n=5,4,5,4, LN-BM, n=8).. Students T-test. 









Section 4.3 Discussion 
 Here we analyzed how human T cells were clonally distributed across blood and tissue 
sites and the role of subset and tissue in clonal maintenance. We report the discovery that human 
CD4+ and CD8+ memory T cell clones are widely disseminated to multiple lymphoid sites, lung, 
and blood, and terminal effectors cells further disseminated. Moreover, we found the degree of 
dissemination and maintenance of T cells clones was compartmentalized within specific T cell 
subsets. Several subset-specific features were conserved across tissue sites, including the high 
diversity among CD4+TCM clones, and low diversity among CD8+TEMRA. Further, we found 
tissue-specific differences in T cell clone dissemination, including a high degree of overlap 
between CD4+TEM and CD4+TRM clones within the lung, and a high degree of overlap between 
CD4+TEM from Spl and CD4+TEM from BM. Additionally, both CD8+TEM and CD8+TRM 
clones displayed a high degree of overlap across lymphoid sites. Together these results add new 
insights into T cell differentiation in tissues. We summarize these insights graphically in Figure 
4-10, by indicating the subset-specific and tissue-specific features of T cell clone sharing and 
diversity across sites. 
 Cellular adaptive immunity is mediated by generation of diverse effector and memory T 
cell subsets that each have distinct functions and roles as elucidated by mouse models. A single 
naïve T cell with a given T cell receptor specificity can generate distinct memory subsets 
including both TCM and TRM cells in response to skin adjuvants. [159] Additionally, studies in 
mice tracking the response to vesicular stomatitis virus (VSV) show that T cell clones 
disseminate to multiple tissues regardless of their site of origin [184]. In humans, the distribution 
and fate of effector and memory T cell subsets that derive from clonal expansion of single naïve 
T cells is not known. Our data show that there is substantial overlap in T cell clones between 
different sites and subsets, but that the extent of overlap is influenced by the subset and lineage. 
  
166 
For example, CD8+ TEMRA cells are the most widely distributed across sites including BM, Spl 
blood, and lung. Additionally, recent studies on flu-specific responses in human tissues found a 
common CD8+ T cell clone in human lung, Spl and LN, consistent with our results that CD8+ T 
cell clones are widely disseminated in diverse sites. [332] While our results imply shared antigen 
specificities across tissues, we have not directly looked at antigen specificity in this study and 
this is an important area for further investigation. 
 In general, it is thought that increased T cell receptor diversity is a valuable asset as this 
allows more potential to recognize pathogens for clearance. To support this, a study in humans 
examining T-cell receptor α-β diversity of pathogen-specific T cells to Cytomegalovirus (CMV), 
a chronic virus, found that a diverse T cell receptor repertoire is a biomarker of better outcomes 
to infection. Mechanistically this could be due to maintenance of T cells that are able to respond 
to different viruses. Alternatively, the fact that chronic antigen drives T cell clonal expansion and 
therefore decreases the diversity of a TCR repertoire may be due to viral replication and 
therefore be a result of infection rather than causative of increased protection. [333] Our results 
reveal that in LN sites CD4+ and CD8+ memory T cell repertoires display a higher degree of 
diversity compared to BM sites. We have previously shown evidence for this specifically in 
CD8+ T cells [334]. This suggests that LN may serve as a reservoir for diverse memory T cells 
that retain the capacity for recognition of different pathogens, to respond and populate tissue 
sites. Additionally, the high degree of clonal expansions observed in the BM suggest it is a niche 
for T cells that have previously undergone high levels of proliferation that has been suggested by 
mouse models [271, 335], and may be important for circulation, maintenance and dissemination 
of these effector clones throughout the body. 
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 Our previous study of human CMV-specific T cell responses in tissues, indicates two 
patterns of responses: in one pattern individuals had abundant antigen specific responses in bone 
marrow that were highly disseminated across many sites (including blood, spleen and lungs), in  
Figure 4-10. Overview of subset and tissue specific features of TCR repertoires.  
(A) Each T cell clone, identified by sequencing of the TCR Vb-chain genomic locus, is 
represented by a circle filled with a unique color.  (B) Summary of subset-specific features of T 
cell clones. The ranking of subsets in regard to diversity, from highest to lowest is CD4+ TCM, 
CD4+ TEM/TRM, CD8+ TEM/TRM, and CD8+ TEMRA cells and this is conserved across 
tissues. The ranking of subsets with regards to degree of overlap between tissues (inter-tissue) 
from lowest to highest is CD4+ TCM, CD4+ TEM/TRM, CD8+ TEM/TRM, and CD8+ TEMRA 
cells. These results are shown for BM and Spl as examples, with similar findings in blood, lung 
and LN sites (left box). The degree of overlap between CD4+ TEM and TRM cell populations in 
different tissues is indicated by the color of the connecting lines. Darker shades indicate higher 
degrees of overlap (right box). Results shown are representative of BM, Spl and LN sites. (C) 
Summary of tissue-specific features of T cell clones. High intra-tissue overlap between TEM and 
TRM cells in the lung and LN for CD4+ and CD8+ T cells respectively (left box). CD4+ and 
CD8+ T cells exhibit higher diversity in LN compared to BM (middle box). For TEM and TRM 
subsets, the degree of overlap between tissues (inter-tissue) is indicated by the color of the 




























the second pattern, individuals had antigen specific responses only in lymph nodes (including 
those draining the lung, mesentery, and iliac). [10] The results from our study showing highly 
expanded clones in BM compared to smaller clone sized in lymph nodes may be indicative of 
functioning in active responses versus maintenance of memory respectively. 
 Characterizations of the T cell receptor sequences in blood and disease tissues have 
revealed the potential of this information as a diagnostic biomarker, however the healthy immune 
response in tissues remains elusive and important for understanding protective immunity in 
humans [329, 336-338]. Our results indicate that sampling of T cells in peripheral blood by 
analyzing different subsets can be indicative of what is occurring in distant tissue sites. This 
provides support for the use of peripheral blood as an important resource for immune monitoring 
in human studies. Overall, our findings provide insight into memory T cell differentiation in 
tissues. Our results suggest that in terms of T cell lineage and differentiation, cell subset and 
tissue site are large determinants of T cell receptor repertoires. This data could be a useful 
resource for future modeling and estimates of T cell receptor diversity, which thus far have been 




CHAPTER 5: Conclusions 
 
 Memory T cell generation, function and maintenance occur at diverse sites, yet most 
knowledge on human T cell immunity derives from study of peripheral blood samples. Initially, 
two subsets of T cells were identified in human peripheral blood based on homing capacity and 
function. Effector memory T cells (TEM) displayed increased abilities to migrate to non-
lymphoid tissues and confer immediate effector function upon antigen encounter, while central 
memory T cells (TCM) displayed increased abilities to home to lymphoid sites and proliferate 
upon antigen encounter [121, 339].  Further, studies from mouse models have revealed a 
specialized subset of T cells that confer protective immunity remain resident in lymphoid and 
non-lymphoid sites termed tissue-resident memory (TRM). [177-183] Although the role of TRM 
in human immune responses is not yet defined, they are implicated in a number of tissue-
localized disease states, such as psoriasis in the skin and are associated with tumors specific to 
skin, liver, lung and breast tissues[326-329]. In humans, how T cell differentiation is occurring to 
generate diverse subsets remains an active area of investigation. While mouse models cannot 
recapitulate the length and diversity of exposures to pathogens that takes place over many 
decades in humans, the extent to which this difference impacts the generalizability of findings on 
tissue immunity in mice is not known, and will be an important area of investigation in order to 
translate findings in mice to man. 
 A significant difference in memory T cell populations between mice and man includes 
that in humans, lymph nodes maintain a significant fraction (>50%) of CD8+TRM phenotype 
cells, marked by CD69 expression; however, in specific pathogen free (SPF) mice, CD8+TRM 
are infrequent. [211] Possible reasons for this discrepancy include differences in genetics or 
microbial exposure. Interestingly, in pet store mice which harbor more pathogens and 
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commensal microorganisms (non-SPF), CD8+CD69+ memory T cells are abundant and at similar 
levels to adult humans[278]. Further, mice co-housed with pet store mice also have similarly 
increased levels of CD8+CD69+ T cells [211]. Therefore, microbial exposure is likely to 
contribute to the apparent discrepancy in TRM phenotype cells in humans versus SPF mice. 
Further, previous studies in SPF mice have underestimated the importance of memory T cell 
populations, and in humans, lymph nodes are significant reservoirs of memory T cells. Our 
hypothesis is that T cells are playing unique roles in LNs and we sought to define their 
functional capacity as well as mechanisms for maintenance. 
 In studies comparing memory T cell populations in blood, LN, BM, spleen and lung, we 
identified substantial phenotypic and functional diversity of T cells in different anatomical sites. 
We found that CD8+TEM cells in blood, bone marrow, spleen and lung, displayed high effector 
function marked by expression of T-bet. In contrast, in lymph nodes, CD8+TEM cells displayed 
phenotypes of quiescence marked by expression of TCF-1. Lymph nodes also maintain a 
significant fraction (>50%) of CD8+TRM phenotype cells (not found in peripheral blood) and 
marked by CD69 expression. Interestingly, CD8+TRM cells also expressed higher levels of TCF-
1 in LN compared to in BM, Spl, and lung. Additionally, we found that CD8+TEM and TRM 
cells displayed correspondingly higher expression of Lef-1 in LN compared to other sites. We 
found additional tissue-specific phenotypes of CD8+TEM cells in LN including lower expression 
of CD57 and Perforin and higher expression of CXCR5, CD28, and CD27. Together, we 
identified a protein signature that identified memory LN T cells as distinct from TEM and TRM 
in other sites and we designate this subset TLN. Upon TCR stimulation with CD3 and CD28, 
TLN had increased capacity for proliferation compared to total memory in BM, Spl, and lung. 
Additionally, upon stimulation, TLN highly upregulated T-bet indicating their capacity for 
differentiation into effector phenotype cells. We identified that exposure to IFN α/β during TCR 
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stimulation resulted in increased down regulation of TCF-1 expression in LN memory T cells. 
Therefore, we propose that perhaps lymph nodes provide a niche absent of type 1 interferon 
signaling, allowing maintenance of TCF-1+ T cells. Together, these results indicate maintenance 
of distinct subsets with high capacity for divisions or immediate effector functions. 
 What is the role of memory T cells in lymph nodes, and why are they maintained with 
distinct functional capacity? One hypothesis is that lymph node localized memory T cells are 
providing protective immunity to pathogens in lymph nodes, similar to roles in mice of influenza 
specific TRM in the lung [179]. Humans are exposed to several pathogens that selectively infect 
lymphoid cells including Epstein Barr Virus (EBV) and HIV which establish latent infection in B 
cells and CD4+ T cells respectively.  Consistent with this hypothesis, one study found CD8+TRM 
phenotype cells specific for EBV in tonsils and spleen (up to 8% of total CD8+ T cells) [194]. 
Additionally, multiple studies have shown that increased numbers of cytotoxic CD8+T cells were 
localized in LNs of individuals infected with HIV, with T cell numbers inversely correlated with 
viral load[275, 316, 317]. HIV-antigen driven CD4+ T follicular helper cell clonal expansions 
were found in lymph nodes of HIV+ individuals [340], indicating a site-specific response, which 
may be due to either oligoclonal growth or cell killing. 
 Expression of TCF-1 and increased capacity for cell division, suggest an alternative 
hypothesis for the role memory T cells in lymph nodes; TLN may serve to regenerate effector 
cells and the self-renewing memory pool similar to central memory T cells [99, 341, 342]. 
Unlike canonical central memory T cells, TLN do no express high levels of CCR7, and instead 
the majority express TRM marker CD69, suggesting a CCR7-independent mechanisms for 
maintenance of memory T cells in lymph nodes. In mice, studies of Ag-specific responses to 
influenza challenge have shown that asymmetric division couples the generation of and 
  
173 
maintenance of TCF-1 expressing cells in non-draining lymph nodes with ability to self-renew 
and TCF-1 negative cells in the lung with ability for effector function.[168]  
 Successful immune responses generated against acute viruses such as influenza lead to 
rapid viral clearance and generation of memory T cells. In contrast, chronic viral infections and 
cancer cells evade immune mediated clearance and persist over long periods of time, presenting 
an ongoing challenge to the immune system. Several recent studies found lymphoid specific 
CXCR5+TCF-1+CD8+ T cell populations generated in response to chronic LCMV infection; they 
found these populations responded to PD-1 therapy, leading to robust proliferation of otherwise 
exhausted T cell responses.[154, 248, 303, 316, 317] The TLN cells we identified in humans 
displayed similar phenotype, function, and transcriptional profiles to these recently described 
subsets in mouse models. Perhaps human TLN cells are an analogous subset generated in 
response to chronic viral infection and are responsive to PD-1 therapy. A recent study in humans 
found that stem-like CXCR5+CD8+ T cells reside in tumors [343]. Evidence in mouse models 
further supports that successful response to cancer immunotherapy resulted in coordinated anti-
tumor immunity across the organism.[344] 
 We found that T cell responses to chronic infection with CMV exhibit tissue-specific 
localization patterns. In certain individuals, CMV-specific T cell responses were 
compartmentalized in lymph nodes[10]. In contrast, other individuals had large populations of 
CMV-specific T cells disseminated in many sites including blood, BM, lung and spleen.[10] 
Perhaps LN reservoirs of memory T cells are poised to respond upon reactivation of latent viral 
reservoirs; whereas, disseminated responses are indicative of more recent viral reactivation and 
subsequent control. We have not been able to correlate this with what the virus is doing; we 
detected viral genomes in many sites, most often in the lung. [10] Further investigations of 
  
174 
relationship between T cell responses and virus localization will lead to better insights into 
human responses.  
 In our second study we investigated the relatedness of circulating and tissue T cells by 
clonal analysis of T cell subsets comprising TCM, TEM, TRM and TEMRA cells from Bld, BM, 
Spl, LN and Lung. From diversity analysis, we found that CD4+TCM cells were the most 
diverse, and CD8+TEMRA cells were the least diverse in all sites examined. CD4+TEM and 
TRM cells were more diverse than CD8+ TEM and TRM cells. We looked for tissue specific 
differences and found that diversity of CD4+ and CD8+ T cells was greater in LN compared to 
BM. T cell repertoire diversity displayed an inverse relationship with the degree of clonal 
overlap between T cell subsets. CD4+TCM cells exhibited low overlap whereas CD8+TEMRA 
cells exhibited high overlap, particularly with TEMRA cells in different sites. In addition to these 
subset specific differences, we also found tissue-specific features of T clone sharing. We found 
CD4+ TEM cells were most similar between BM and Spl, more so than with LN and Lung sites. 
We also found substantial overlap between TEM and TRM cells in the lung, suggestive of 
antigen driven compartmentalization in tissue sites. In conclusion, we found that the relatedness 
of T cell clones was largely subset-specific, and to a lesser degree tissue-specific. 
 Future studies tracking T cell responses over time with information on timing of 
pathogen encounter and control or clearance will provide more insights into the drivers of T cell 
differentiation. Additionally, investigations of the antigen specificity of T cell responses in 
human tissues would yield significant insights into history of antigen encounters drive T cell 
responses. In order to discover the Ag-specificity of a given T cell clone, T cells can be screened 
against large libraries of peptide-MHC complexes and reactive clones can be identified. This 
method was recently applied to questions in tumor immunology, where increased T cell 
infiltration in tumors has been associated with better prognosis.[345] In this study, authors 
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identified that only 10% of T cells derived from tumors were tumor-specific, with some tumors 
having even lower percentages, revealing that non-tumor antigens may drive a significant portion 
of T cell populations in tissues, or that they were unable to identify the right tumor antigen due to 
clonal deletion by immune systems of technical limitations. [345] 
 Our results reveal that T cell populations exhibit substantial diversity across tissue sites 
and subsets as depicted in Figure 5-1. Here we show how the magnitude of proliferative capacity 
(purple) and effector function (orange) gradually increase according to according to both 
localization and cell subset identity, with a novel subset we identify in LN sites as TLN. 
Additional properties that correspond with proliferative capacity and effector function are TCR 
diversity (purple) and turnover (orange) respectively. Naive T cells exhibit highest level of 
proliferative capacity and TCR diversity followed by TCM, TLN, TEM & TRM, and TEMRA 
cells in that order. Naive T cells also exhibit the lower levels of effector function and turnover, 
with increasing levels in TCM, TLN, TEM & TRM, and TEMRA cells in that order. Naive and 
TCM cells are found in all sites (Bld, BM, Spl, LN, and lung) however, TLN cells are 
maintained exclusively in LN sites, and distinct in phenotype and function from TEM and TRM 
cells in Bld, BM, Spl, and lung. Additionally, TEMRA are found in Bld, BM, Spl and lung. In 
summary, T cells exhibit substantial heterogeneity by subset and tissue site, leading to new 
insights into T cell differentiation and maintenance in humans including that lymph nodes are an 
important reservoir for distinct and quiescent subset memory T cells with increased T cell 
receptor diversity and proliferative capacity compared to subsets found in vascularized sites 
including blood, BM, spleen, and lung. 
 These results have major implications for lymph nodes as sites for maintenance of 
immune memory such as targeting for immunotherapies and vaccines. Further, lymph nodes may 
provide important reservoirs for maintenance of T cell clones with self-renewal abilities. In 
  
176 
contrast, our results suggest that BM may be a reservoir for highly circulating cells that have 
lower self-renewal abilities and more immediate effector functional capacity. Dissecting the role 
of systemic versus tissue specific responses as well as the interplay between the two in disease 




Figure 5-1. Summary of findings on T cell compartmentalization in tissues. 
T cell subsets: Naive (CCR7+CD45RA+), TCM (CCR7+CD45RA-), TLN (CCR7-CD45RA-
CD69+/-), TEM (CCR7-CD45RA-CD69-), TRM (CCR7-CD45RA-CD69+), and TEMRA 
(CCR7-CD45RA+) shown according to magnitude of properties: 1) TCR diversity and 
proliferative capacity (purple) and 2) effector function and turnover (orange). Anatomical site 
which subset is found is indicated by colored bars below each column (Bld = black, BM = grey, 
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Appendix A. CMV-specific T cell responses in tissues. 
Only data resulting from experiments that I performed are presented in this section, and these 
data are taken from:  
Gordon, C. L., Miron, M., Thome, J. J., Matsuoka, N., Weiner, J., Rak, M. A., Igarashi, S., 
Granot, T., Lerner, H., Goodrum, F., Farber, D. L. (2017). Tissue reservoirs of antiviral T cell 
immunity in persistent human CMV infection. J Exp Med, 214(3), 651-667. 
doi:10.1084/jem.20160758 
 
T cell responses to viruses are initiated and maintained in tissue sites; however, knowledge of 
human antiviral T cells is largely derived from blood. Cytomegalovirus (CMV) persists in most 
humans, requires T cell immunity to control, yet tissue immune responses remain undefined. 
Here, we investigated human CMV-specific T cells, virus persistence and CMV-associated T cell 
homeostasis in blood, lymphoid, mucosal and secretory tissues of 44 CMV seropositive and 28 
seronegative donors. CMV-specific T cells were maintained in distinct distribution patterns, 
highest in blood, bone marrow (BM), or lymph nodes (LN), with the frequency and function in 
blood distinct from tissues. CMV genomes were detected predominantly in lung and also in 
spleen, BM, blood and LN. High frequencies of activated CMV-specific T cells were found in 
blood and BM samples with low virus detection, whereas in lung, CMV-specific T cells were 
present along with detectable virus. In LNs, CMV-specific T cells exhibited quiescent 
phenotypes independent of virus. Overall, T cell differentiation was enhanced in sites of viral 
persistence with age. Together, our results suggest tissue T cell reservoirs for CMV control 
shaped by both viral and tissue-intrinsic factors, with global effects on homeostasis of tissue T 




Persistent CMV infection has important clinical relevance in the global population. While 
immune-mediated control of CMV in healthy individuals prevents disease and overt clinical 
symptoms, immune dysregulation due to immunosuppressive treatments in transplant and cancer 
patients, congenital immunodeficiencies, HIV/AIDS, and/or aging can result in CMV viremia, 
life threatening disease and even death [346-349]. When reactivated, CMV infects multiple 
tissues, causing pneumonitis, colitis, hepatitis and end organ failure [346, 347], for which anti-
viral therapeutics are only partially effective. CMV persistence may also impact immunity in 
immunocompetent individuals, and has been associated with immunosenesence, and differential 
responses to infections or vaccinations [350-352]. The dynamic nature of viral persistence and 
anti-viral T cell responses indicates that both parameters need to be investigated to understand 
the mechanisms for immune-mediated escape and/or other effects on overall immune 
homeostasis.  
We screened for the presence of CMV-specific CD8+ T cells in tissues from seropositive 
donors using up to five HLA-tetramer or -multimer reagents of the appropriate HLA containing 
peptide epitopes of immunodominant CMV proteins pp65, IE-1, and pp50 (CMV-multimers), 
compared to staining with negative control HLA-multimers. We used combinations of CMV 
multimers containing different CMV epitopes in order to maximize our ability to detect CMV-
reactive T cells in each sites. We found that the phenotypes of CMV-specific T cells differed 
depending on the tissue site. CMV-specific T cells in LN displayed lower expression of CD57 
and perforin and higher expression of CD28 and CD127 compared to CMV-specific T cells in 
BM (Figure A.A.1).  Functionally, CMV-specific T cells in LN produced higher levels of IL-2 in 
response to PMA/INO stimulation, and comparable levels of IFN-gamma (Figure A.A.1).   
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Figure A.A.1. Expression of various proteins in resting CD8+ CMV-specific T cells identified by 
MHC-peptide multimer staining of T cells from BM and LN and expression of cytokines in 
response to stimulation. Expression of Perforin, CD57 (top), CD28 and CD127 (middle). 
Expression of cytokines in response to PMA/Ionomycin stimulation (bottom). Paired t-test. NS 
p>0.05, *p<0.05,**p<0.01, ***p<0.001. Lines connect samples from the same donor. 
  
199 
We analyzed the functional abilities of CMV-specific T cells in response to CMV-peptide 
,as described in the methods section, and found expansion of T cells was highest in LN, then Spl, 
and lowest in BM (Figure A.A.2). Further, we found differences in the phenotype of CMV-
specific T cells in different sites; CMV-specific T cells in LN displayed TEM phenotype (CCR7-
CD45RA-) and T cells in Spl and BM displayed TEM and TEMRA phenotypes (CCR7-
CD45RA+). After expansion of CMV-specific T cells over the course of 9 days in culture, the 
phenotype of CMV-specific T cells changed; in the LN, CMV-specific T cells expressed CCR7, 
and in the BM and Spl CMV-specific T cells were mainly TEM phenotype. Additionally, CMV-
specific T cells in the BM expressed CD57 before and after expansion, while CMV-specific T 
cells in the Spl expressed CD57 only before expansion. In the LN, T cells did not express CD57, 
but a portion expressed PD-1, and a higher proportion expressed PD-1 after expansion. 
Additionally, CMV-specific T cells displayed the highest PD-1 expression in the BM compared 
to Spl and LN after 9 days in culture (Figure A.A.2). We analyzed supernatant from Spl 
stimulated CMV-specific T cell cultures and detected increasing levels of IFN-gamma, and 










Figure A.A.2. Function and phenotype of BM, Spl, and LN CMV-specific T cells during 
antigen driven expansion. (A). Identification of CMV-specific T cells from D194 using the 
A24-QYD multimer. On day 0, total mononuclear cells from tissues were incubated with pp65 
peptide and analyzed by flow cytometry on Day 9. See methods for detailed protocol. (B). 
Phenotype of CMV-specific T cell identified in (A) by expression of CCR7 and CD45RA (left) 
and expression of PD-1 and CD57 (right). (C). Supernatants from stimulated cells from spleen 









Appendix B. Transcriptional profiling of CD4+ and CD8+ TRM in bone marrow and lymph 
nodes  
 
As discussed in Chapter 1, populations of TRM phenotype cells, marked by expression of 
CD69, are abundant in lymphoid sites such as BM and LN, however their properties relative to T 
cell subsets in circulation are not well characterized. We purified memory CD4+ and CD8+ T 
cells by FACS sorting and isolated total RNA for whole transcriptome profiling by RNA-
sequencing (see Table A.B.1 below for description of samples). We used DESeq2 in order to 
identify genes differentially expressed between CD69+ and CD69- memory CD4+ and CD8+ T 
cells in BM and LN (Figure A.B.1). For the complete list of genes differentially expressed see 
Table A.B.2 below. 
 In CD8+ T cells, we found about 200 genes differential expressed between CD69+ and 
CD69- T cells in the BM; however, we found only 100 genes differentially expressed between 
CD69+ and CD69- T cells in the LN indicating higher transcriptional similarity between CD69- 
and CD69+ T cells in the LN compared to the BM (Figure A.B.3). When compared with the core 
TRM gene set identified in Kumar et al. 2017, CD69+CD8+ T cells were transcriptionally 
distinct from CD8+CD69- memory T cells in BM and LN by MDS analysis, and CD69- T cells 
were more similar to memory T cells from blood (Figure A.B.3). Included in the genes 
conserved with core TRM gene expression are downregulation of KLF2, KLF3, and S1PR1 in 
CD69+ relative to CD69- memory T cells in BM and LN (Figure A.B.3). In CD4+ T cells, ~350 
genes were differentially expressed between CD69+ and CD69- T cells in BM, and ~200 genes 
were differentially expressed in L; for both tissues more genes were differentially expressed in 
CD4+T cells than in CD8+ T cells (Figure A.B.4). The relationship between T cells from Bld, 
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BM, Spl, LN and Lung was analyzed by MDS analysis using the list of genes differentially 
expressed between BM CD69- and CD69+ T cells. We found that CD69+ T cells from all sites 
clustered together, and CD69- T cells from all sites clustered together with blood (Figure A.B.4). 
Taken together, both CD4+ and CD8+, CD69+ and CD69- memory T cells display distinct 
transcriptional profiles in LN and BM. Memory T cells expressing CD69 were transcriptionally 
similar to TRM in spleen and lung, and memory T cells not expressing CD69 were 
transcriptionally similar to circulating memory T cells. We analyzed the abundance of T cells in 
BM biopsies by immunohistochemistry, and found 10-15% of total nucleated cells were T cells, 
by CD3 staining (Figure A.B.5). Further studies are needed to investigate whether CD69+ and 
CD69- T cells display differential localization patterns within the BM, or if CD69+ and CD69- T 






Figure A.B.1. Whole transcriptome profiling by RNA-seq of CD69+ and CD69-  memory CD8+ 
and CD4+  cells from BM and LN.  
(A) Acquisition of purified T cells from BM and LN and subsequent analysis strategy using 
DESeq2. (B). Gating strategy (left to right): lymphocytes, singlets, memory T cells 
(CD3+CD45RO+), CD8+ or CD4+ and CD69+/- from BM of a representative individual for 
RNASeq. (C) Stacked bar graph of the number of significantly up (grey) or (down) regulated 
genes by DESeq2 analysis (FDR<0.05 and |log2FC| > 1). For differential expression analysis, 
CD69+ versus CD69- memory T cells were compared to identify up and down regulated genes 
relative to CD69+ memory T cells. Results are for CD4+ and CD8+ T cells in LN and BM. Total 





















Table A.B.1. RNASeq sample information. Columns indicate tissue (BM or LN), CD69 
expression (neg = negative, pos = positive), donor number, and lineage (CD4+ or CD8+) of 
samples. 
Sample Tissue CD69 donor CD4 or CD8 
DM001 BM neg D280 CD4 
DM002 BM neg D287 CD4 
DM003 BM neg D229 CD4 
DM004 LN neg D280 CD4 
DM005 LN neg D229 CD4 
DM006 LN neg D287 CD4 
DM007 BM neg D280 CD8 
DM008 BM neg D287 CD8 
DM009 BM neg D229 CD8 
DM010 LN neg D280 CD8 
DM011 LN neg D229 CD8 
DM012 LN neg D287 CD8 
DM013 BM pos D280 CD4 
DM014 BM pos D287 CD4 
DM015 BM pos D229 CD4 
DM016 LN pos D280 CD4 
DM017 LN pos D229 CD4 
DM018 LN pos D287 CD4 
DM019 BM pos D280 CD8 
DM020 BM pos D287 CD8 
DM021 BM pos D229 CD8 
DM022 LN pos D280 CD8 
DM023 LN pos D229 CD8 






Table A.B.2. Differentially expressed genes in CD4+ and CD8+ TRM vs. TEM (CD69+ vs. 
CD69-) cells in BM and LN. Results from differential expression analysis from three donors for 
each group (samples specified in Table A.B.1 above). 
 Log2FC 
CD69(+) vs. CD69(-) 
FDR Adjusted p-value, if p <0.05 
(grey) 
 

















GPR12 5.6 3.2 3.6 2.9 0.00 NA NA NA 6.7 
GLIS1 5.6 1.8 0.8 2.8 0.00 NA 1.00 0.10 11.1 
CDHR1 5.0 3.2 2.3 1.7 0.00 0.00 0.00 0.13 145.1 
MEIS3 4.9 1.6 4.8 0.3 0.00 NA NA NA 4.5 
LOC100129316 4.9 2.2 1.1 1.6 0.03 0.77 1.00 1.00 38.7 
BCAM 4.5 0.0 2.0 1.4 0.04 1.00 NA 1.00 8.5 
FLJ43390 4.5 0.0 4.0 2.3 0.02 NA 0.14 NA 4.6 
PROKR2 4.1 1.5 4.6 1.9 NA NA 0.00 NA 5.4 
LOC100128909 4.0 1.4 1.1 1.3 0.00 1.00 0.28 0.85 53.6 
PKDCC 3.9 3.5 2.3 2.1 0.00 0.10 0.26 NA 23.5 
DAB2IP 3.7 0.3 1.6 2.3 0.00 1.00 1.00 0.02 199.8 
IL2 3.7 3.1 2.2 2.2 0.00 0.00 0.49 0.03 34.5 
LOC100507103 3.7 3.1 1.3 1.8 0.00 0.50 0.52 0.53 29.0 
RAPGEF5 3.6 1.6 2.0 2.0 0.00 0.59 0.75 0.02 41.4 
IL23R 3.1 1.5 1.1 2.4 0.00 0.61 1.00 0.14 159.8 
KCNQ3 3.1 3.3 1.7 1.0 0.00 0.00 0.85 1.00 52.1 
LOC285463 3.1 1.5 1.1 0.4 0.02 0.71 1.00 NA 7.9 
CCDC165 3.0 1.0 1.7 1.1 0.00 1.00 0.72 1.00 12.6 
SLC16A2 3.0 1.4 1.1 0.9 0.00 1.00 1.00 NA 8.3 
AQP7P1 2.9 1.1 2.1 1.0 0.04 0.99 0.73 1.00 21.6 
CD160 2.9 -1.0 3.2 2.3 0.01 NA 0.06 0.02 152.6 
LOC100507390 2.9 0.2 0.8 4.1 0.03 NA NA NA 4.9 
IL10 2.9 1.4 1.7 1.9 0.00 0.03 0.59 1.00 124.4 
EPAS1 2.8 0.4 1.0 1.2 0.00 NA 0.89 1.00 213.7 
GNB3 2.8 0.7 1.1 0.2 0.00 1.00 1.00 NA 11.3 
XCL1 2.8 0.3 2.8 2.3 0.00 1.00 0.00 0.00 100.4 
JAG2 2.7 1.0 2.5 2.0 0.00 0.73 0.00 0.03 57.2 
WNK2 2.7 1.1 4.3 -0.6 NA 1.00 0.01 NA 6.0 
GLT25D2 2.7 1.8 0.6 1.7 0.00 0.01 1.00 0.00 107.5 
COL5A1 2.7 0.0 1.2 2.0 0.00 1.00 1.00 0.33 134.0 
LOC440300 2.6 1.9 -0.3 0.3 0.01 0.22 1.00 1.00 17.7 
FREM2 2.6 5.6 NA 3.2 NA 0.02 NA NA 2.2 
GLP1R 2.6 2.6 2.6 0.0 0.24 0.05 NA NA 9.8 
CRIM1 2.6 1.6 1.4 1.2 0.00 0.13 0.00 0.30 479.2 
CCND1 2.6 1.9 2.6 1.5 0.01 0.02 0.00 0.29 42.5 
IGSF11 2.5 3.6 1.4 2.0 0.03 0.00 NA NA 16.0 
WNT11 2.5 2.3 0.2 0.6 0.00 0.15 1.00 1.00 23.0 
C2orf85 2.5 0.4 0.0 0.4 0.01 1.00 1.00 1.00 48.6 
HTRA1 2.5 1.2 1.0 2.3 0.03 1.00 1.00 NA 11.7 
MIR4772 2.5 2.2 0.7 1.6 0.01 0.56 1.00 NA 13.9 
ADRB1 2.5 4.0 2.4 2.4 0.39 NA 0.03 0.20 13.8 
FCRL6 2.5 0.4 -0.2 0.5 0.00 1.00 1.00 1.00 342.4 
IL1RL1 2.4 1.2 1.0 1.4 0.00 0.43 1.00 NA 34.4 
GFOD1 2.3 1.3 1.2 0.8 0.00 0.10 0.05 0.73 387.3 
B3GAT1 2.3 1.1 -1.3 0.3 0.00 0.85 0.57 1.00 96.5 




CD69(+) vs. CD69(-) 
FDR Adjusted p-value, if p <0.05 
(grey) 
 

















ITGA1 2.3 2.3 2.4 1.7 0.00 0.00 0.00 0.09 308.0 
SDK1 2.3 2.1 0.3 0.8 0.30 0.02 NA NA 23.9 
PDZD2 2.3 1.1 -1.3 1.6 0.01 1.00 1.00 NA 12.4 
CCL4 2.3 1.7 1.1 1.2 0.00 0.01 0.25 1.00 1040.4 
DTHD1 2.2 1.4 1.6 0.4 0.01 0.00 0.14 1.00 850.9 
FER1L4 2.2 1.5 1.8 1.5 0.01 0.01 0.35 0.02 39.4 
IL17RE 2.2 0.9 0.4 1.7 0.04 1.00 1.00 1.00 56.8 
CPNE7 2.2 1.1 1.1 0.9 0.04 0.60 1.00 1.00 62.5 
PTGDR 2.2 1.2 0.6 0.5 0.00 0.13 0.00 1.00 541.0 
KCNA6 2.1 0.5 2.0 1.3 0.00 1.00 0.00 0.69 175.0 
AATK 2.1 1.7 1.0 3.0 0.01 0.02 0.99 NA 55.8 
TP53I11 2.1 1.4 0.6 0.7 0.00 0.39 1.00 1.00 236.6 
RGS1 2.1 0.6 3.5 1.0 0.00 1.00 0.00 0.92 12373.5 
LOC100130872 2.0 0.7 0.2 0.3 0.00 0.82 1.00 1.00 722.4 
PLXDC1 2.0 1.0 1.5 0.7 0.00 0.00 0.00 0.89 415.4 
MS4A1 2.0 0.8 1.8 0.2 0.00 0.85 0.00 1.00 128.6 
LEPREL2 2.0 1.2 1.0 0.3 0.00 0.20 0.48 1.00 64.7 
SHISA2 2.0 0.9 0.9 0.7 0.02 1.00 NA 1.00 71.1 
LGR6 2.0 1.0 0.8 0.6 0.00 0.86 1.00 1.00 147.3 
HIC1 2.0 0.7 1.8 1.4 0.01 1.00 0.00 1.00 366.0 
TRPM2 2.0 0.4 1.2 1.6 0.00 1.00 0.24 0.43 198.0 
LIF 1.9 2.0 2.3 0.8 0.25 0.02 0.08 1.00 29.2 
P2RX5-
TAX1BP3 1.9 1.2 0.7 0.9 0.01 0.42 1.00 1.00 34.0 
CD101 1.9 0.0 1.4 1.1 0.00 1.00 0.09 0.64 118.8 
ERRFI1 1.8 0.6 1.1 0.3 0.01 1.00 0.28 1.00 308.1 
TGFBI 1.8 0.9 1.2 1.3 0.03 0.84 0.16 0.06 257.2 
MYO1B 1.8 1.1 0.9 1.1 0.01 1.00 1.00 1.00 212.2 
MCAM 1.8 0.3 1.0 0.7 0.02 1.00 1.00 1.00 254.1 
MMRN1 1.8 1.4 0.2 0.1 0.03 0.22 1.00 1.00 118.6 
ASB2 1.8 0.5 1.0 0.7 0.00 1.00 0.73 1.00 152.9 
GNAO1 1.8 1.0 0.1 0.4 0.00 0.25 1.00 1.00 218.5 
STARD9 1.7 0.6 1.3 1.0 0.00 0.47 0.00 0.01 679.6 
ZCCHC12 1.7 2.2 -0.1 -0.3 0.50 0.01 NA 1.00 56.6 
IL12RB2 1.7 0.1 0.8 1.3 0.00 1.00 1.00 0.00 241.9 
IFNG 1.7 1.2 0.1 0.9 0.03 0.01 1.00 0.79 538.7 
GFI1 1.7 1.3 0.7 1.1 0.00 0.00 0.00 0.00 775.4 
SAMD4A 1.7 0.6 2.0 0.8 0.00 1.00 0.02 1.00 74.8 
MIR3687 1.7 -0.7 1.2 0.3 0.00 1.00 0.02 1.00 6138.7 
FAM110C 1.7 -0.9 1.5 -0.2 0.00 1.00 0.02 1.00 54.0 
SPEG 1.7 1.0 1.3 1.4 0.05 0.48 1.00 0.24 110.1 
CSF1 1.7 0.5 2.8 1.3 0.02 1.00 0.00 0.01 403.5 
SOAT2 1.7 1.3 1.2 0.8 0.00 0.91 0.55 1.00 37.7 
LOC100128342 1.6 0.4 0.6 1.5 0.03 1.00 1.00 1.00 93.6 
IL18RAP 1.6 1.7 0.3 2.0 0.00 0.00 1.00 0.00 1114.8 
CARD10 1.6 1.0 2.1 1.3 0.21 1.00 0.04 1.00 17.0 
KCNK5 1.6 1.7 1.4 1.2 0.01 0.00 0.34 0.07 220.9 
C8orf80 1.6 0.1 -0.1 0.4 0.00 1.00 1.00 1.00 185.1 
F2R 1.6 0.8 0.3 0.5 0.00 0.78 1.00 1.00 840.2 
YPEL1 1.6 0.4 0.2 0.5 0.01 1.00 1.00 1.00 422.6 
FAM125B 1.6 1.1 0.2 0.7 0.00 0.23 1.00 1.00 585.4 
ADAM23 1.6 2.4 0.2 0.2 0.04 0.31 1.00 1.00 483.3 
GRID2IP 1.5 1.5 0.8 0.9 0.03 0.32 1.00 1.00 25.4 




CD69(+) vs. CD69(-) 
FDR Adjusted p-value, if p <0.05 
(grey) 
 

















AFF3 1.5 1.0 0.8 0.8 0.00 0.00 1.00 1.00 211.9 
DUSP2 1.5 0.2 1.1 0.5 0.04 1.00 0.14 0.44 7510.6 
ZNF618 1.5 0.3 0.5 0.9 0.04 1.00 1.00 1.00 36.7 
IFNGR1 1.5 1.0 0.8 1.0 0.00 0.01 0.62 0.00 1653.8 
SPRY1 1.5 1.6 1.0 1.5 0.03 0.01 0.65 0.00 271.5 
SLC4A4 1.5 0.7 1.0 0.9 0.12 1.00 0.00 0.16 153.2 
SLC41A2 1.5 1.7 0.8 1.1 0.05 0.02 0.65 0.45 61.8 
DUSP6 1.5 1.3 1.0 1.2 0.01 0.00 0.00 0.27 863.5 
PLXND1 1.5 1.0 0.2 1.1 0.06 0.02 1.00 0.00 1859.9 
PTGFRN 1.5 0.3 1.5 0.6 0.00 1.00 1.00 1.00 33.9 
SEMA7A 1.4 0.6 1.6 0.9 0.01 0.78 0.00 0.03 205.1 
C9orf173 1.4 1.0 1.7 0.9 0.24 0.38 0.01 1.00 66.4 
NRBP2 1.4 0.8 0.6 0.5 0.00 0.25 0.95 1.00 358.2 
RYR1 1.4 0.8 1.3 0.7 0.00 0.94 0.10 1.00 98.6 
SLC7A5 1.4 0.8 0.5 0.8 0.05 1.00 1.00 1.00 2519.9 
LOC692247 1.4 0.5 1.0 0.9 0.00 1.00 0.06 0.53 105.2 
COL6A1 1.4 0.9 0.4 0.7 0.00 0.22 1.00 1.00 98.8 
PFKFB3 1.4 0.9 1.0 1.1 0.00 0.12 0.01 0.18 6098.7 
RIMS3 1.4 0.4 1.2 0.8 0.02 1.00 0.16 1.00 130.9 
PTGER4 1.4 0.3 0.8 0.7 0.00 0.37 0.00 0.03 7482.4 
PHLDB1 1.4 0.4 1.5 0.4 0.03 1.00 0.01 1.00 143.9 
SFMBT2 1.4 0.8 1.0 0.6 0.00 0.01 0.07 0.03 1433.9 
ARHGAP18 1.3 0.6 1.3 0.8 0.00 0.85 0.00 0.96 398.9 
NLRP6 1.3 1.2 0.6 0.7 0.00 0.00 0.07 0.08 566.4 
ADAMTS17 1.3 0.3 2.2 1.0 0.00 0.94 0.01 0.00 336.7 
UBE2Q2P1 1.3 0.7 0.3 0.5 0.01 0.57 1.00 1.00 121.9 
TBX21 1.3 0.4 -0.3 0.5 0.00 1.00 1.00 0.29 1088.6 
IGLL5 1.3 -0.5 1.1 2.9 0.92 1.00 1.00 0.01 71.2 
GIPR 1.3 0.6 0.8 0.4 0.02 0.94 0.10 1.00 77.1 
CD8A 1.3 0.1 0.0 0.3 0.05 1.00 1.00 1.00 4033.2 
PDCD1 1.3 0.6 0.2 0.1 0.00 0.66 1.00 1.00 660.9 
FLT4 1.3 1.3 0.2 1.0 0.27 0.01 1.00 0.45 528.3 
VAV2 1.3 0.8 1.1 1.2 0.00 0.15 0.09 0.07 97.9 
ID2 1.3 0.9 0.6 0.6 0.01 0.13 0.78 0.82 2959.4 
CCR5 1.3 0.0 0.5 0.5 0.00 1.00 0.55 1.00 1351.9 
BMF 1.3 0.2 1.0 0.5 0.00 1.00 0.02 1.00 195.3 
CKLF 1.3 0.1 0.4 -0.2 0.02 1.00 1.00 1.00 33.5 
PLXNB1 1.3 0.6 0.8 0.8 0.02 0.62 0.27 0.98 71.0 
CD69 1.3 0.5 1.7 0.8 0.00 1.00 0.00 1.00 17091.7 
STX1A 1.2 -0.3 0.2 0.4 0.00 1.00 1.00 1.00 75.0 
KSR2 1.2 1.8 -1.6 -0.1 NA 0.02 NA NA 11.5 
SESN1 1.2 1.2 0.8 1.0 0.03 0.01 0.92 0.24 1722.0 
COLQ 1.2 0.1 0.5 1.7 0.01 1.00 1.00 0.61 489.6 
DUSP5 1.2 0.4 1.3 0.9 0.01 0.44 0.00 0.00 2630.0 
EOMES 1.2 0.9 0.8 0.4 0.06 0.41 0.00 1.00 1113.7 
SLC6A8 1.2 0.7 0.6 0.4 0.04 1.00 1.00 1.00 83.0 
P2RX5 1.2 0.9 0.7 0.7 0.00 0.09 0.84 1.00 100.7 
CDK5R1 1.2 1.1 1.2 0.6 0.01 1.00 0.04 1.00 651.8 
NOXA1 1.2 0.2 0.9 0.3 0.01 1.00 0.30 1.00 93.2 
CAPN5 1.2 0.2 0.2 0.3 0.03 1.00 1.00 1.00 40.3 
SARDH 1.2 0.5 1.7 0.5 0.04 1.00 0.00 1.00 135.2 
EGR3 1.2 0.3 1.2 0.4 0.03 1.00 0.00 1.00 223.3 




CD69(+) vs. CD69(-) 
FDR Adjusted p-value, if p <0.05 
(grey) 
 

















PBX4 1.2 0.4 0.3 0.5 0.01 1.00 1.00 1.00 914.2 
ZCCHC24 1.2 0.6 0.8 0.8 0.04 1.00 0.30 1.00 77.5 
ATP10D 1.1 0.4 0.5 0.8 0.04 1.00 1.00 0.30 245.6 
CH25H 1.1 2.2 0.1 0.6 0.24 0.00 1.00 1.00 453.9 
IRGM 1.1 0.4 0.6 1.0 0.01 1.00 0.62 0.10 136.3 
SGSM1 1.1 0.7 -0.4 0.5 0.03 0.53 1.00 1.00 81.7 
LOC100506023 1.1 0.3 0.4 0.2 0.02 1.00 1.00 1.00 172.8 
TBKBP1 1.1 0.7 0.1 0.5 0.02 0.15 1.00 1.00 310.5 
TOX 1.1 0.8 0.7 0.4 0.03 0.15 0.17 1.00 481.3 
ZNF80 1.1 0.4 1.8 -0.3 0.36 0.85 0.01 1.00 169.0 
FAM18B2 1.1 0.5 0.3 0.1 0.02 0.57 1.00 1.00 350.9 
HDAC9 1.1 0.5 1.8 1.3 0.16 1.00 0.01 0.47 162.1 
AGRN 1.1 1.0 0.9 1.2 0.51 0.08 0.67 0.02 101.3 
IL6ST 1.1 0.9 1.1 0.4 0.29 0.14 0.01 1.00 6786.1 
SMOX 1.1 2.1 1.1 1.2 0.44 0.04 0.98 1.00 26.9 
PDE4A 1.1 0.1 0.6 0.8 0.04 1.00 0.47 1.00 272.4 
FGFRL1 1.1 0.5 0.8 0.6 0.03 1.00 0.01 1.00 329.5 
PIK3AP1 1.1 0.1 0.8 1.5 0.15 1.00 0.53 0.00 878.0 
MCC 1.0 1.0 0.6 0.6 0.00 0.07 1.00 1.00 460.8 
C17orf107 1.0 0.5 1.5 0.7 0.02 1.00 0.01 1.00 1199.8 
SNTB2 1.0 0.5 0.4 0.5 0.00 0.98 0.79 1.00 1341.2 
FAM46C 1.0 -0.2 1.0 0.2 0.00 1.00 0.02 1.00 4817.6 
GBGT1 1.0 1.6 1.0 0.7 0.06 0.00 0.76 1.00 70.1 
SMPD3 1.0 0.4 2.3 1.4 0.43 1.00 0.00 1.00 54.2 
PTPRN2 1.0 0.5 1.5 0.5 0.32 1.00 0.04 1.00 67.5 
AOAH 1.0 1.1 0.5 0.3 0.50 0.04 1.00 1.00 1160.6 
MIR155HG 1.0 1.5 1.0 0.6 0.34 0.02 0.73 1.00 89.0 
MMP25 1.0 0.2 0.8 0.6 0.00 1.00 0.61 1.00 87.4 
CRTAM 1.0 1.1 0.8 0.8 0.52 0.42 0.04 1.00 1039.1 
MIR663 1.0 -0.6 0.6 0.1 0.04 1.00 0.12 1.00 9984.5 
RAB15 1.0 0.3 1.6 0.6 0.38 1.00 0.00 1.00 71.5 
CCL3 1.0 0.3 2.4 1.9 0.70 1.00 0.00 0.99 387.8 
KLRB1 0.9 0.7 0.1 1.8 0.03 0.87 1.00 1.00 3315.9 
LOC643733 0.9 1.0 0.6 0.5 0.15 0.01 1.00 1.00 139.0 
PLCB1 0.9 1.1 0.2 0.8 0.01 0.01 1.00 0.71 379.9 
CHN2 0.9 0.8 1.1 0.7 0.28 0.57 0.01 0.78 154.6 
GJC2 0.9 0.3 2.0 0.8 0.67 1.00 0.02 1.00 84.6 
SNTA1 0.8 0.5 0.5 1.2 0.31 0.73 0.89 0.01 138.0 
SIPA1L2 0.7 1.2 -0.2 0.2 0.57 0.00 1.00 1.00 307.2 
LOC100507209 0.7 1.4 0.2 -0.3 0.74 0.05 1.00 1.00 61.6 
CCL20 0.6 2.0 1.3 3.3 0.88 0.00 1.00 0.01 60.3 
PLCG2 0.6 0.0 1.3 0.3 0.43 1.00 0.00 1.00 393.5 
PHLDA2 0.6 1.5 0.6 1.1 0.84 0.02 1.00 1.00 25.5 
ITGAE 0.6 0.4 1.1 1.3 0.38 1.00 0.02 0.47 190.3 
KLRD1 0.6 0.9 -0.6 1.1 0.93 1.00 1.00 0.00 842.5 
MMP9 0.5 -0.5 0.2 2.5 0.97 1.00 1.00 0.01 307.2 
FRMPD3 0.5 -1.2 -1.6 -1.4 0.95 NA 0.02 0.10 34.3 
MAP7 0.5 1.7 0.2 -0.2 0.90 0.04 1.00 1.00 38.3 
C5orf62 0.4 0.5 0.0 1.3 0.80 1.00 1.00 0.03 91.6 
CACNA2D2 0.3 0.8 -1.4 0.1 0.89 0.22 0.00 1.00 185.1 
FCGR3A 0.3 -1.7 -2.1 -0.9 0.98 0.84 0.02 1.00 325.8 
ACVR2A 0.3 0.3 -1.5 -0.5 0.80 1.00 0.03 1.00 368.5 




CD69(+) vs. CD69(-) 
FDR Adjusted p-value, if p <0.05 
(grey) 
 

















SYNE1 0.2 0.2 -1.1 -0.9 0.92 1.00 0.00 0.00 6891.7 
PCDH1 0.1 -0.1 -3.9 0.9 NA 1.00 0.02 1.00 14.2 
CHI3L1 0.0 -1.8 0.1 8.5 1.00 0.87 1.00 0.00 38.2 
TGFBR3 0.0 -0.3 -1.2 -0.5 0.99 0.93 0.04 1.00 1224.4 
MED12L 0.0 1.9 -0.3 0.5 1.00 0.01 1.00 1.00 41.7 
ANK2 0.0 2.3 0.7 1.3 NA 0.01 NA NA 12.4 
LILRB1 -0.1 -1.4 -2.1 -0.1 0.99 1.00 0.02 1.00 79.8 
SPRY2 -0.2 -1.1 2.2 1.7 0.99 NA 0.00 0.23 49.7 
NCF2 -0.2 -2.8 0.0 -1.5 0.97 0.00 1.00 0.95 166.4 
ABCA2 -0.2 -1.0 -0.3 -0.3 0.90 0.03 1.00 1.00 1792.9 
ADAM8 -0.3 -1.2 -0.7 -0.2 0.88 0.00 0.42 1.00 1222.2 
APOBEC3H -0.3 -1.3 -1.3 -0.7 0.96 0.66 0.02 1.00 50.2 
ITGAM -0.3 -2.5 -1.5 -1.5 0.88 0.00 0.14 0.05 427.3 
ATP10A -0.3 -0.1 -1.2 0.0 0.53 1.00 0.01 1.00 602.5 
TSPAN2 -0.3 -2.0 -1.6 -1.7 0.97 0.00 1.00 0.05 71.8 
PYROXD2 -0.3 -0.1 -1.3 -0.7 0.85 1.00 0.00 1.00 90.8 
HLA-DOA -0.3 -1.5 0.3 -0.4 0.95 0.01 1.00 1.00 105.8 
TFEB -0.4 -0.6 -1.4 -0.6 0.75 0.97 0.00 1.00 156.2 
SEMA4C -0.4 -0.5 -1.0 -0.7 0.53 1.00 0.04 1.00 518.2 
CEP78 -0.5 -0.4 -1.0 -0.6 0.21 0.67 0.00 0.14 347.1 
CYB561 -0.5 -0.3 -1.1 -0.3 0.33 1.00 0.01 1.00 329.6 
TMCC3 -0.6 -0.9 -2.8 -0.3 0.85 1.00 0.01 1.00 87.2 
CLIC3 -0.6 -0.8 -1.2 -0.7 0.83 1.00 0.02 1.00 35.7 
S100A4 -0.6 -1.1 -0.7 -0.4 0.32 0.01 0.84 1.00 1710.6 
PHLDB2 -0.6 -0.1 -1.1 0.1 0.23 1.00 0.01 1.00 215.1 
TNFAIP8L2 -0.6 -1.1 -0.8 -1.1 0.19 0.85 0.01 1.00 130.0 
CASP10 -0.6 -1.0 -0.9 -0.7 0.35 0.02 0.01 0.49 367.4 
ALOX5 -0.7 -2.5 -0.1 -1.4 0.46 0.00 1.00 0.59 147.2 
GPR56 -0.7 -0.2 -2.6 -0.4 0.74 1.00 0.00 1.00 378.4 
MYO1G -0.7 -1.2 -0.7 -0.7 0.10 0.00 0.52 0.08 2302.2 
MTSS1 -0.7 -1.0 -1.6 -0.9 0.59 0.01 0.03 0.09 259.0 
CFP -0.7 -1.7 0.0 -0.1 0.67 0.00 1.00 1.00 103.0 
PLEKHG3 -0.7 -2.2 -2.0 -2.0 0.47 0.02 0.00 1.00 776.4 
LRRC8C -0.7 -0.5 -1.2 -0.8 0.19 0.62 0.02 0.01 2036.7 
LGALS1 -0.8 -1.8 -1.3 -0.5 0.62 0.00 1.00 1.00 238.4 
ANXA2P2 -0.8 -1.4 -0.4 -0.4 0.15 0.00 1.00 1.00 628.9 
SSBP3 -0.8 0.1 -1.7 -0.5 0.11 1.00 0.02 1.00 121.8 
TSHZ3 -0.8 -0.5 -2.5 -0.6 0.51 1.00 0.01 NA 32.7 
HBEGF -0.8 -1.6 0.2 -0.4 0.79 0.01 1.00 1.00 87.5 
GRASP -0.8 -1.1 -0.6 -0.4 0.01 0.62 1.00 1.00 656.3 
ITGA5 -0.9 -0.6 -1.6 -0.6 0.00 0.68 0.00 0.82 888.2 
CCDC65 -0.9 -1.6 -1.0 -0.8 0.01 0.02 0.09 1.00 127.1 
KCNH2 -0.9 -1.5 0.5 -0.7 0.50 0.03 1.00 NA 32.2 
DPYSL2 -0.9 -1.1 -1.0 -0.4 0.02 0.00 0.34 1.00 318.6 
SAMD3 -0.9 -2.1 -0.7 -0.8 0.36 0.00 0.15 0.97 879.3 
INF2 -0.9 -1.0 -1.0 -1.3 0.00 0.01 0.11 0.01 416.8 
C14orf49 -0.9 -1.2 -0.6 -0.8 0.00 0.00 1.00 0.08 489.5 
GABBR1 -0.9 -1.3 -0.4 -0.7 0.00 0.01 1.00 0.38 231.8 
ANLN -1.0 -2.1 -0.4 -1.9 0.59 0.01 1.00 0.32 72.8 
CDCA7 -1.0 -1.6 -0.6 -1.6 0.27 0.09 1.00 0.02 69.9 
HKDC1 -1.0 -2.4 -0.7 -1.2 0.07 0.01 0.72 1.00 101.2 
HELLS -1.0 -0.5 -0.2 -1.1 0.01 0.87 1.00 0.00 203.1 




CD69(+) vs. CD69(-) 
FDR Adjusted p-value, if p <0.05 
(grey) 
 

















CLSPN -1.0 -1.2 -0.3 -1.4 0.18 0.02 1.00 0.09 84.6 
S1PR5 -1.0 -0.1 -1.2 0.3 0.54 1.00 0.00 1.00 371.5 
SLCO3A1 -1.0 -1.4 -1.3 -1.3 0.00 0.00 0.00 0.00 251.1 
PRR11 -1.0 -1.8 -0.3 -1.1 0.10 0.00 1.00 0.63 76.7 
NDC80 -1.0 -1.2 -0.1 -1.2 0.04 0.02 1.00 0.07 132.1 
ABLIM1 -1.0 -0.5 -0.7 -0.5 0.00 0.62 0.32 1.00 2165.2 
IL2RA -1.0 -0.2 -0.2 1.2 0.02 1.00 1.00 0.01 725.7 
SELPLG -1.0 -1.3 -1.3 -1.0 0.00 0.00 0.00 0.00 2226.2 
IGSF9B -1.0 -1.2 0.2 -1.1 0.02 0.38 1.00 0.59 217.1 
ITGB7 -1.1 -1.5 -0.8 -0.6 0.21 0.00 0.93 0.87 1224.5 
STMN1 -1.1 -0.2 -0.4 -0.4 0.02 1.00 1.00 1.00 405.6 
SYT11 -1.1 -0.7 -0.9 -0.7 0.00 0.41 0.32 0.08 482.1 
AGPAT4-IT1 -1.1 -0.4 -2.8 -0.6 0.49 1.00 0.00 1.00 70.8 
LINC00341 -1.1 -1.2 -1.0 -1.1 0.02 0.02 0.80 0.22 140.7 
CCR4 -1.1 -0.3 0.0 -1.2 0.00 1.00 1.00 0.06 1618.0 
NUSAP1 -1.1 -1.0 -0.4 -0.8 0.01 0.07 1.00 0.78 185.0 
LOC728554 -1.1 -1.1 -0.4 -1.0 0.05 0.02 1.00 0.79 95.1 
MYO6 -1.1 -0.3 -1.2 -0.2 0.21 1.00 0.02 1.00 142.8 
BUB1 -1.1 -1.1 -0.3 -0.7 0.11 0.04 1.00 1.00 105.9 
PITPNM2 -1.1 -1.0 0.2 -0.2 0.03 0.00 1.00 1.00 246.0 
MAST4 -1.1 -0.4 -1.0 -0.7 0.00 1.00 0.19 1.00 486.8 
CIT -1.1 -0.7 0.1 -0.6 0.02 0.54 1.00 1.00 116.9 
C11orf21 -1.1 -1.3 -0.9 -0.5 0.00 0.12 0.01 0.74 420.1 
SCARNA16 -1.1 0.3 -0.5 0.8 0.04 1.00 1.00 1.00 52.8 
CORO1B -1.1 -1.1 -0.3 -0.4 0.00 0.16 1.00 1.00 136.2 
SNX29 -1.1 -0.5 -0.5 -0.4 0.03 0.72 0.76 0.79 608.2 
POLQ -1.1 -1.4 -0.5 -1.6 0.17 0.05 1.00 0.07 67.2 
CBLL1 -1.2 -0.3 -0.4 -0.2 0.00 1.00 0.91 1.00 484.0 
CD52 -1.2 -1.1 -1.3 -1.0 0.00 0.01 0.00 0.11 2020.8 
TIMP1 -1.2 -1.7 -1.2 -0.7 0.01 0.00 0.02 1.00 164.9 
PDE3B -1.2 -0.4 -1.3 -0.3 0.00 0.63 0.06 1.00 4253.6 
TMEM169 -1.2 -1.3 -0.7 -1.8 0.04 0.64 1.00 NA 29.8 
HIST1H3F -1.2 -1.0 -0.2 -0.6 0.01 0.38 1.00 1.00 318.8 
HIST1H2BH -1.2 -0.7 -0.3 -0.4 0.00 0.70 1.00 1.00 482.5 
SCARNA6 -1.2 0.5 -0.6 0.7 0.02 1.00 1.00 1.00 1668.0 
TIAM1 -1.2 0.4 -1.5 -0.7 0.00 1.00 0.20 0.78 1110.3 
AQP3 -1.2 -0.9 -0.1 -0.2 0.00 0.04 1.00 1.00 758.3 
ARHGEF18 -1.2 -1.0 -0.7 -1.0 0.00 0.00 0.10 0.00 2538.2 
MB21D2 -1.2 -0.7 -0.7 -1.3 0.00 0.69 1.00 1.00 84.0 
BAIAP3 -1.2 -0.7 -1.0 -0.5 0.01 1.00 0.80 1.00 270.4 
ADD3 -1.2 -0.8 -0.7 -0.9 0.00 0.00 0.01 0.00 3352.6 
HIST1H4F -1.2 -0.5 -0.6 -0.1 0.00 0.60 0.18 1.00 576.0 
CENPE -1.2 -1.1 -0.3 -1.0 0.00 0.00 1.00 0.35 181.5 
BIRC3 -1.2 -0.6 -0.1 -0.2 0.00 0.17 1.00 1.00 6396.7 
RASA3 -1.2 -0.8 -1.1 -0.8 0.00 0.06 0.00 0.00 2857.6 
FAM129B -1.3 -1.2 -0.9 -0.3 0.06 0.01 0.83 1.00 133.1 
CXCR7 -1.3 -0.8 -1.5 -0.7 0.01 0.98 0.00 1.00 47.1 
HPGD -1.3 -1.1 0.0 -0.1 0.03 0.02 1.00 1.00 351.7 
S1PR4 -1.3 -1.4 -1.0 -1.2 0.00 0.00 0.00 0.08 825.5 
USP46 -1.3 -1.4 -0.7 -1.5 0.00 0.00 0.13 0.05 209.4 
KIF11 -1.3 -1.5 -0.4 -1.4 0.02 0.00 1.00 0.01 164.3 
TPX2 -1.3 -2.0 -0.6 -1.5 0.03 0.00 1.00 0.43 118.5 




CD69(+) vs. CD69(-) 
FDR Adjusted p-value, if p <0.05 
(grey) 
 

















NCAPG -1.3 -1.3 -0.3 -1.3 0.05 0.01 1.00 0.28 78.1 
RMRP -1.3 0.1 -0.9 0.4 0.03 1.00 0.14 1.00 76059.3 
KIF2C -1.3 -1.7 -0.7 -1.5 0.03 0.01 1.00 0.89 61.3 
LEF1 -1.3 -0.1 -2.0 -0.8 0.00 1.00 0.00 0.22 1874.7 
NT5E -1.3 -0.7 -0.6 -0.4 0.03 1.00 1.00 1.00 91.5 
VCL -1.3 -1.1 -1.5 -0.9 0.00 0.04 0.04 0.30 645.6 
FLNA -1.3 -1.2 -1.2 -0.8 0.00 0.07 0.06 0.85 21453.9 
PLK1 -1.3 -1.5 -0.5 -1.0 0.01 0.19 1.00 1.00 52.0 
CSGALNACT1 -1.3 -0.9 -0.9 -1.8 0.04 0.00 1.00 0.05 439.6 
EEPD1 -1.3 -1.1 -1.1 -1.0 0.00 0.04 0.31 0.57 108.8 
CENPF -1.3 -0.9 -0.5 -1.5 0.03 0.05 1.00 0.01 320.3 
ESPL1 -1.3 -1.2 -0.7 -1.5 0.02 0.55 1.00 0.74 64.2 
KIF23 -1.3 -1.6 -0.7 -1.0 0.19 0.02 1.00 1.00 53.1 
LOC100506609 -1.3 -0.8 -1.5 -1.0 0.20 1.00 0.03 1.00 38.4 
ZNF365 -1.3 -0.5 -4.0 -1.8 0.34 0.91 0.02 0.46 62.8 
C12orf75 -1.4 -1.8 -1.2 -1.0 0.00 0.00 0.08 0.09 186.9 
JAM3 -1.4 -0.2 -0.7 -0.1 0.01 1.00 0.73 1.00 105.1 
PGAP1 -1.4 0.2 -0.4 0.2 0.00 1.00 1.00 NA 1008.3 
STK38 -1.4 -1.1 -1.2 -1.2 0.00 0.00 0.00 0.00 2196.2 
EMP3 -1.4 -1.5 -1.1 -1.1 0.00 0.00 0.02 0.00 454.3 
DLEC1 -1.4 -0.8 -1.0 -1.0 0.00 0.27 0.03 0.08 121.8 
CCNA2 -1.4 -1.5 -0.8 -1.7 0.05 0.01 1.00 0.02 95.9 
FMN1 -1.4 -0.9 -2.3 -1.8 0.16 1.00 0.00 0.17 445.1 
FOXP3 -1.4 -1.1 0.0 0.0 0.00 0.63 NA 1.00 129.8 
HIST1H3B -1.4 -1.0 -0.5 -0.9 0.11 0.02 1.00 0.37 490.2 
RRM2 -1.4 -2.2 -0.5 -2.1 0.14 0.00 1.00 0.11 114.3 
CCR8 -1.4 -1.7 -3.2 -1.4 0.04 0.16 NA 1.00 61.2 
GCNT4 -1.4 0.5 -0.4 -0.8 0.05 1.00 1.00 0.45 516.1 
FAM63A -1.4 -1.3 -0.8 -1.1 0.06 0.00 0.95 0.92 113.3 
HJURP -1.4 -1.7 -0.9 -1.9 0.04 0.18 1.00 0.91 39.3 
FGFBP2 -1.4 -2.0 -4.9 -3.1 0.35 NA 0.00 0.02 156.5 
NOSIP -1.4 -1.1 -0.8 -0.9 0.00 0.00 0.06 0.03 613.7 
KLF3 -1.4 -1.2 -1.4 -1.5 0.00 0.14 0.00 0.01 1367.5 
MAL -1.5 -0.2 -2.0 -0.7 0.00 1.00 0.13 0.98 347.5 
KIFC1 -1.5 -1.3 -0.5 -0.6 0.00 0.21 1.00 1.00 69.8 
TK1 -1.5 -1.4 -0.2 -1.5 0.52 0.05 1.00 1.00 39.4 
CDCA8 -1.5 -1.3 -0.7 -1.5 0.04 0.49 1.00 0.98 40.5 
CASC5 -1.5 -1.5 -0.2 -1.6 0.00 0.00 1.00 0.02 135.8 
KIAA0101 -1.5 -3.1 -0.2 -2.0 0.26 0.00 1.00 0.33 34.5 
MELK -1.5 -2.0 -0.8 -1.5 0.03 0.01 1.00 1.00 29.6 
ASPM -1.5 -1.5 -0.6 -1.6 0.00 0.01 0.68 0.11 236.6 
SH3BP5 -1.5 -2.1 -1.4 -1.5 0.00 0.00 0.00 0.00 627.6 
SNORD89 -1.5 -0.1 -1.1 0.1 0.01 1.00 0.26 1.00 235.4 
AGPAT4 -1.5 -0.5 -2.6 -0.7 0.00 1.00 0.00 1.00 350.1 
CKAP2L -1.5 -1.9 -1.0 -1.3 0.03 0.28 0.73 NA 25.4 
FAM164A -1.5 -1.0 -0.9 -1.1 0.05 0.23 1.00 1.00 54.6 
TJP2 -1.6 -0.6 -1.4 -0.9 0.00 0.56 0.61 1.00 91.2 
SNORD15B -1.6 0.7 -0.9 0.9 0.02 1.00 1.00 1.00 139.3 
PROCR -1.6 -1.8 -2.0 -0.9 0.41 NA 0.00 NA 17.5 
SNORD13 -1.6 0.5 -0.8 1.2 0.03 1.00 1.00 0.81 142.8 
RBBP8 -1.6 -0.2 -0.4 0.5 0.02 1.00 1.00 1.00 128.6 
KIF15 -1.6 -1.6 -0.6 -2.3 0.09 0.04 1.00 0.02 61.5 




CD69(+) vs. CD69(-) 
FDR Adjusted p-value, if p <0.05 
(grey) 
 

















ITGB1 -1.6 -1.2 -1.9 -1.1 0.00 0.00 0.01 0.00 3004.1 
ODZ1 -1.6 -0.7 -2.2 -1.7 0.11 0.98 0.01 0.08 133.2 
MYBL2 -1.6 -1.5 -0.4 -1.9 0.32 0.05 1.00 0.63 58.5 
LOC100506029 -1.6 -0.8 -1.2 -1.4 0.02 0.76 0.30 0.35 34.4 
C16orf45 -1.6 0.7 -2.3 -0.3 0.50 1.00 0.00 1.00 30.9 
KIF14 -1.6 -1.7 -0.8 -1.9 0.08 0.05 1.00 0.09 75.2 
STIL -1.7 -0.6 -0.4 -0.7 0.03 0.82 1.00 1.00 65.3 
TOP2A -1.7 -1.5 -0.6 -1.8 0.02 0.00 1.00 0.00 350.0 
LOC100506051 -1.7 -0.8 -1.2 -1.2 0.00 0.75 0.18 0.45 42.5 
MSX2P1 -1.7 -2.2 -2.0 -1.8 0.00 0.18 0.00 1.00 35.2 
KLF2 -1.7 -1.9 -1.1 -1.2 0.00 0.00 0.01 0.00 4440.4 
NELL2 -1.7 -0.5 -0.7 -0.2 0.03 0.73 1.00 1.00 1084.4 
SNORA48 -1.7 0.6 -0.7 1.2 0.01 0.72 1.00 0.47 442.0 
TTC16 -1.7 -2.5 -1.0 -0.8 0.02 0.00 0.12 0.09 186.0 
DLGAP5 -1.7 -2.4 -0.7 -1.8 0.13 0.00 1.00 0.46 66.8 
ARHGEF10 -1.7 -0.6 -0.1 -0.1 0.00 0.54 1.00 1.00 58.8 
PRSS23 -1.7 -0.2 -5.0 0.4 0.31 1.00 0.01 1.00 69.8 
CDCA2 -1.7 -1.3 -0.6 -1.5 0.04 0.26 1.00 0.92 40.6 
AURKB -1.7 -1.3 -0.7 -1.9 0.00 0.36 1.00 1.00 31.6 
HIST1H3C -1.7 -0.9 -0.5 -0.8 0.00 0.49 1.00 0.89 204.6 
NHSL2 -1.7 -2.4 -2.7 -1.6 0.00 0.00 0.00 0.08 116.3 
CDCA5 -1.7 -1.6 -0.5 -1.6 0.02 0.22 1.00 0.57 38.9 
LOC729041 -1.7 -2.4 -3.0 -1.1 0.03 0.05 0.00 1.00 26.4 
DSEL -1.7 -0.7 -2.0 -0.8 0.00 1.00 0.00 1.00 168.9 
RNU4-2 -1.7 1.0 -1.3 1.1 0.00 1.00 0.57 1.00 807.8 
ALS2CL -1.8 -1.2 -0.3 -0.8 0.00 0.01 1.00 1.00 162.2 
EEF1DP3 -1.8 -2.5 -2.8 -5.3 0.04 0.10 0.29 NA 15.8 
FAM65B -1.8 -1.6 -1.6 -1.5 0.00 0.00 0.00 0.00 4509.4 
TRIM2 -1.8 -0.5 -1.7 -1.0 0.00 0.83 NA 1.00 59.7 
BIRC5 -1.8 -2.4 -0.7 -2.5 0.03 0.00 1.00 0.16 48.9 
CCNB2 -1.8 -1.9 -1.0 -2.0 0.06 0.03 1.00 0.38 45.5 
SVIL -1.8 -1.9 -1.7 -2.2 0.00 0.00 0.00 0.00 694.2 
MFGE8 -1.8 -1.4 -0.8 -0.5 0.09 0.01 1.00 1.00 106.0 
KLF7 -1.8 -0.8 -1.6 -1.2 0.00 0.22 0.09 0.42 138.4 
D4S234E -1.8 -1.0 -2.2 -0.7 0.08 0.37 0.00 1.00 190.0 
GYLTL1B -1.8 -2.4 -0.5 -1.6 0.05 0.01 1.00 0.51 23.1 
KLF8 -1.8 -1.0 -1.5 -0.3 0.00 0.62 0.35 1.00 40.2 
KIF19 -1.8 -2.3 -4.4 -1.9 0.12 0.82 0.00 NA 23.2 
CX3CR1 -1.8 -1.5 -4.3 -2.9 0.08 0.38 0.00 0.02 269.7 
GLB1L3 -1.8 -0.2 -3.5 -0.5 0.04 1.00 0.08 1.00 30.3 
MKI67 -1.8 -2.5 -0.8 -2.5 0.00 0.00 1.00 0.01 486.2 
HIST1H3G -1.8 -2.4 -0.7 -2.2 0.01 0.00 1.00 0.02 189.7 
CDC25B -1.9 -1.4 -1.3 -1.0 0.00 0.00 0.00 0.00 1211.8 
SNORD17 -1.9 0.8 -1.6 1.0 0.00 1.00 0.01 1.00 4213.8 
LOC641518 -1.9 -0.6 -2.3 -1.6 0.03 1.00 0.36 0.52 30.2 
SNORD94 -1.9 0.9 -1.3 1.5 0.02 1.00 0.56 1.00 86.3 
RNU4-1 -1.9 0.8 -1.1 0.5 0.00 1.00 0.91 1.00 146.4 
GPR146 -1.9 -2.0 -0.9 0.0 0.02 0.02 1.00 1.00 19.1 
GPR15 -1.9 -1.0 -1.0 -0.7 0.01 1.00 1.00 1.00 331.1 
ELOVL4 -1.9 -1.5 -1.0 -0.5 0.00 0.12 0.82 1.00 90.1 
FAM111B -1.9 -1.2 -1.0 -2.2 0.01 0.30 1.00 0.21 23.3 
VSIG1 -1.9 -1.7 -1.3 -1.4 0.00 0.00 0.44 0.01 135.8 




CD69(+) vs. CD69(-) 
FDR Adjusted p-value, if p <0.05 
(grey) 
 

















PPP4R4 -1.9 -0.7 -0.8 -0.1 0.04 1.00 1.00 1.00 20.8 
FOXM1 -2.0 -1.7 -0.3 -1.8 0.00 0.06 1.00 0.93 42.7 
DNAI2 -2.0 -2.6 -3.2 -1.8 0.02 0.02 0.04 0.79 16.9 
TTYH2 -2.0 -1.6 -2.1 -1.8 0.00 0.00 0.01 0.03 141.3 
CRYBG3 -2.0 -1.6 -2.7 -1.7 0.00 0.00 0.00 0.00 273.8 
SSTR3 -2.0 -0.4 -0.4 -0.5 0.01 1.00 NA NA 20.0 
PACSIN1 -2.0 -0.5 -2.4 -1.7 0.02 1.00 0.06 0.01 48.5 
SNORD10 -2.0 0.7 -1.3 1.2 0.00 1.00 0.56 0.82 495.7 
MAP1A -2.0 0.1 -0.2 0.2 0.04 1.00 1.00 1.00 97.7 
VIPR1 -2.0 -1.2 -1.8 -1.3 0.01 0.53 1.00 0.73 292.9 
SELL -2.0 -0.7 -2.0 -1.8 0.18 0.76 0.00 0.00 2583.7 
SNORD33 -2.1 -0.2 -1.4 0.1 0.04 1.00 0.64 1.00 39.2 
SNORA52 -2.1 0.5 -1.2 0.8 0.02 1.00 0.80 1.00 50.9 
NTN4 -2.1 -1.4 -1.4 -0.4 0.01 0.66 0.26 1.00 57.9 
SBK1 -2.1 -1.8 -1.7 -1.4 0.00 0.00 0.00 0.00 140.4 
SULT1B1 -2.1 -2.3 -0.6 -1.8 0.01 0.00 1.00 NA 29.6 
MIR3609 -2.1 0.3 -0.6 1.1 0.00 1.00 1.00 1.00 1296.4 
CR1 -2.1 -1.1 -1.9 -0.7 0.00 0.09 0.04 1.00 291.3 
GAL3ST4 -2.1 -0.7 -0.3 -0.5 0.02 1.00 NA NA 16.6 
BCL7A -2.2 -0.4 -1.8 -1.2 0.02 1.00 0.36 1.00 24.9 
SNORA12 -2.2 0.6 -1.8 0.5 0.00 1.00 0.30 1.00 179.9 
PKIA -2.2 -1.0 -1.7 -1.3 0.00 0.00 0.01 0.02 144.2 
RNU2-2 -2.2 1.2 -1.5 1.7 0.00 1.00 1.00 1.00 9485.0 
PLXNA4 -2.2 -1.5 0.5 -1.2 0.01 0.50 1.00 1.00 34.1 
NGFRAP1 -2.2 -1.0 -1.0 -1.1 0.00 0.05 1.00 0.58 74.0 
GNLY -2.2 -1.9 -3.8 -1.1 0.00 0.07 0.01 1.00 409.3 
HPCAL4 -2.3 -1.3 -3.4 -1.7 0.00 0.03 0.11 0.01 141.2 
SNORA54 -2.3 1.1 -1.0 2.3 0.00 1.00 1.00 1.00 703.6 
EDA -2.3 -0.7 -1.7 -0.9 0.00 1.00 0.64 1.00 30.7 
LOC100652903 -2.3 -0.5 -2.0 -1.0 0.00 0.82 0.13 0.93 56.9 
SNORA7B -2.3 0.6 -1.6 1.3 0.01 1.00 0.44 1.00 35.6 
SNORA73A -2.3 0.3 -1.4 0.4 0.00 1.00 0.26 1.00 2320.3 
RNU105A -2.3 0.4 -1.5 0.5 0.00 1.00 0.08 1.00 2075.9 
ARHGEF11 -2.4 -2.2 -1.1 -2.0 0.00 0.00 0.17 0.00 158.8 
FHIT -2.4 -1.0 0.0 -1.1 0.00 0.43 1.00 1.00 39.5 
SNORA57 -2.4 0.7 -1.1 1.2 0.00 1.00 1.00 1.00 124.1 
CCR7 -2.4 -0.3 -1.8 -0.6 0.00 1.00 0.03 1.00 2207.2 
CRIP2 -2.4 -1.9 -0.1 -0.3 0.10 0.00 1.00 1.00 33.3 
E2F2 -2.4 -3.1 -0.6 -3.5 0.00 0.00 1.00 0.00 120.0 
SNORA49 -2.4 0.9 -1.3 1.4 0.00 1.00 0.61 1.00 142.7 
SOX13 -2.5 -2.3 -2.7 -1.6 0.00 0.25 0.00 0.41 89.4 
KRT72 -2.5 -2.8 -3.0 -2.0 0.00 0.00 0.00 0.14 36.7 
TSHZ2 -2.5 -0.5 -1.1 -0.5 0.00 0.05 NA 1.00 290.0 
SNORA63 -2.5 0.8 -1.5 1.1 0.00 1.00 1.00 1.00 616.9 
CBR3 -2.5 -1.3 -1.7 -1.2 0.02 0.47 1.00 1.00 19.5 
LOC100505551 -2.5 -1.2 -0.2 -1.0 0.04 0.66 1.00 1.00 13.7 
SNORA22 -2.5 0.5 -0.7 1.0 0.04 1.00 1.00 1.00 17.0 
C6orf105 -2.6 -0.2 -0.6 -0.3 0.02 1.00 1.00 1.00 118.8 
AK5 -2.6 -2.2 -3.6 -2.6 0.06 0.02 0.30 0.24 48.6 
LAMA2 -2.6 -1.1 -2.0 -1.1 0.01 0.98 0.02 1.00 39.4 
SNORA34 -2.6 0.7 -1.5 1.0 0.02 1.00 0.77 1.00 65.7 
KCTD15 -2.6 -2.8 -2.4 -1.6 0.00 0.00 0.10 1.00 46.5 




CD69(+) vs. CD69(-) 
FDR Adjusted p-value, if p <0.05 
(grey) 
 

















10-Sep -2.7 -1.0 -1.1 -0.1 0.04 0.74 NA 1.00 16.6 
PTGDS -2.7 -3.7 -3.7 -2.4 0.00 0.00 0.00 0.06 61.2 
RAP1GAP2 -2.7 -2.4 -3.7 -3.7 0.00 0.00 0.01 0.00 476.6 
SPSB1 -2.7 0.3 -1.5 -0.6 0.00 1.00 0.48 1.00 66.7 
TSPAN18 -2.7 -2.8 -2.1 -2.8 0.00 0.00 0.08 0.00 169.7 
MCOLN3 -2.8 -3.0 -3.0 -3.2 0.02 0.12 NA NA 8.1 
KRT73 -2.8 -2.2 -2.1 -2.3 0.00 0.01 0.16 0.02 53.4 
HAPLN3 -2.8 -1.6 -1.1 -1.3 0.00 0.00 0.22 0.00 250.9 
F5 -2.8 -1.1 -0.5 -1.9 0.00 0.32 1.00 0.01 211.6 
RGMB -2.8 -1.4 -3.1 -1.9 0.00 0.00 0.01 0.00 88.5 
FAM19A1 -2.8 -3.0 -2.1 -3.0 0.02 0.02 0.20 0.36 20.6 
GP5 -2.9 -0.6 -1.4 0.0 0.00 1.00 0.60 1.00 39.8 
EPHA4 -3.0 -2.1 -2.3 -1.9 0.00 0.00 0.00 0.00 688.7 
GPA33 -3.0 -1.6 -1.7 -1.4 0.00 0.00 0.00 0.11 158.4 
DST -3.0 -1.0 0.2 0.1 0.00 0.01 1.00 1.00 112.0 
ISM1 -3.1 -4.1 -2.3 -1.4 0.03 0.00 NA NA 15.4 
PI16 -3.1 -3.2 -2.8 -2.8 0.00 0.00 NA 0.05 38.8 
FUT7 -3.2 -3.2 -1.4 -2.5 0.00 0.00 0.48 0.06 76.7 
KALRN -3.2 -2.0 -2.5 -2.2 0.00 0.00 0.58 1.00 27.2 
NEFL -3.3 -2.2 -2.5 -5.4 0.00 0.00 NA NA 34.3 
S1PR1 -3.3 -2.3 -3.1 -2.6 0.00 0.00 0.00 0.00 1315.8 
WNT7A -3.3 -2.5 -4.5 -3.4 0.00 0.00 0.17 0.00 46.1 
SEMA3G -3.3 -2.7 -0.4 -0.2 0.00 0.00 1.00 1.00 64.3 
NPDC1 -3.4 -2.1 -2.8 -2.5 0.00 0.00 0.00 0.00 196.1 
SGCD -3.5 -2.3 -3.3 -1.1 NA NA 0.01 1.00 12.0 
CXCL9 -3.6 -2.8 2.3 6.5 0.05 0.10 1.00 0.00 22.1 
DSC1 -3.7 -0.7 -0.7 -0.6 0.03 1.00 1.00 1.00 16.7 
ST6GALNAC1 -3.8 -2.4 -0.1 -0.4 0.00 0.00 NA NA 32.4 
SEMA5A -4.2 -1.4 -2.5 -2.1 0.01 0.43 NA 0.68 22.9 
RASSF6 -5.1 -0.6 1.9 0.8 0.01 1.00 NA NA 6.8 
HSD11B1 -5.2 -2.8 1.8 -2.5 0.01 NA NA NA 3.3 
SPP1 -5.2 0.0 3.4 3.4 0.00 1.00 1.00 1.00 34.0 





Figure A.B.3. Human lymphoid tissue CD8+CD69+TEM cells display core features of 
tissue-resident memory T cells (TRM).  
(A) Number of differentially expressed genes between transcriptomes of CD69- and CD69+ 
CD8+TEM cells from BM and LN either up or down-regulated (P-adj. <0.05). 
(B) Multidimensional scaling (MDS) analysis of gene expression of CD69- and CD69+ 
CD8+TEM cells from indicated tissues of three individuals based on the core TRM gene 
signature from Kumar et al [8]. Samples from LN and BM are from the same three individuals, 
lung and blood TEM cells are from an additional six individuals. (D) Normalized read counts of 
indicated genes from CD8+ TEM cells from BM and LN of three individuals. LN= lymph node. 
LLN, MLN, and ILN = lung-, mesenteric-, and iliac- draining lymph nodes respectively. Error 



























Figure A.B.4. Human lymphoid tissue CD4+CD69+ memory T cells display core features of 
TRM. 
(A) Number of differentially expressed genes between transcriptomes of CD69+ CD4+TEM cells 
relative to CD69-CD4+TEM from BM and LN either up or down-regulated (P-adj. <0.05). 
(B) Multidimensional scaling (MDS) analysis of gene expression of CD69- and CD69+ 
CD4+TEM cells from indicated tissues of three individuals based on the differentially expressed 
genes between CD69+ and CD69- CD4+TEM in BM (357 total genes). Samples from LN and 
BM are from the same three individuals, lung and blood TEM cells are from an additional six 




























Figure A.B.5. Abundance of CD3+ T cells in bone marrow by immunohistochemistry.  
Immunohistochemistry staining of a BM section using CD3. Paraffin embedded BM sections 
(5μM) were mounted onto slides for immunostaining with CD3 antibody. T cells are stained in 
brown (CD3+) and all other nucleated cells are stained in blue (nuclei). Bar graph shown the 
percentage of all nucleated cells in BM from three individuals of varying ages as indicated. 
Percentage was averaged from three equal sized sections per slide, as shown by the enlarged 















Appendix C. Scripts in Python and R 
Section C-1: Cytometry by Time of Flight (CyTOF)  
 The code used for analyzing CyTOF data is located on my github page 
(https://michellemiron.github.io/Human-T-cell-CyTOF/). This page includes a reproducible 
analysis using workflowr, an R package. 
 
Section C-2: T cell receptor sequencing  
QC of raw sequencing reads 
Before running the ImmuneDB pipeline, quality control of FASTQ files was performed 
using pRESTO. First, sequences were trimmed of poor-quality bases on the end farthest from the 
primer where base call confidence degrades. Using default parameters, sequences are then 
trimmed to the point where a window of 10 nucleotides has an average quality score of at least 
20. If reads are paired, the next step is to align the R1 and R2 reads into full-length, contiguous 
sequences. Short sequences, those with less than 100 bases, are then removed from further 
analysis. Finally, any base with a quality score less than 20 is replaced with an N and any 
sequence containing more than 10 such bases is removed from further analysis. In the case of 
FASTA input which has no quality information, only paired-end assembly and short sequence 
removal are recommended. The script for running this process, from Dr. Wenzhao Meng, can be 
found below. After this process, the remaining filtered sequences are presumed to be of adequate 
quality for germline inference and clonal assignment using Immune DB. 
1. '''''takes sequence files within a folder through the various modules from pRESTO to filter data prior to performing  
2. VDJ alignment  
3. '''   
4.    
5. import os   
6.    
7. f = open('~/list of files.txt', 'r')   
8. files = f.readlines()   
9. f.close()   
10.    
11. for line in files:   
12.     line = line.strip()   
13.     base_line = os.path.basename(line)   
14.     directory = os.path.dirname(line)+'/'   
15.     file_name = os.path.splitext(base_line)[0]   
16.     ext = '.fastq'   
17.     ext2 = '.fasta'   
18.     extension1 = '_log.txt'   
19.     extension2 = '_convert.fasta'   
20.        
21.     if line[-12:-10] == 'R1':   
22.        
23.         #Aligns sequences from Read 1 and Read 2   
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24.         R1line = line   
25.         R2line = line[:-11] + '2_001.fastq'   
26.         assemble_log_file_name = file_name + '_assemble'+ extension1   
27.        
28.         os.system('python AssemblePairs.py align -1' + R1line + ' -2 ' + R2line + ' --rc tail --nproc 4 --coord illumina --
failed --log ' + directory + assemble_log_file_name)   
29.        
30.         #qualtrim data based on a sliding window   
31.         assemble_file = line[:-6] + '_assemble-pass'   
32.         qualtrim_log_file_name = file_name + '_trimqual' + extension1   
33.        
34.         os.system('python FilterSeq.py trimqual -s '+ assemble_file + ext + ' -q 30 --nproc 4 --win 10 --failed --
log ' + directory + qualtrim_log_file_name)   
35.        
36.         #trims sequences so that shorter sequences are removed   
37.         qual_file = assemble_file + '_trimqual-pass'   
38.         length_log_file_name = file_name + '_length' + extension1   
39.        
40.         os.system('python FilterSeq.py length -s ' + qual_file + ext + ' -n 100 --nproc 4 --failed --
log ' + directory + length_log_file_name)   
41.            
42.         #maskqual makes low scoring nucleotides become missing values (N)   
43.         len_file = qual_file + '_length-pass'   
44.         maskqual_log_file_name = qual_file + '_maskqual' + extension1   
45.        
46.         os.system('python FilterSeq.py maskqual -s '+ len_file + ext + ' -q 30 --nproc 4 --failed')   
47.        
48.         #eliminates sequences with too many missing nucleotides   
49.         maskqual_file = len_file + '_maskqual-pass'   
50.         missing_log_file_name = file_name + '_missing' + extension1   
51.        
52.         os.system('python FilterSeq.py missing -s '+ maskqual_file + ext + ' -n 10 --nproc 4 --failed --
log ' + directory + missing_log_file_name)   
53.  
Calculating Clonality 
The input of this script is the clone overlap data format exported from the ImmuneDB web 
interface. This script calculates the clonality for each sample and outputs the calculation for 
every sample in a single table as a .txt file.   
1. #### SET DATE AND LOAD PACKAGES -----   
2. options(stringsAsFactors=FALSE)   
3. date <- Sys.Date()    
4. library(gsubfn)   
5. library(lsa)   
6. library(stringr)   
7. library(dplyr)   
8. library(data.table)   
9. library(reshape)   
10. library(pheatmap)   
11. library(RColorBrewer)   
12. library(colorspace)   
13. library(ggplot2)   
14.    
15. dostats <- function(i) {   
16. cloneoverlap <- read.csv("/Users/michellemiron/Desktop/TCR-paper-Oct-2018/data/2018-10-31-17-
26_clone_overlap.tsv",   
17.                          sep="\t",   
18.                          header=T)   
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19. ### remove the uniques column ###   
20. clonoverlap2 <- cloneoverlap[,-c(3,5)]   
21. ### filter data by donor and replicate ###   
22.    
23. clean<- clonoverlap2 %>%   
24.           dplyr::filter(!str_detect(sample, "remove"), !str_detect(sample,"Fb"))   
25. donors <- c("D299", "D287",  "D280",   "D233", "D383",  "D324",  "D229",  "D255",  "LD1",  "LD2",  "LD3")   
26. donor <- donors[i]   
27. donordf <- clean %>%   
28.           dplyr::filter(str_detect(sample,donor))   
29.    
30. #### cast the dataframe so each column is a sample and rows are unique clones ####   
31. ddf <- dcast(donordf, clone_id ~ sample, value.var = "copies", fill=0)   
32.    
33. #### THE FUNCTIONS ----   
34. #These are the functions used to calculate clonality, obtained from Dr. Yufeng Shen's lab   
35. normalize <- function(data) {   
36.   nc = ncol(data)   
37.   for (i in 1:nc) {   
38.     data[,i] = data[,i] / sum(data[,i]) 
39.   }   
40.   return(data) 
41. } 
42.    
43. shannon.entropy <- function(p){   
44.   if (min(p) < 0 || sum(p) <= 0)   
45.     return(NA)   
46.   p.norm <- p[p>0]/sum(p)   
47.   -sum(log2(p.norm)*p.norm)   
48. }   
49.  
50. Clonality <- function(p) {   
51.   x = p[p>0] / sum(p)   
52.   l = length(x)   
53.   entropy = shannon.entropy(p)   
54.   maxentropy = -log2(1/l)   
55.   return(signif(1 - entropy / maxentropy, 3))    
56. }   
57.  
58. calcSI<-function(vals){   
59.                    vals=vals[vals>0]   
60.                    fq=vals/sum(vals)   
61.                    si=sum(fq^2)   
62.                    return(si)   
63.          }   
64.  
65. calcr20 = function(X){   
66.                    X=sort(X,decreasing=T)   
67.                    X=X[X>0]   
68.                    CX=cumsum(X)   
69.                    num=length(which(CX/sum(X)<=0.2))   
70.                    den=length(X)   
71.                    return(num/den)   
72.          }   
73. calcr50 = function(X){   
74.                    X=sort(X,decreasing=T)   
75.                    X=X[X>0]   
76.                    CX=cumsum(X)   
77.                    num=length(which(CX/sum(X)<=0.5))   
78.                    den=length(X)   
79.                    return(num/den)   
80.          }   
81.    
  
225 
82. df <- ddf[,-1]   
83.    
84. # Apply function to all files in a given directory   
85. entropy <- apply(df,2,shannon.entropy)   
86. clonality <- apply(df,2,Clonality)   
87. SI <- apply(df,2,calcSI)     
88. R20<-  apply(df,2,calcr20)     
89. R50<- apply(df,2,calcr50)     
90. NumberUniqueClones <- apply(df,2,function(c)sum(c!=0))    
91. is.na(df) <- df==0   
92. Mean <- colMeans(df, na.rm=TRUE)    
93. Mean50cutoffvalue <- Mean*0.5   
94.    
95. statistics<- data.frame(entropy,   
96.            clonality,   
97.            SI,   
98.            R20,   
99.            R50,   
100.            NumberUniqueClones,   
101.            Mean,   
102.            Mean50cutoffvalue)   
103.                   
104. return(statistics)   
105. }   
106.    
107. cstats<- data.frame()   
108.    
109. df1 <- dostats(1)   
110. df2 <- dostats(2)   
111. df3 <- dostats(3)   
112. df4 <- dostats(4)   
113. df5 <- dostats(5)   
114. df6 <- dostats(6)   
115. df7 <- dostats(7)   
116. df8 <- dostats(8)   
117. df9 <- dostats(9)   
118. df10 <- dostats(10)   
119. df11 <- dostats(11)   
120.    
121. T_df <- do.call("rbind", list(df1, df2, df3,  df4, df5, df6, df7,df8,df9,df10,df11))   
122.    
123. write.table(T_df,file = paste("/Users/michellemiron/Desktop/TCR-paper-Oct-2018/data_outputs/Stats_allsamples",   
124.                 date,   
125.                 "txt",   
126.                 sep=""),   
127.           col.names=T,   
128.           row.names=T,    
129.           sep="\t")   
Plotting Clonality   
This script inputs the file from the above script, and produces boxplots of clonality data. 
1. #### Load required pacakges ####   
2. library(dplyr)   
3. library(ggplot2)   
4. library(ggbeeswarm)   
5. #### Load in the raw data, diversity metrics #####   
6. rawdata <- read.table("/Users/michellemiron/Desktop/TCR-paper-Oct-2018/data_outputs/Stats_allsamples2018-11-
01txt",header=T)   
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7.    
8. #### convert rowname to a column to make it easier to filter ###   
9. rawdata$sample <- rownames(rawdata)   
10.    
11. #### plot of clonality vs. Number of unique clones of all samples ####   
12. ggplot(rawdata) + geom_point(aes(clonality,NumberUniqueClones))   
13.    
14. #### in order to color by donor and sample, add categorgical data ####   
15.    
16. # load in metadata   
17. metadata <- read.csv("/Users/michellemiron/Desktop/TCR-paper-Oct-2018/data/2018-11-01-00-
54_samples.tsv", sep = "\t", header = T )   
18.    
19. ##combine metadata and data into one df, dropping non matching rows in metadata ##   
20.    
21. metadata <- as_tibble(metadata)   
22. metadata$name <- as.character(metadata$name)   
23. rawdata <- as_tibble(rawdata)   
24.    
25. data_a <- left_join(rawdata,metadata, by= c("sample" = "name"))   
26.    
27. ##filter data to remove water, and etc. ###   
28. data_ac <- data_a %>%    
29.           filter(subset == "CD4" | subset == "CD8" ) %>%   
30.           filter(replicate != "3" & replicate !="4" & replicate !="3A"    
31.                  & replicate != "2" &  replicate != "5" &  replicate != "6"    
32.                  &  replicate != "7") %>%   
33.           filter(subset2 != "TMEM")   
34.              
35. data_ac$subset2 <- factor(data_ac$subset2, levels = c("TCM", "TEM", "TMEM",   
36.                                                             "TRM","TEMRA"))   
37.    
38. data_ac$tissue <- factor(data_ac$tissue, levels = c("Bld", "BM", "Spl",   
39.                                                       "Lung","LN"))   
40.    
41. ggplot(data_ac) + geom_point(aes(clonality,NumberUniqueClones, color=subject))   
42. ggplot(data_ac) + geom_point(aes(entropy,clonality, color=subset2))   
43.    
44. ##comparing different subsets in each tissue ###   
45. pdf("/Users/michellemiron/Desktop/TCR-paper-Oct-2018/Clonality/clonality-nov.pdf",   
46.     width=6,   
47.     height=4,   
48.     paper='special',   
49.     onefile=FALSE)   
50.    
51. ggplot(data_ac) +    
52.           geom_boxplot(aes(subset2,clonality,   
53.                            color=interaction(subset2)),   
54.                        outlier.shape = NA) +   
55.           facet_grid(subset~tissue, scales="free_x") +   
56.           theme(axis.text.x = element_text(angle=90,hjust=1))   
57. dev.off()   
58.    
59.    
60. pdf("/Users/michellemiron/Desktop/TCR-paper-Oct-2018/Clonality/clonality-nov2.pdf",   
61.     width=6,   
62.     height=4,   
63.     paper='special',   
64.     onefile=FALSE)   
65.    
66. ggplot(data_ac) +    
67.           geom_boxplot(aes(tissue,clonality,   
68.                            color=interaction(tissue)),   
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69.                      outlier.shape = NA) +   
70.           facet_grid(subset~subset2, scales="free_x") +   
71.           theme(axis.text.x = element_text(angle=90,hjust=1))   
72. dev.off()   
73.    
74. pdf("/Users/michellemiron/Desktop/TCR-paper-Oct-2018/Clonality/clonality-tissuenov.pdf",   
75.     width=6,   
76.     height=4,   
77.     paper='special',   
78.     onefile=FALSE)   
79.    
80. ggplot(data_ac) +    
81.           geom_boxplot(aes(tissue,clonality,   
82.                            color=interaction(tissue)),   
83.                        outlier.shape = NA) +   
84.           facet_grid(~subset, scales="free_x") +   
85.           theme(axis.text.x = element_text(angle=90,hjust=1))   
86.    
87.    
88. dev.off()   
89.    
90. give.n <- function(x){   
91.           return(c(y = mean(x), label = length(x)))   
92. }   
93.    
94. ggplot(data_ac,aes(tissue,clonality)) +    
95.           geom_boxplot(aes(color=interaction(tissue)),   
96.                        outlier.shape = NA) +    
97.           stat_summary(fun.data = give.n, geom = "text") +   
98.           facet_grid(~subset, scales="free_x") +   
99.           theme(axis.text.x = element_text(angle=90,hjust=1))   
100.    
101.              
102.    
103. subsetc <- "CD4"   
104. CDcdat <- data_ac %>% filter (subset == subsetc,tissue!="Bld")   
105. pairwise.t.test(CDcdat$clonality,   
106.                 interaction(CDcdat$tissue),   
107.                 paired = FALSE,   
108.                 p.adjust="none",   
109.                 conf.level = 0.95)   
110.    
111.    
112. ##Comparing subset ###   
113. pdf("/Users/michellemiron/Desktop/TCR-paper-Oct-2018/Clonality/clonality-subsets-nov3.pdf",   
114.     width=6,   
115.     height=4,   
116.     paper='special',   
117.     onefile=FALSE)   
118.    
119. ggplot(data_ac) +    
120.           geom_boxplot(aes(subset2,clonality,   
121.                            color=interaction(subset2)),   
122.                        outlier.shape = NA) +   
123.           facet_grid(~subset, scales="free_x")    
124.    
125. dev.off()   
126.    
127. ggplot(data_ac,aes(subset2,clonality)) +    
128.           geom_boxplot(aes(color=interaction(subset2)),   
129.                        outlier.shape = NA) +   
130.           stat_summary(fun.data = give.n, geom = "text") +   
131.           facet_grid(~subset, scales="free_x")    
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132.    
 
Clonal Proportion Plots 
The input to this script is the "vdjtools" data format exported from ImmuneDB web interface. 
This script produces clonal proportion plots. 
1. #Use tcR package for analysis of TCR sequencing data   
2. library("tcR")   
3.    
4. donor<- c("D229",  "D233",  "D299",  "D287",  "D280",  "D255",  "D324",  "D383",  "LD1",  "LD2",  "LD3")   
5.  
6. i<-11   
7. for (i in 1:length(donor)) {   
8. Location <-
 file.path("/Users","michellemiron","Dropbox","TCR data Brian and Michelle","ImmuneDBdata",donor[i])   
9. List_of_files<- list.files(Location)   
10. listofdf <- list()   
11.    
12.    
13. for (y in 1:length(List_of_files)){   
14.         filepath <- paste(Location,"/",List_of_files[y], sep="")   
15.         data <- parse.cloneset(filepath,   
16.                               "cdr3nt",   
17.                               "cdr3aa",   
18.                               "count",   
19.                               "count",   
20.                               "v","j","d",   
21.                               NA,NA,NA, NA,NA,NA,FALSE,   
22.                               "\t")   
23.         name <- List_of_files[y]   
24.         tmp <- list(data)   
25.         listofdf[[name]] <- tmp   
26. }   
27.    
28.    
29. plotname <- paste("clonal_proportion","_",donor[i],sep="")   
30.    
31. pdf(paste("~/Desktop/TCR-paper-Oct-2018/Clonal-Proportion/",plotname,".pdf",sep=""),   
32.     width=6,   
33.     height=4,   
34.     paper='special',   
35.     onefile=FALSE)   
36.    
37. print(vis.top.proportions(listofdf, c(10, 100, 1000, 10000,20000), .col = "Read.count"))   
38. dev.off()   
39. }   
 




The input to this script is the clone overlap data format exported from ImmuneDB web interface. 
This script produces heatmaps of calculated cosine similarity values. 
1. #### temporary donor IDS ####   
2. d <- 3   
3. j <- 2   
4. cutoff = "no"   
5. ##### Cluster method #####   
6. cluster_method <-"complete"   
7.    
8. library(gsubfn)   
9. library(lsa)   
10. library(stringr)   
11. library(dplyr)   
12. library(data.table)   
13. library(reshape)   
14. library(pheatmap)   
15. library(RColorBrewer)   
16. library(colorspace)   
17. library(ggplot2)   
18.    
19.    
20. ###### Create list of all donors and lineages that will be plotted #####   
21.    
22. donors <- c("D287",  "D233",  "D280",  "D299",  "D229",  "D255",  "D383",  "D324",  "LD1",  "LD2", "LD3")    
23. lineages <- c("CD4","CD8")  
24.    
25. ####### Load in the data ######   
26. cloneoverlap <- read.csv("/Users/michellemiron/Desktop/TCR-paper-Oct-2018/data/2018-10-31-17-
26_clone_overlap.tsv",   
27.           sep="\t",   
28.           header=T)     
29.    
30. ###### filter the data for CD4 or CD8 T cells for reps 1 and 2 ######     
31. donor <- donors[d]   
32. lineage <- lineages[j]      
33. clonoverlap2 <- cloneoverlap[,-3]   
34.    
35. ### filter data by donor and replicate ###   
36. donordf <- clonoverlap2 %>% filter(str_detect(sample, donors[d]) &   
37.                                              str_detect(sample, lineages[j]))   
38. notmem <- donordf %>% filter(!str_detect(sample, "TMEM"))   
39.    
40. donor_remove<- notmem %>%   
41.           filter(!str_detect(sample, "remove"), !str_detect(sample,"Fb"))   
42. donordfRep12<- donor_remove %>%   
43.           filter(str_detect(sample, "_1") | str_detect(sample, "_2"))   
44.    
45. #### cast the dataframe so each column is a sample and rows are unique clones ####   
46. c_donordf <- dcast(donordf, clone_id ~ sample, value.var = "copies", fill=0)   
47. c_donordfrep12 <- dcast(donordfRep12, clone_id ~ sample, value.var = "copies", fill=0)   
48.    
49. ##calculate mean freq for each sample   
50. #filter df to have no zeros   
51. nadf <- c_donordfrep12   
52. nadf[nadf==0] <- NA   
53. df.mean <- colMeans(nadf, na.rm=TRUE)    
54. cut.off<- 0.5*df.mean   
55. cut.off <- cut.off[-1]   
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56.    
57. df.50mean <- c_donordfrep12[,-1]   
58. head(df.50mean)   
59. apply(df.50mean,2,min, na.rm=TRUE)   
60. i <- 1   
61.    
62. for (i in 1:length(cut.off)) {   
63.           df.50mean[,i][df.50mean[,i]<cut.off[i]] <- 0   
64. }   
65.    
66.    
67. #### calculcate cosine ####   
68. cosdf <- cosine(as.matrix(c_donordf[,-1]))   
69. cosdf12reps <- cosine(as.matrix(c_donordfrep12[,-1]))   
70.    
71. cos.50meandf<- cosine(as.matrix(df.50mean[,-1]))   
72.    
73. #### pick data to plot #####   
74. if (cutoff == "yes") {   
75. df<- cos.50meandf } else {   
76. df <-cosdf12reps   
77. }   
78.    
79. if (cutoff == "yes") {   
80.           PlotName <-  paste("Cosine",   
81.                              donors[d],   
82.                              cluster_method,   
83.                              lineages[j], "50MeanFreq")             
84. } else {   
85. PlotName <-  paste("Cosine",   
86.                    donors[d],   
87.                    cluster_method,   
88.                    lineages[j])   
89. }   
90.  
91. ##make settings for heatmaps   
92. breaksList = seq(0.0, max(df, na.rm=TRUE), by = 0.005)   
93. customcolor = colorRampPalette(c("black", "red", "yellow","white"))(length(breaksList))   
94.    
95. ### make cluster labels ###   
96. conditions <- data.frame(   
97.           Tissue = unlist(gsubfn::strapplyc(colnames(df),"Bld|BM|LLN|Lung|Spl|LN",simplify = TRUE)),   
98.           CellType = unlist(gsubfn::strapplyc(colnames(df),"TCM|TEMRA|TEM|TRM|TMEM",simplify = TRUE)),   
99.           Lineage = unlist(gsubfn::strapplyc(colnames(df),"CD4|CD8",simplify = TRUE)),   
100.           Replicate = unlist(gsubfn::strapplyc(colnames(df),"_1|_2|_3|_4|_5|_6|_7",simplify = TRUE))   
101. )   
102.    
103. conditions2 <- cbind(conditions,population=paste(conditions$Tissue,conditions$CellType,sep=""))   
104. conditions2$Replicate <- gsub("_1","rep1",conditions2$Replicate)   
105. conditions2$Replicate <- gsub("_2","rep2",conditions2$Replicate)   
106. conditions2$Replicate <- as.factor(conditions2$Replicate)   
107.    
108.    
109. rowlab <- gsub(paste(donors[d],"_",sep=""),"",rownames(df))   
110. rowlab2 <- gsub(paste("CD4","_",sep=""),"",rowlab)   
111. rowlab3 <- gsub(paste("CD8","_",sep=""),"",rowlab2)   
112.    
113. conditions2 <- conditions2[,c(1,2,5,4,3)]   
114.    
115. rownames(df) <- gsub(paste(donors[d],"_",sep=""),"",rownames(df))   
116. colnames(df) <- gsub(paste(donors[d],"_",sep=""),"",colnames(df))   
117. colnames(df) <- gsub(paste(lineages[j],"_",sep=""),"",colnames(df))   
118. rownames(df) <- gsub(paste(lineages[j],"_",sep=""),"",rownames(df))   
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119. colnames(df) <- gsub("_"," ",colnames(df))   
120. rownames(df) <- gsub("_"," ",rownames(df))   
121.    
122. rownames(conditions2) <- colnames(df)   
123.    
124. palette <- brewer.pal(4, "Set2")   
125. tisspal <- brewer.pal(11, "RdGy")   
126.    
127. ann_colors = list(   
128.           Replicate = c(rep1 = "orange", rep2 = "blue"),   
129.           Tissue = c(BM=tisspal[7],   
130.                      Spl =tisspal[8],   
131.                      Lung=tisspal[9],   
132.                      LN=tisspal[10],   
133.                      Bld=tisspal[11]   
134.           ),   
135.           CellType = c(TCM=palette[2],   
136.                        TEM =palette[1],   
137.                        TRM=palette[3],   
138.                        TEMRA=palette[4]   
139.                        )   
140.           )   
141.    
142. conditions3 <- conditions2[,c("Tissue","Replicate",   
143.                               "CellType")]   
144. pdf(paste("~/Desktop/CosineCalc/plots/cosineheatmap/",PlotName,".pdf",sep=""),   
145.     width=4,   
146.     height=6,   
147.     paper='special',   
148.     onefile=FALSE)   
149.    
150. pheatmap(df,   
151.          color = customcolor,   
152.          cluster_rows=T,   
153.          cluster_cols = T,   
154.          border_color = NA,   
155.          main=PlotName,   
156.          breaks = breaksList,   
157.          cellwidth = 5,   
158.          cellheight = 5,   
159.          fontsize_row = 5,   
160.          fontsize_col = 5,   
161.          legend = TRUE,   
162.          annotation_legend = TRUE,   
163.          annotation_row = conditions3,   
164.          annotation_col = conditions3,   
165.          annotation_colors = ann_colors,   
166.          clustering_method = cluster_method,   
167.          treeheight_row = 4,   
168.          treeheight_col =4,   
169.          fontsize=3,   
170.          drop_levels= TRUE   
171.          )   
172.    
173. dev.off()   
174. ###### take the mean of cosine between replicates #####   
175.    
176. ##how to calculate cosine between reps   
177. ### keep X1 and X2 which are different from eachother   
178. if (cutoff == "yes") {   
179.           cosUnique <- melt(cos.50meandf) %>%   
180.                     filter(X1 != X2)   
181. } else {   
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182. cosUnique <- melt(cosdf12reps) %>%   
183.           filter(X1 != X2)   
184. }   
185.    
186. ### keep X1 and X2 which are not reps of eachother   
187. cos_ext <- cosUnique %>%   
188.           filter(str_sub(   
189.                     cosUnique$X1,1,   
190.                     str_length(cosUnique$X1)-2)!=   
191.                            str_sub(cosUnique$X2,1,str_length(cosUnique$X2)-2))   
192.    
193.    
194. cos_mean <- cos_ext   
195.    
196. cos_mean$X1 <- str_sub(as.character(cos_mean$X1),1,   
197.                        str_length(as.character(cos_mean$X1))-2)   
198.    
199. cos_mean$X2 <- str_sub(as.character(cos_mean$X2),1,   
200.                        str_length(as.character(cos_mean$X2))-2)   
201.    
202. cos_sumMean <- cos_mean %>%   
203.           group_by(.dots=c("X1","X2")) %>%   
204.           summarize(x=mean(value))   
205.    
206. cos_mean_matrix <-dcast(cos_sumMean,X1~X2, value.var= "x", fill=1)   
207. rownames(cos_mean_matrix) <- cos_mean_matrix[,1]   
208.    
209. df <-cos_mean_matrix[,-1]   
210.    
211. ##set plot name   
212. if (cutoff == "yes") {   
213.           PlotName2 <- paste("Cosine",   
214.                              donor,   
215.                              "mean R1&2",   
216.                              cluster_method,   
217.                              lineages[j], "50MeanFreq")   
218. } else {   
219.           PlotName2 <- paste("Cosine",   
220.                              donor,   
221.                              "mean R1&2",   
222.                              cluster_method,   
223.                              lineages[j])   
224. }   
225.    
226.    
227. ##make settings for heatmaps   
228. breaksList = seq(0.0, max(df, na.rm=TRUE), by = 0.005)   
229. customcolor = colorRampPalette(c("black", "red", "yellow","white"))(length(breaksList))   
230.    
231. ### make cluster labels ###   
232. conditions <- data.frame(   
233.           Tissue = unlist(gsubfn::strapplyc(colnames(df),"Bld|BM|LLN|Lung|Spl|LN",simplify = TRUE)),   
234.           CellType = unlist(gsubfn::strapplyc(colnames(df),"TCM|TEMRA|TEM|TRM|TMEM",simplify = TRUE)),   
235.           Lineage = unlist(gsubfn::strapplyc(colnames(df),"CD4|CD8",simplify = TRUE)))   
236.    
237.    
238. rownames(conditions) <- colnames(df)     
239. conditions2 <- as.data.frame(conditions[,c("Tissue","CellType")])   
240. rownames(conditions2) <- colnames(df)   
241. rownames(df) <- gsub(paste(donors[d],"_",sep=""),"",rownames(df))   
242. colnames(df) <- gsub(paste(donors[d],"_",sep=""),"",colnames(df))   
243. colnames(df) <- gsub(paste(lineages[j],"_",sep=""),"",colnames(df))   
244. rownames(df) <- gsub(paste(lineages[j],"_",sep=""),"",rownames(df))   
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245. colnames(df) <- gsub("_"," ",colnames(df))   
246. rownames(df) <- gsub("_"," ",rownames(df))   
247. rownames(conditions2) <- colnames(df)   
248.    
249. palette <- brewer.pal(4, "Set2")   
250. tisspal <- brewer.pal(11, "RdGy")   
251.    
252. ann_colors = list(Tissue = c(BM=tisspal[7],   
253.                              Spl =tisspal[8],   
254.                              Lung=tisspal[9],   
255.                              LN=tisspal[10],   
256.                              Bld=tisspal[11]),   
257.                   CellType = c(TCM=palette[2],   
258.                                TEM =palette[1],   
259.                                TRM=palette[3],   
260.                                TEMRA=palette[4])   
261.                   )   
262.              
263.    
264. pdf(paste("~/Desktop/CosineCalc/plots/cosineheatmap/mean/",PlotName2,".pdf",sep=""),   
265.     width=4,   
266.     height=6,   
267.     paper='special',   
268.     onefile=FALSE)   
269.    
270. pheatmap(df,   
271.          color = customcolor,   
272.          cluster_rows=T,   
273.          cluster_cols = T,   
274.          main=PlotName2,   
275.          breaks = breaksList,   
276.          border_color = NA,   
277.          cellwidth = 8,   
278.          cellheight = 8,   
279.          fontsize_row = 5,   
280.          fontsize_col = 5,   
281.          legend = TRUE,   
282.          annotation_legend = TRUE,   
283.          annotation_row = conditions2,   
284.          annotation_col = conditions2,   
285.          annotation_colors = ann_colors,   
286.          clustering_method = cluster_method,   
287.          treeheight_row = 5,   
288.          treeheight_col =5,   
289.          fontsize=8,   
290.          lables_row= gsub(paste(donor,"_",sep=""),"",rownames(df)),   
291.          lables_col= gsub(paste(donor,"_",sep=""),"",colnames(df))   
292.          )    
293. dev.off()   
 
Plotting Jaccard Index Boxplots 
The input to this script are excel sheets containing matrices of Jaccard index calculations. This 
script produces boxplots of the Jaccard index values. 
1. ##This code will input the 06082018 data from Wenzhao for Jaccard   
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2. ## file is Jaccard_50fc_inFraction   
3.    
4. library(readxl)   
5. library(dplyr)   
6. library(ggplot2)   
7. library(dplyr)   
8. library(ggsci)   
9. library(ggbeeswarm)   
10. library(reshape2)   
11.    
12. #### converting the excel sheet with multiple tabs into data frames in R   
13. ####MAKING THE DATAFRAME #####   
14. ##This is a help page with a function to read excel sheets and make data frames from the tabs:   
15. #https://stackoverflow.com/questions/12945687/read-all-worksheets-in-an-excel-workbook-into-an-r-list-with-data-
frames   
16. read_excel_allsheets <- function(filename, tibble = FALSE) {   
17.         # I prefer straight data.frames   
18.         # but if you like tidyverse tibbles (the default with read_excel)   
19.         # then just pass tibble = TRUE   
20.         sheets <- readxl::excel_sheets(filename)   
21.         x <- lapply(sheets, function(X) readxl::read_excel(filename, sheet = X))   
22.         if(!tibble) x <- lapply(x, as.data.frame)   
23.         names(x) <- sheets   
24.         x   
25. }   
26.    
27. mysheets <- read_excel_allsheets("~/Desktop/TCR-paper-Oct-
2018/Jaccard Index/Jaccard_50fc_inFraction_Reps.xlsx")   
28. # Now we have a list of dataframes, each data frame was a tab in the excel sheet   
29.    
30. str(mysheets[[1]])   
31.    
32. df <- melt(mysheets)   
33. df <- df[,-4]   
34. str(df)   
35. #remove duplicated values   
36. dfSingle <- df[!duplicated(df$value), ]   
37. str(dfSingle)   
38. colnames(dfSingle) <- c("Sample1","Sample2", "value")   
39. dfSingle$Sample2 <- as.character(dfSingle$Sample2)   
40.    
41. #rename a column in the datafame   
42.    
43. celltype <- paste(gsubfn::strapplyc(dfSingle[,1],"CD4|CD8",simplify = TRUE),   
44.                   gsubfn::strapplyc(dfSingle[,1], 
45.    "LN|Spl|BM|Lung|Blood",simplify = TRUE),   
46.                   gsubfn::strapplyc(dfSingle[,1], 
47.    "TEM|TRM|TEMRA|TCM",simplify = TRUE),   
48.                   "-",   
49.                   gsubfn::strapplyc(dfSingle[,2],"CD4|CD8",simplify = TRUE),   
50.                   gsubfn::strapplyc(dfSingle[,2], 
51.    "LN|Spl|BM|Lung|Blood",simplify = TRUE),   
52.                   gsubfn::strapplyc(dfSingle[,2],"TEM|TRM|TEMRA|TCM",simplify = TRUE))   
53.    
54.    
55. celltype <- as.factor(celltype)   
56. str(celltype)   
57. donor <-  gsubfn::strapplyc(dfSingle[,1],"D229|D233|D280|D287|D299|D383|D324|D255",simplify = TRUE)   
58.    
59. Lineage <- paste(gsubfn::strapplyc(dfSingle[,1],"CD4|CD8",simplify = TRUE),   
60.                   "-",   
61.                   gsubfn::strapplyc(dfSingle[,2],"CD4|CD8",simplify = TRUE))   
62.    
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63. Tissue <- paste(gsubfn::strapplyc(dfSingle[,1], 
64.   "LN|Spl|BM|Lung|Blood",simplify = TRUE),   
65.                   "-",   
66.                 gsubfn::strapplyc(dfSingle[,2], 
67.    "LN|Spl|BM|Lung|Blood",simplify = TRUE))   
68.    
69. Subset <- paste(gsubfn::strapplyc(dfSingle[,1],"TEM|TRM|TEMRA|TCM",simplify = TRUE),   
70.                   "-",   
71.                 gsubfn::strapplyc(dfSingle[,2],"TEM|TRM|TEMRA|TCM",simplify = TRUE))   
72.    
73. Sample1SubsetTissue <- paste(gsubfn::strapplyc(dfSingle[,1],   
74.                                                "TEM|TRM|TEMRA|TCM",simplify = TRUE),   
75.                              "-",   
76.                              gsubfn::strapplyc(dfSingle[,1],   
77.                                                "LN|Spl|BM|Lung|Blood",simplify = TRUE)   
78.                              )   
79.    
80.    
81. Sample2SubsetTissue <- paste(gsubfn::strapplyc(dfSingle[,2],   
82.                                                "TEM|TRM|TEMRA|TCM",simplify = TRUE),   
83.                              "-",   
84.                              gsubfn::strapplyc(dfSingle[,2],   
85.                                                "LN|Spl|BM|Lung|Blood",simplify = TRUE)   
86.                              )   
87.    
88. plotData <- dfSingle %>%   
89.         cbind(celltype) %>%    
90.         cbind(donor) %>%   
91.         cbind(Lineage) %>%   
92.         cbind(Tissue) %>%   
93.         cbind(Subset) %>%   
94.         cbind(Sample1SubsetTissue) %>%   
95.         cbind(Sample2SubsetTissue)   
96.    
97.    
98. library(summarytools)   
99.    
100. #order the data by mean   
101. plotData$celltype <- with(plotData, reorder(celltype, value, mean))   
102. CD4CD8 <- plotData %>% filter(Lineage == "CD4 - CD8" | Lineage == "CD8 - CD4")   
103. mean(CD4CD8$value)   
104. ##### PLOTTING ALL THE SPLEEN BM AND LN SAMPLES #####   
105.    
106. ##summarize the data to plot error bars toO!   
107. #+++++++++++++++++++++++++   
108. # Function to calculate the mean and the standard deviation   
109. # for each group   
110. #+++++++++++++++++++++++++   
111. # data : a data frame   
112. # varname : the name of a column containing the variable   
113. #to be summariezed   
114. # groupnames : vector of column names to be used as   
115. # grouping variables   
116.    
117.    
118. plotCD4 <- plotData %>% filter(Lineage == "CD4 - CD4",    
119.                                  Tissue !="Spl - Lung",   
120.                                  Tissue !="BM - Lung",   
121.                                  Tissue !="Blood - Lung",   
122.                                  Tissue !="LN - Lung",   
123.                                  Tissue !="Spl - Blood",   
124.                                  Tissue !="BM - Blood",   
125.                                  Tissue !="Blood - Lung",   
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126.                                  Tissue !="LN - Blood",   
127.                                  Tissue !="Lung - Spl",   
128.                                  Tissue !="Lung - BM",   
129.                                  Tissue !="Lung - Blood",   
130.                                  Tissue !="Lung - LN",   
131.                                  Tissue !="Blood - Spl",   
132.                                  Tissue !="Blood - BM",   
133.                                  Tissue !="Lung - Blood",   
134.                                  Tissue !="Blood - LN",   
135.                                  Tissue != "Lung - Lung",   
136.                                  Tissue != "Blood - Blood",   
137.                                  Subset != "TCM - TCM",   
138.                                  Subset != "TCM - TEM",   
139.                                  Subset != "TCM - TRM",   
140.                                  Subset != "TEM - TCM",   
141.                                  Subset != "TRM - TCM"   
142.                                )   
143.    
144. plotCD8 <- plotData %>% filter(Lineage == "CD8 - CD8",    
145.                                Tissue !="Spl - Lung",   
146.                                Tissue !="BM - Lung",   
147.                                Tissue !="Blood - Lung",   
148.                                Tissue !="LN - Lung",   
149.                                Tissue !="Spl - Blood",   
150.                                Tissue !="BM - Blood",   
151.                                Tissue !="Blood - Lung",   
152.                                Tissue !="LN - Blood",   
153.                                Tissue !="Lung - Spl",   
154.                                Tissue !="Lung - BM",   
155.                                Tissue !="Lung - Blood",   
156.                                Tissue !="Lung - LN",   
157.                                Tissue !="Blood - Spl",   
158.                                Tissue !="Blood - BM",   
159.                                Tissue !="Lung - Blood",   
160.                                Tissue !="Blood - LN",   
161.                                Tissue != "Lung - Lung",   
162.                                Tissue != "Blood - Blood",   
163.                                Subset != "TEMRA - TEMRA",   
164.                                Subset != "TEMRA - TEM",   
165.                                Subset != "TEMRA - TRM",   
166.                                Subset != "TEM - TEMRA",   
167.                                Subset != "TRM - TEMRA"   
168.                                )    
169.            
170. min.mean.sd.max <- function(x) {   
171.         r <- c(min(x), mean(x) - sd(x), mean(x), mean(x) + sd(x), max(x))   
172.         names(r) <- c("ymin", "lower", "middle", "upper", "ymax")   
173.         r   
174. }   
175.    
176. q1.mean.sd.q3 <- function(x) {   
177.         r <- c(quantile(x, c(.25)), mean(x) - sd(x), mean(x), mean(x) + sd(x), quantile(x, c(.75)))   
178.         names(r) <- c("ymin", "lower", "middle", "upper", "ymax")   
179.         r   
180. }   
181.    
182.    
183. min.mean.se.max <- function(x) {   
184.         sem <- function(X) {   
185.                 se <- sd(x)/sqrt(length(x))   
186.                 se   
187.         }   
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188.         r <- c(min(x), mean(x) - sem(x), mean(x), mean(x) + sem(x), max(x))   
189.         names(r) <- c("ymin", "lower", "middle", "upper", "ymax")   
190.         r   
191. }   
192.    
193. q1.mean.se.q3 <- function(x) {   
194.         sem <- function(X) {   
195.                 se <- sd(x)/sqrt(length(x))   
196.                 se   
197.         }   
198.         r <- c(quantile(x, c(.25)), mean(x) - sem(x), mean(x), mean(x) + sem(x), quantile(x, c(.75)))   
199.         names(r) <- c("ymin", "lower", "middle", "upper", "ymax")   
200.         r   
201. }   
202.    
203.    
204. ###try plotting replicates, separate from non reps..separate from within tissue   
205. #####--------------Plot Reps CD4---------------------------------####   
206.    
207. ##Reps:   
208. RepsCD4 <- plotCD4 %>% filter((celltype == "CD4 BM TRM - CD4 BM TRM" |    
209.                                        celltype == "CD4 BM TEM - CD4 BM TEM" |   
210.                                        celltype == "CD4 LN TEM - CD4 LN TEM" |   
211.                                        celltype == "CD4 Spl TEM - CD4 Spl TEM" |   
212.                                        celltype == "CD4 LN TRM - CD4 LN TRM" |   
213.                                        celltype == "CD4 Spl TRM - CD4 Spl TRM"   
214.                                        )   
215.                               )   
216.    
217. #####------------------Plot Reps CD8 -----------------------------####   
218.    
219. RepsCD8 <- plotCD8 %>% filter((celltype == "CD8 BM TRM - CD8 BM TRM" |    
220.                                        celltype == "CD8 BM TEM - CD8 BM TEM" |   
221.                                        celltype == "CD8 LN TEM - CD8 LN TEM" |   
222.                                        celltype == "CD8 Spl TEM - CD8 Spl TEM" |   
223.                                        celltype == "CD8 LN TRM - CD8 LN TRM" |   
224.                                        celltype == "CD8 Spl TRM - CD8 Spl TRM"   
225.                                )   
226.                               )   
227.    
228. #####--------------------Plot within CD4 Tissue---------------------------####   
229.    
230.    
231. ##within Tissue:   
232. WithinCD4 <- plotCD4 %>% filter((celltype == "CD4 BM TRM - CD4 BM TEM" |    
233.                                        celltype == "CD4 BM TEM - CD4 BM TRM" |   
234.                                        celltype == "CD4 LN TEM - CD4 LN TRM" |   
235.                                        celltype == "CD4 Spl TEM - CD4 Spl TRM" |   
236.                                        celltype == "CD4 LN TRM - CD4 LN TEM" |   
237.                                        celltype == "CD4 Spl TRM - CD4 Spl TEM"   
238.                                  )   
239.                                 )   
240.    
241. #####--------------------Plot within CD8 Tissue---------------------------####   
242.    
243.    
244. WithinCD8 <- plotCD8 %>% filter((celltype == "CD8 BM TRM - CD8 BM TEM" |    
245.                                          celltype == "CD8 BM TEM - CD8 BM TRM" |   
246.                                          celltype == "CD8 LN TEM - CD8 LN TRM" |   
247.                                          celltype == "CD8 Spl TEM - CD8 Spl TRM" |   
248.                                          celltype == "CD8 LN TRM - CD8 LN TEM" |   
249.                                          celltype == "CD8 Spl TRM - CD8 Spl TEM"   
250.                                  )   
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251.                                 )   
252.    
253. #####--------------------Plot between CD8 Tissue---------------------------####   
254.    
255.    
256. BetweenCD8 <- plotCD8 %>% filter((celltype == "CD8 Spl TEM - CD8 BM TEM" |    
257.                                          celltype == "CD8 Spl TRM - CD8 BM TRM" |   
258.                                          celltype == "CD8 LN TEM - CD8 BM TEM" |   
259.                                          celltype == "CD8 LN TRM - CD8 BM TRM" |   
260.                                           celltype == "CD8 LN TRM - CD8 BM TEM" |   
261.                                           celltype == "CD8 LN TEM - CD8 BM TRM" |   
262.                                          celltype == "CD8 Spl TEM - CD8 LN TEM" |   
263.                                          celltype == "CD8 Spl TRM - CD8 LN TRM" |   
264.                                           celltype == "CD8 Spl TEM - CD8 BM TRM" |   
265.                                           celltype == "CD8 Spl TEM - CD8 LN TRM" |   
266.                                           celltype == "CD8 Spl TRM - CD8 LN TEM" |   
267.                                           celltype == "CD8 Spl TRM - CD8 BM TEM"   
268.                                  )   
269.                                 )   
270.    
271.    
272.    
273. #####--------------------Plot between CD4 Tissue----------------------####   
274.    
275. BetweenCD4 <- plotCD4 %>% filter((celltype == "CD4 Spl TEM - CD4 BM TEM" |    
276.                                           celltype == "CD4 Spl TRM - CD4 BM TRM" |   
277.                                           celltype == "CD4 LN TEM - CD4 BM TEM" |   
278.                                           celltype == "CD4 LN TRM - CD4 BM TRM" |   
279.                                           celltype == "CD4 LN TRM - CD4 BM TEM" |   
280.                                           celltype == "CD4 LN TEM - CD4 BM TRM" |   
281.                                           celltype == "CD4 Spl TEM - CD4 LN TEM" |   
282.                                           celltype == "CD4 Spl TRM - CD4 LN TRM" |   
283.                                           celltype == "CD4 Spl TEM - CD4 BM TRM" |   
284.                                           celltype == "CD4 Spl TEM - CD4 LN TRM" |   
285.                                           celltype == "CD4 Spl TRM - CD4 LN TEM" |   
286.                                           celltype == "CD4 Spl TRM - CD4 BM TEM"   
287.                                   )   
288.                                  )   
289.    
290. #####--------------------Plotting the data---------------------------####   
291. DataList <- list(RepsCD4,   
292.                  RepsCD8,   
293.                  WithinCD4,   
294.                  WithinCD8,   
295.                  BetweenCD8,   
296.                  BetweenCD4,   
297.                  plotCD4,   
298.                  plotCD8)   
299.    
300. for (i in 1:8) {   
301. data <- DataList[[i]]   
302.    
303. give.n <- function(x){   
304.           return(c(y = mean(x), label = length(x)))   
305. }   
306. pdf(paste("plot",i,".pdf",sep = ""))   
307. plot <- ggplot(aes(y = value, x = factor(celltype)), data = data)   
308. p <- plot +    
309.         stat_summary(fun.data = q1.mean.se.q3, geom = "boxplot") +   
310.         #geom_boxplot(width=0.5) +   
311.         #geom_jitter(aes(shape= donor), 
312.   position=position_jitter(width=.1), size=3) +   
313.         ggtitle("Overlap between two samples line at mean, 
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314.   SEM, quantile 1 and 3") +    
315.         xlab("Sample 1 and 2") +    
316.         ylab("Overlap Index") +   
317.         scale_shape_manual(values=c(0,1,5,6,15,16,17,18)) +   
318.         theme(legend.key.size = unit(0.4,"cm"),   
319.               axis.text.x = element_text(angle=90, hjust=1)) +   
320.         geom_hline(yintercept = mean(CD4CD8$value)) +   
321.         ylim(0,0.44) +   
322.         coord_flip() +   
323.         stat_summary(fun.data = give.n, geom = "text")   
324. print(p)   
325. dev.off()   
326. }     
327.    
328.   ggplot(aes(x=interaction(celltype), y=value )) +   
329.         #colour=interaction(celltype))) +    
330.         #geom_violin() +   
331.         theme_minimal() +    
332.         #geom_bar(position = "dodge", stat = "summary", fun.y = "mean") +   
333.         geom_boxplot(outlier.shape = NA, fill= "grey") +    
334.         #geom_quasirandom(aes(shape= donor),size=2) +    
335.         scale_shape_manual(values=c(0,1,5,6,15,16,17,18)) +   
336.         ggtitle("Jaccard CD8") +   
337.         theme(legend.key.size = unit(0.35,"cm"),   
338.               axis.text.x = element_text(angle=90, hjust=1)) +   
339.         ylim(0,0.44) +    
340.         coord_flip() +   
341.         geom_hline(yintercept = mean(CD4CD8$value))   
Clone Tracking Script #1 
 
The input for this script is the file produced by Clone Tracking function from VDJtools 
[312](test.tracking.strict.table.collapsed.txt). The output is a text file to be used for the Clone 
Tracking Script #2 below. 
1. ### take input file of test.tracking.strict.table.collapsed.txt   
2. #and fix the peak column to be the top frequency column   
3. print(getwd())   
4. setwd("..")   
5. print(getwd())   
6. library(data.table)   
7. dt <- read.table("VDJtools_output/test.tracking.strict.table.collapsed.txt",   
8.            header=T)   
9.    
10. meta <- read.table("data/metadata.txt", sep="\t",   
11.                  header=T)   
12.    
13. freq.df <- dt[,c(as.character(meta$sample_id))]   
14. freq.dt <- as.data.table(freq.df)   
15. freq.dt[, MAX := colnames(.SD)[max.col(.SD, ties.method="first")]]    
16. df.max <- freq.dt   
17. df.peak.empty <- data.frame(maxsample = c(df.max$MAX), peak= c(NA))   
18.    
19. ##fill peak number based on key using match function   
20. key <- data.frame(sample= meta$sample_id, number=    
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21.                             c(0:(nrow(meta)-1))   
22.                   )   
23.    
24. peak.correct <- (match(df.peak.empty[,1],key[,1]))-1   
25.    
26. dt$peak <- peak.correct   
27.    
28.    
29. file.loc <- "VDJtools_output/test.tracking.strict.table.collapsed2.txt"   
30. write.table(dt,    
31.             file= file.loc,   
32.             sep="\t",   
33.             quote= FALSE)   
34.                   
Clone Tracking Script #2 
 
The input for this script is the text file from the above script. This script is modified from the 
VDJtools software[312] and produced the clone tracking plots. 
1. #currentRscript <- rstudioapi::getSourceEditorContext()$path   
2. #setwd(gsub("/tracking_stackplot_custom.R*","",currentRscript))   
3.    
4. args <- c("sample",    
5.           "VDJtools_output/test.tracking.strict.table.collapsed2.txt",    
6.           "plots/custom.stackplot.pdf",   
7.           "data/metadata.txt")   
8. .libPaths("/usr/local/Cellar/vdjtools/1.1.8/Rpackages/")   
9. # data input   
10. firstwd <-getwd()   
11. setwd("..")   
12. #args <- commandArgs(TRUE)   
13.    
14. require(ggplot2); require(reshape)   
15. require(gridExtra); require(grid)   
16. require(RColorBrewer); require(stringr)   
17. require(dplyr)   
18.    
19. label    <- args[1] #"time since HSCT, months"   
20. file_in  <- args[2] #"luc_table_collapsed.txt"   
21. file_out <- args[3] #"out.pdf"   
22. meta_in <- args[4] # "metadata.txt"   
23.  
24. #load metadata to make labels   
25. meta    <- read.table(meta_in, comment="", sep = "\t", header = TRUE)   
26. custom.x.label <- as.character(meta$sample_id)   
27.    
28. # load time points, create some auxillary variables   
29. x <- matrix(as.numeric(0:(nrow(meta)-1)))   
30. n <- length(x)   
31.    
32. # load data   
33. #df <- data.frame(read.delim(file_in))   
34. df    <- read.table(file_in, comment="", sep = "\t", header = TRUE)   
35. xcols <- (ncol(df) - n + 1):ncol(df)   
36. fcols <- 1:(ncol(df) - n)   
37. xlbls <- colnames(df)[xcols]   
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38.    
39. # convert abundance columns to numeric   
40. df[, xcols] <- apply(df[, xcols], 2, as.numeric)   
41.    
42. # set up Non-overlapping and Not-shown   
43. df$peak[nrow(df)-1] <- -1   
44. df$peak[nrow(df)] <- -2   
45.    
46. # reshape data   
47. df.m <- melt(df, id = fcols)   
48.    
49. # replace sample ids (factor) by time (numeric)   
50. ind <- match(df.m$variable, xlbls)   
51. df.m$variable <- x[ind]   
52.    
53. df.m$sign <- paste(df.m$cdr3nt, df.m$v, df.m$d, df.m$j, sep="_")   
54. palette <- brewer.pal(4, "Set2")   
55. pal <- colorRampPalette(c(palette[1],   
56.                           palette[2],    
57.                           palette[3],   
58.                           palette[4])   
59.                         )   
60.    
61. #draw   
62.    
63. if (grepl("\\.pdf$",file_out)){   
64.    pdf(file_out)   
65. } else if (grepl("\\.png$",file_out)) {   
66.    png(file_out, width     = 3.25,   
67.                  height    = 3.25,   
68.                  units     = "in",   
69.                  res       = 1200,   
70.                  pointsize = 4)   
71. } else {   
72.    stop('Unknown plotting format')   
73. }   
74.    
75. # make current pallet   
76. ## make map of label to color   
77.    
78. df_map2 <- read.table("data/colorpalette.map.txt",header=T, sep="\t",   
79.                       comment.char = "")   
80.    
81. #df_map <- data.frame(sample_map=sample_map, pal_map=pal_map)   
82. # loop over custom.x.label   
83. df_answer <- data.frame(sample_answer=custom.x.label, pal_answer=rep(NA,n))   
84. df_answer$pal_answer <- df_map2$pal_map[match(df_answer$sample_answer,df_map2$sample_map)]   
85. df_answer$peakNumber <- c(0:(n-1))   
86.    
87. #filter df_answer for rows that match the present factors in peak   
88. peaks_to_filter_by <- as.integer(levels(as.factor(df.m$peak)))[-c(1,2)]   
89. df_answer_c <- df_answer[df_answer$peakNumber %in% peaks_to_filter_by, ]   
90.    
91. # for each entry, look in the map to find the color   
92. # add that color to the pallet   
93.    
94. # prepare plot   
95. g<-ggplot() +   
96.    geom_area(data = df.m,   
97.              aes(variable, value, group = sign, fill = factor(peak)),   
98.              colour = "gray25", position = 'stack', size = 0) +   
99.    scale_fill_manual(   
100.       name   = "Peak position",   
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101.       breaks = c(-2, -1, df_answer_c$peakNumber),   
102.       labels = c("Non-overlapping", "Not-shown", as.character(df_answer_c$sample_answer)),   
103.       values = c("grey50", "grey70", as.character(df_answer_c$pal_answer))   
104.       ) +   
105. scale_x_continuous(breaks = 0:(n-1),   
106.                    labels = paste0(c(custom.x.label))) +   
107.           #scale_x_continuous(expand = c(0,0), limit = c(min(x), max(x)), breaks = x) +   
108.    scale_y_continuous(expand = c(0,0)) +   
109.    theme_bw() +   
110.    xlab(label) +   
111.    ylab("abundance") +   
112.    theme(axis.text.x = element_text(angle = 90, vjust = 0.5, hjust = 0.5), panel.border = element_blank()) +   
113.    guides(size = F)   
114.    
115. # disable label cropping   
116. gg_table <- ggplot_gtable(ggplot_build(g))   
117. gg_table$layout$clip[gg_table$layout$name=="panel"] <- "off"   
118.    
119. grid.draw(gg_table)   
120.    
121. dev.off()   
122.  
 
Section C-3: RNA-seq analysis script 
The input to this script are the text files from each sample containing a count matrix. This script 
performs differential expression analysis.  
1. #Run Deseq pipeline ----   
2.         #HERE IS THE VIGNETTE: https://bioconductor.org/packages/3.7/bioc/vignettes/DESeq2/inst/doc/DESeq2.html 
3.    
4. #DEPENDENCIES ----   
5. library("Rcpp")   
6. library("colorspace")   
7. library("DESeq2")   
8.    
9. # COUNT TABLE ALL SAMPLES ----   
10. CountTable <-
 read.table("/Volumes/Dom_CCTI$/CCTI_USERS/Michelle  Miron/BM and LN CD69 data/AllRawCounts.csv",    
11.                          header=T,sep=",",   
12.                          row.names=1)   
13.    
14. Samples <- data.frame(row.names=colnames(CountTable), condition=as.factor(c(rep("LNCD4_RO+69-",3),   
15.                                                                             rep("LNCD4_RO+69+",3), rep("BMCD4_RO+69-",3),   
16.                                                                             rep("BMCD4_RO+69+",3),rep("LNCD8_RO+69-",3),   
17.                                                                             rep("LNCD8_RO+69+",3),rep("BMCD8_RO+69-",3),   
18.                                                                             rep("BMCD8_RO+69+",3)   
19.                                                                             )   
20.                                                                           )   
21.                       )   
22.    
23. # COUNT TABLE FOR EACH SAMPLE PAIR ----   
24. Cts_LNCD4 <- CountTable[1:25559,1:6]   
25. Cts_BMCD4 <- CountTable[1:25559,7:12]   
26. Cts_LNCD8 <- CountTable[1:25559,13:18]   
27. Cts_BMCD8 <- CountTable[1:25559,19:24]   
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28.    
29. Samp__LNCD4 <- data.frame(row.names=colnames(Cts_LNCD4), 
30.  condition=as.factor(c(rep("69neg",3), 
31.    rep("69pos",3) 
32.     ) 
33.    ) 
34.   )   
35.    
36. Samp__BMCD4 - data.frame(row.names=colnames(Cts_BMCD4), 
37.  condition=as.factor(c(rep("69neg",3), 
38.    rep("69pos",3) 
39.     ) 
40.    ) 
41.   )   
42.    
43. Samp__LNCD8 <- data.frame(row.names=colnames(Cts_LNCD8), 
44.  condition=as.factor(c(rep("69neg",3), 
45.    rep("69pos",3) 
46.     ) 
47.    )  
48.   )   
49.    
50. Samp__BMCD8 <- data.frame(row.names=colnames(Cts_BMCD8), 
51.  condition=as.factor(c(rep("69neg",3), 
52.    rep("69pos",3) 
53.    )  
54.   )   
55.  )   
56.    
57. # RUNNING DESEQ ----   
58.    
59. ddsLN4 <- DESeqDataSetFromMatrix(countData = Cts_LNCD4, colData=Samp__LNCD4, design=~condition)   
60. ddsBM4 <- DESeqDataSetFromMatrix(countData = Cts_BMCD4, colData=Samp__BMCD4, design=~condition)   
61. ddsLN8 <- DESeqDataSetFromMatrix(countData = Cts_LNCD8, colData=Samp__LNCD8, design=~condition)   
62. ddsBM8 <- DESeqDataSetFromMatrix(countData = Cts_BMCD8, colData=Samp__BMCD8, design=~condition)   
63.    
64.    
65. ddsLN4<- DESeq(ddsLN4)   
66. ddsBM4<- DESeq(ddsBM4)   
67. ddsLN8<- DESeq(ddsLN8)   
68. ddsBM8<- DESeq(ddsBM8)   
69.    
70. resLN4 <- results(ddsLN4)   
71. resBM4 <- results(ddsBM4)   
72. resLN8 <- results(ddsLN8)   
73. resBM8 <- results(ddsBM8)   
74.    
75. setwd("/Users/michellemiron/Dropbox/Dissertation/resources/")   
76. write.csv(as.data.frame(resLN4),    
77.           file="resLN4condition_treated_results.csv")   
78. write.csv(as.data.frame(resBM4),    
79.           file="resBM4condition_treated_results.csv")   
80. write.csv(as.data.frame(resLN8),    
81.           file="resLN8condition_treated_results.csv")   
82. write.csv(as.data.frame(resBM8),    
83.           file="resBM8condition_treated_results.csv")   
84.    
85.    
86. browseVignettes("DESeq2")   
87. #log fold change shrinkage for ranking and visualization   
88.    
89. resLN4LFC <- lfcShrink(ddsLN4, coef="condition_69pos_vs_69neg")   
90. resBM4LFC <- lfcShrink(ddsBM4, coef="condition_69pos_vs_69neg")   
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91. resLN8LFC <- lfcShrink(ddsLN8, coef="condition_69pos_vs_69neg")   
92. resBM8LFC <- lfcShrink(ddsBM8, coef="condition_69pos_vs_69neg")   
93.    
94.    
95.    
96. rldLN4 <- rlog(ddsLN4, blind=FALSE)   
97. ntdLN4 <- normTransform(ddsLN4)   
98.    
99. #MAKING VISUALIZATIONS -----   
100.    
101. plotMA(resLN4LFC, ylim=c(-2,2))   
102. plotMA(resLN8LFC, ylim=c(-2,2))   
103. plotMA(resBM4LFC, ylim=c(-2,2))   
104. plotMA(resBM8LFC, ylim=c(-2,2))   
105.    
106.    
107. #idx <- identify(resLN4$baseMean, resLN4$log2FoldChange)   
108. #plotCounts(ddsLN4, gene=which.min(resLN4$padj), intgroup="condition")   
109.    
110. install.packages("pheatmap")   
111. library("pheatmap")   
112.    
113. select <- order(rowMeans(counts(ddsLN4,normalized=TRUE)),   
114.                 decreasing=TRUE)[1:100]   
115.    
116. ntdLN4 <- normTransform(ddsLN4)   
117.    
118. log2.norm.counts <- assay(ntdLN4)[select,]   
119.    
120. testnames <- c(colnames(log2.norm.counts))   
121.    
122. df <- as.data.frame(colData(ddsLN4)[,c("condition")])   
123.    
124. rownames(df) <- testnames   
125.    
126. pheatmap(log2.norm.counts, cluster_rows=FALSE, show_rownames=TRUE,   
127.          cluster_cols=FALSE, annotation_col=df)   
128.    
129. plotPCA(rldLN4, intgroup=c("condition"))   
130.    
131.    
132. #TESTING SOME HEATMAPS -----   
133. #from this website: https://www.biostars.org/p/178748/   
134. library(RColorBrewer)   
135. breaksList = seq(-1, 1, by = 0.005)   
136. plotUpDownSigGenes <- function(results, colNums, sampleNames, rld, title) {   
137.            
138.         # make the lists   
139.         upgenes <- rownames(head(results[order(results$log2FoldChange),], n=200))   
140.         downgenes <- rownames(head(results[order(-results$log2FoldChange),], n=200))   
141.            
142.         # this gives us the rows we want   
143.         rows <- match(upgenes,row.names(rld))   
144.         mat <- assay(rld)[rows,colNums]   
145.         mat <- mat - rowMeans(mat)   
146.            
147.         # the labels are hard coded at the moment :(   
148.         df <- as.data.frame(colData(rld)[,c("condition")])   
149.         rownames(df) <- c(sampleNames)   
150.         pheatmap(mat,    
151.                  color = colorRampPalette(rev(brewer.pal(n = 7, name = "RdYlBu")))(length(breaksList)),cluster_rows=FAL
SE,   
152.                  fontsize=3, annotation_col=df, main=paste(title,"top 200 DE genes"),breaks = breaksList)   
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153.            
154.         # this gives us the rows we want   
155.         rows <- match(downgenes, row.names(rld))   
156.         mat <- assay(rld)[rows,colNums]   
157.         mat <- mat - rowMeans(mat)   
158.            
159.         df <- as.data.frame(colData(rld)[,c("condition")])   
160.         rownames(df) <- c(sampleNames)   
161.         pheatmap(mat,    
162.                  color = colorRampPalette(rev(brewer.pal(n = 7, name = "RdYlBu")))(length(breaksList)),cluster_rows=FAL
SE,   
163.                  fontsize=3, annotation_col=df, main=paste(title,"top 200 DE genes"),breaks = breaksList)   
164. }   
165. aCols <- c(1,2,3)   
166. bCols <- c(4,5,6)   
167.    
168. ##make a combined heatmap up and down regulated genes   
169. breaksList1 = seq(-3, -1.0, by = 0.5)   
170. breaksList2 = seq(-1.01, 1, by = 0.05)   
171. breaksList3 = seq(1.01, 3, by = 0.5)   
172. breaksList <- c(breaksList1,breaksList2,breaksList3)   
173. plotUpDownSigGenes <- function(results, colNums, sampleNames, rld, title) {   
174.            
175.         # make the lists   
176.         upgenes <- rownames(head(results[order(results$log2FoldChange),], n=40))   
177.         downgenes <- rownames(head(results[order(-results$log2FoldChange),], n=40))   
178.            
179.         # this gives us the rows we want   
180.         rows <- match(upgenes,row.names(rld))   
181.         mat <- assay(rld)[rows,colNums]   
182.         mat <- mat - rowMeans(mat)   
183.            
184.         rows2 <- match(downgenes, row.names(rld))   
185.         mat2 <- assay(rld)[rows2,colNums]   
186.         mat2 <- mat2 - rowMeans(mat2)   
187.            
188.         # the labels are hard coded at the moment :(   
189.         df <- as.data.frame(colData(rld)[,c("condition")])   
190.         rownames(df) <- c(sampleNames)   
191.            
192.         pheatmap(rbind(mat,mat2),    
193.                  color = colorRampPalette(rev(brewer.pal(n = 11, name = "RdBu")))(length(breaksList)),   
194.                  cluster_rows=F,cluster_cols = F,   
195.                  fontsize=6, annotation_col=df, main=paste(title,"top 80 DE genes"),breaks = breaksList)   
196. }   
197.    
198. #CD4 LN   
199. contrastDEGenes <- subset(results(ddsLN4), padj < 0.05)   
200. sampleNames <- c("DM004","DM005","DM006","DM016","DM017","DM018")   
201. rldLN4 <- rlog(ddsLN4, blind=F)   
202. plotUpDownSigGenes(contrastDEGenes,c(aCols, bCols),sampleNames,rldLN4,"Lymph node CD4 Memory")   
203.    
204. #CD4 BM   
205. contrastDEGenes2 <- subset(results(ddsBM4), padj < 0.05)   
206. sampleNames2 <- colnames(assay(ddsBM4))   
207. rldBM4 <- rlog(ddsBM4, blind=F)   
208. plotUpDownSigGenes(contrastDEGenes2,c(aCols, bCols),sampleNames2,rldBM4,"Bone Marrow CD4 Memory")   
209.    
210. #CD8 LN   
211. contrastDEGenes3 <- subset(results(ddsLN8), padj < 0.05)   
212. sampleNames3 <- colnames(assay(ddsLN8))   
213. rldLN8 <- rlog(ddsLN8, blind=F)   
214. plotUpDownSigGenes(contrastDEGenes3,c(aCols, bCols),sampleNames3,rldLN8,"LN CD8 Memory")   
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215.    
216. #CD8 BM   
217. contrastDEGenes4 <- subset(results(ddsBM8), padj < 0.05)   
218. sampleNames4 <- colnames(assay(ddsBM8))   
219. rldBM8 <- rlog(ddsBM8, blind=F)   
220. plotUpDownSigGenes(contrastDEGenes4,c(aCols, bCols),sampleNames4,rldBM8,"Bone Marrow CD8 Memory")   
221.    
222. # OVERLAP BETWEEN BM AND LN ----   
223.    
224. numberDEgenes <- function(dds) {   
225.         genelistPvalLNCD4 <- subset(results(dds, condition=c("69pos","69neg")), padj < 0.05)   
226.         listUpLNCD4 <- rownames(subset(genelistPvalLNCD4,log2FoldChange>1))   
227.         listDownLNCD4 <- rownames(subset(genelistPvalLNCD4,log2FoldChange<(-1)))   
228.         print(c(length(listUpLNCD4),"up"))   
229.         print(c(length(listDownLNCD4),"down"))   
230.               }   
231.    
232. # LN CD4 gene lists   
233. genelistPvalLNCD4 <- subset(results(ddsLN4, condition=c("69pos","69neg")), padj < 0.05)   
234. listUpLNCD4 <- rownames(subset(genelistPvalLNCD4,log2FoldChange>1))   
235. listDownLNCD4 <- rownames(subset(genelistPvalLNCD4,log2FoldChange<(-1)))   
236.    
237.    
238. # BM CD4 gene lists   
239. genelistPvalBMCD4 <- subset(results(ddsBM4, condition=c("69pos","69neg")), padj < 0.05)   
240. listUpBMCD4 <- rownames(subset(genelistPvalBMCD4,log2FoldChange>1))   
241. listDownBMCD4 <- rownames(subset(genelistPvalBMCD4,log2FoldChange<(-1)))   
242.    
243.    
244. ListLNBMCD4UP <- intersect(listUpLNCD4,listUpBMCD4)   
245. ListLNBMCD4Down <- intersect(listDownLNCD4,listDownBMCD4)   
246. ListLNBMCD4UpDOWN <- intersect(listUpLNCD4,listDownBMCD4)   
247. ListLNBMCD4UpDOWN2 <- intersect(listDownLNCD4,listUpBMCD4)   
248.    
249. numberDEgenes(ddsBM4)   
250. numberDEgenes(ddsLN4)   
251. numberDEgenes(ddsBM8)   
252. numberDEgenes(ddsLN8)   
253.    
254.    
255. #making matrixes of gene lists   
256. #Combined DEseq BM and LN   
257.    
258. Cts_CD4 <- CountTable[1:25559,1:12]   
259. Samp__CD4 <- data.frame(row.names=colnames(Cts_CD4),   
260.                         condition=as.factor(c(rep("69neg",3),rep("69pos",3),   
261.                                               rep("69neg",3),rep("69pos",3)   
262.                                               )   
263.                                             )   
264.                         )   
265.    
266.    
267. ddsCD4 <- DESeqDataSetFromMatrix(countData = Cts_CD4, colData=Samp__CD4, design=~condition)   
268. ddsCD4<- DESeq(ddsCD4)   
269. rldCD4 <- rlog(ddsCD4, blind=F)   
270.    
271. breaksList1 = seq(-3, -1.0, by = 0.5)   
272. breaksList2 = seq(-1.01, 1, by = 0.05)   
273. breaksList3 = seq(1.01, 3, by = 0.5)   
274. breaksList <- c(breaksList1,breaksList2,breaksList3)   
275. plotOverlapSigGenes <- function(listUP1,listUP2,listDown1,listDown2,colNums, sampleNames, rld, title) {   
276.            
277.         # make the lists   
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278.         ListUP <- intersect(listUP1,listUP2)   
279.         ListDown <- intersect(listDown1,listDown2)   
280.         
281.         # this gives us the rows we want   
282.         rows <- match(ListUP,row.names(rld))   
283.         mat <- assay(rld)[rows,colNums]   
284.         mat <- mat - rowMeans(mat)   
285.            
286.         rows2 <- match(ListDown, row.names(rld))   
287.         mat2 <- assay(rld)[rows2,colNums]   
288.         mat2 <- mat2 - rowMeans(mat2)   
289.            
290.         # the labels are hard coded at the moment :(   
291.         df <- as.data.frame(colData(rld)[,c("condition")])   
292.         rownames(df) <- c(sampleNames)   
293.            
294.         pheatmap(rbind(mat,mat2),    
295.                  color = colorRampPalette(rev(brewer.pal(n = 11, name = "RdBu")))(length(breaksList)),   
296.                  cluster_rows=F,cluster_cols = T,   
297.                  fontsize=6, annotation_col=df, main=paste(title,"Overlapping DE genes"),breaks = breaksList)   
298. }   
299.    
300. plotOverlapSigGenes(listUpBMCD4,listUpLNCD4,listDownBMCD4,   
301.                     listDownLNCD4, 1:12,colnames(ddsCD4),rldCD4,"LN and BM" )   
302.    
303. rowsLNCD4 <- match(listUpLNCD4,row.names(ddsLN4))   
304. rldLN4 <- rlog(ddsLN4, blind=F)   
305. matLNCD4 <- assay(ddsLN4)[rowsLNCD4,c(1:6)]   
306. matLNCD4 <- mat - rowMeans(mat)   
307.    
308.    
309.    
310. ##MODIFY THIS TO GET OVERLAP BETWEEN TWO SAMPLES AND PLOT THEM BOTH   
311. plotUpDownSigGenes2 <- function(results1, results2, colNums, sampleNames, rld, title) {   
312.            
313.         # make the lists   
314.         upgenes <- rownames(results1[order(results1$log2FoldChange),])   
315.         downgenes <- rownames(results1[order(-results1$log2FoldChange),])   
316.            
317.         print(length(upgenes))   
318.         print(length(downgenes))   
319.            
320.         # make the lists from second data set   
321.         upgenes2 <- rownames(results2[order(results2$log2FoldChange),])   
322.         downgenes2 <- rownames(results2[order(-results2$log2FoldChange),])   
323.            
324.         print(length(upgenes2))   
325.         print(length(downgenes2))   
326.            
327.         # this gives us the rows we want   
328.         rows <- match(upgenes,row.names(rld))   
329.         mat <- assay(rld)[rows,colNums]   
330.         mat <- mat - rowMeans(mat)   
331.            
332.         rows2 <- match(downgenes, row.names(rld))   
333.         mat2 <- assay(rld)[rows2,colNums]   
334.         mat2 <- mat2 - rowMeans(mat2)   
335.            
336.         # the labels are hard coded at the moment :(   
337.         df <- as.data.frame(colData(rld)[,c("condition")])   
338.         rownames(df) <- c(sampleNames)   
339.            
340.         pheatmap(rbind(mat,mat2),    
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341.                  color = colorRampPalette(rev(brewer.pal(n = 11, name = "RdBu")))(length(breaksList)),   
342.                  cluster_rows=F,cluster_cols = F,   
343.                  fontsize=6, annotation_col=df, main=paste(title,"top 80 DE genes"),breaks = breaksList)   
344. }   
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2017 Oral Presentation: Tissue-reservoirs of anti-viral T cell immunity in persistent 
human CMV infection. 
  Federation of Clinical Immunology Societies (FOCIS)  
2017 Annual Meeting in Chicago, IL 
  FCE Fusion Award Recipient  
 
Authors: Michelle Miron, Claire L. Gordon, Joseph J.C. Thome, Dustin Carpenter, Takashi 
Senda, Nobuhide Matsuoka, Joshua Weiner, Michael A. Rak, Suzu Igarashi, Tomer Granot, 
Harvey Lerner, Felicia Goodrum, and Donna L. Farber. 
 
Abstract: 
T cell responses to viruses are initiated and maintained in tissue sites; however, knowledge of 
human anti-viral T cells is largely derived from blood.  Cytomegalovirus (CMV) persists in most 
humans, requires T cell immunity to control, yet tissue immune responses remain undefined. 
Here, we investigated human CMV-specific T cells, virus persistence and CMV-associated T cell 
homeostasis in blood, lymphoid, mucosal and secretory tissues of 44 CMV seropositive and 28 
seronegative donors. CMV-specific T cells were maintained in distinct distribution patterns, 
highest in blood, bone marrow (BM), or lymph nodes (LN), with the frequency and function in 
blood distinct from tissues. CMV genomes were detected predominantly in lung and also in 
spleen, BM, blood and LN. High frequencies of activated CMV-specific T cells were found in 
blood and BM samples with low virus detection, while in lung, CMV-specific T cells were 
present along with detectable virus. In LNs, CMV-specific T cells exhibited quiescent 
phenotypes independent of virus. We observed differential responses of CMV-specific T cells in 
distinct tissues to stimulation by CMV antigen. Additionally, certain epitope-specific T cell 
populations in BM were tissue-resident in phenotype (CD69+) and localized to the BM, while 
others were TEM (CD69-) and circulatory. Polyclonal T cell differentiation was enhanced in 
sites of viral persistence with age. Together, our results suggest tissue T cell reservoirs for CMV 
control shaped by both viral and tissue-intrinsic factors, with global effects on homeostasis of 





2018  Oral Presentation: Human lymph nodes maintain a distinct subset of TCF-1hi 
resident memory T cells throughout life. 
  Keystone Symposia on Molecular and Cellular Biology 
  Translational Systems Immunology Meeting 
 
Authors: Michelle Miron, Brahma Kumar, Wenzhao Meng,Tomer Granot, Dustin Carpenter, 




Tissue resident memory T cells (TRM) predominate in barrier sites and mediate protective 
immunity, while their role in lymphoid tissues is undefined. Here we analyzed memory CD8+ T 
cells in different lymphoid compartments including bone marrow, spleen, and lymph nodes (LN) 
relative to lung within diverse individuals. We identify an organ-specific subset in human LN 
(TLN) not found in blood or other tissues, expressing high levels of TCF-1 and transcriptionally 
enriched for markers of quiescence, self-renewal and follicular-helper cells. High dimensional 
CyTOF analysis reveals TLN as intermediate in differentiation between naive and TRM cells, 
with circulating memory T cells the most differentiated. TLN exhibit higher TCR diversity, 
lower in vivo turnover, yet higher proliferative responses compared to memory cells in other 
lymphoid or mucosal sites. These findings establish human LN as reservoirs for diverse memory 




2018 Oral Presentation: Human lymph nodes are reservoirs for self-renewing 
memory T cells throughout life. 
Women in Science at Columbia (WISC) 
   2nd Annual Graduate Research Symposium 
 
 
Authors:  Michelle Miron, Brahma V. Kumar, Dustin J. Carpenter, Takashi Senda,Yufeng Shen4 




In an immune response, T cells are activated and differentiate to effector and memory subsets 
that play distinct roles in adaptive immunity and immune homeostasis.  Effector cells are short 
lived and secrete proinflammatory cytokines and cytotoxic mediators for pathogen destruction, 
while memory T cells are long-lived and can mediate rapid recall responses upon antigen re-
encounter. Studies in mouse models have identified key transcription factors (TF) that determine 
effector versus memory T cell fate; T cell factor-1 (TCF-1) is essential for memory T cell 
formation and maintenance in the periphery and T-bet promotes effector over memory T cell 
differentiation. For human T cells, the role of specific TF in the differentiation and maintenance 
of effector and memory T cells remain unclear. In addition to T cell intrinsic factors, the tissue 
environment also influences T cell fate and memory maintenance. Human memory T cells are 
diversely distributed across multiple anatomic sites and comprise the predominant subset in most 
tissues for the majority of life. In this study, we investigated the tissue determinants of human T 
cell differentiation using our unique human tissue resource where we obtain blood, multiple 
lymphoid and mucosal tissues from individual organ donors of all ages through a longstanding 
collaboration with LiveOnNY, the organ procurement organization for the New York City 
metropolitan area. By studying T cells across tissues of individuals, we have identified that 
memory CD8+T cells maintained in human LN are organ-specific. Notably, LN memory CD8+T 
cells maintain high expression of transcription factor TCF-1 associated with cellular quiescence 
and self-renewal, exhibit low turnover and a higher proliferative capacity compared to memory T 
cells in other lymphoid (spleen, bone marrow) and peripheral sites (e.g., lungs). Together these 
findings establish human LN as important targets for promoting protection in vaccines and a 





2018 Oral Presentation: Mapping Memory T-cell Clones in Human Tissues. 
Cold Spring Harbor Laboratories (CSHL) 
Biennial Biological Data Science Meeting. 
 
Authors: Michelle Miron, Wenzhao Meng, Eline T. Luning Prak, and Donna L. Farber. 
 
Abstract:  
New T cell responses result in the expansion of T cell clones which disseminate to lymphoid and 
barrier tissues where they are maintained as memory T cells and provide long-lived protective 
immunity. T cells that can be detected in peripheral blood provide a sampling of a T cell 
response but may not be representative of memory T cell responses in tissues that accumulate 
over lifetime of previous antigen encounters. We have established a collaboration and protocol 
with Live On NY, the organ donor network for the NY metropolitan area, which enables us to 
procure multiple healthy lymphoid and mucosal tissues from individual organ donors.  Here we 
present a high-throughput T cell receptor (TCR) sequencing approach to characterize the human 
memory T cell response in diverse tissues. The large size and diversity of the human memory T 
cell response presents a great technical challenge; we therefore developed tools to quantify and 
statistically analyze T cell repertoire diversity and sharing between samples. Using both our 
unique resource and these newly developed tools, we present a map of memory T cell clones 
within the body. We sequenced 110 biological samples across eight individuals each with over 
100,000 clones identified per sample. We mapped these clones to all four major memory T cell 
subsets (ie. TCM, central-; TEM, effector-; TEMRA, terminally differentiated effector; and 
TRM, tissue-resident-memory) and five tissue sites including blood, bone marrow, lymph nodes, 
spleen and lung. Our results reveal that all CD4+ T cell subsets are more clonally diverse than all 
CD8+ subsets independent of tissue site. In particular, the most clonally expanded CD8+ T cell 
subset are TEMRA cells, and the most diverse CD4+ T cell subset to be the TCM subset. We also 
find tissue-specific features of memory T cell responses, including an increased diversity of 
TEM and TRM cells within lymph nodes compared to other sites. We applied cosine similarity 
and Jaccard Index calculations to the TCR data to assess clonal overlap between subsets and 
tissues. Notably, TEM subsets are more connected to TEM subsets in other tissues than they are 
to TRM counterpart subsets in other tissues – and likewise for TRM subsets with other TRM 
subsets in tissues. This suggests a lineage connection between TRM subsets across tissues, and a 
lineage connection between TEM subsets across tissues. Overall, our findings provide a map of 
T-cell memory clone connectivity in tissues. These methods and results show what a healthy 
immune response looks like and can serve as a baseline for future studies investigating T cell 




Appendix E. Abstracts of contributing author manuscripts 
 
Szabo, P.A., Levitin, H.M., Miron, M., Snyder, M., Senda, T., Yuan, J., Cheng, Y.L., Bush, 
E.C., Dogra, P., Thapa, P.,  Farber, D.L., and Sims, P.A. (Submitted) Single cell transcriptomics 
defines activation states and relates human blood and tissue T cells. 
Human T cells coordinate adaptive immunity by localization in diverse tissue sites, though blood 
T cells are the most readily studied. We investigated the role of tissue site in T cell responses by 
single-cell RNA-seq profiling of >50,000 resting and TCR-stimulated T cells isolated from 
human lungs (LG), lymph nodes (LN), bone marrow (BM) and blood. Using new factorization 
methods, we defined cellular states for resting and activated T cells conserved across tissues, 
including an IFN-response activation state in CD4+T cells and distinct effector states specific to 
CD8+T cells. Between sites, T cells from LG and LN were distinct; blood T cells were most 
similar to those in BM and contained trace numbers of cells bearing tissue resident profiles. Our 
results reveal signatures for the maintenance and activation of human tissue and blood-derived T 




Fu, J., Zuber, J., Martinez, M, Shonts, B; Obradovic, A; Wang, H., Lau, S., Xia, A., Waffarn, E; 
Frangaj, K., Savage, T., Simson, M., Yang, S; Guo, X., Miron, M., Senda, T., Rogers, K., 
Rahman, A., Ho, S., Shen, Y., Griesemer, A., Farber, D.L., Kato, T., Sykes, M. (2018) Human 
Intestinal Allografts Contain Functional Hematopoietic Stem and Progenitor Cells that Are 
Maintained by a Circulating Pool. Cell Stem Cell. doi: 10.1016/j.stem.2018.11.007 
 
Human intestinal transplantation often results in long-term mixed chimerism of donor and 
recipient blood in transplant patients. We followed the phenotypes of chimeric peripheral blood 
cells in 21 patients receiving intestinal allografts over 5 years. Donor lymphocyte phenotypes 
suggested a contribution of hematopoietic stem and progenitor cells (HSPCs) from the graft. 
Surprisingly, we detected donor-derived HSPCs in intestinal mucosa, Peyer’s patches, 
mesenteric lymph nodes, and liver. Human gut HSPCs are phenotypically similar to bone 
marrow HSPCs and have multilineage differentiation potential in vitro and in vivo. Analysis of 
circulating post-transplant donor T cells suggests that they undergo selection in recipient 
lymphoid organs to acquire immune tolerance. Our longitudinal study of human HSPCs carried 
in intestinal allografts demonstrates their turnover kinetics and gradual replacement of donor-
derived HSPCs from a circulating pool. Thus, we have demonstrated the existence of functioning 




Senda, T., Dogra, P., Granot, T., Furuhashi, K., Snyder, M.E., Carpenter, D.J., Szabo, P.A., 
Thapa, P., Miron, M., and Farber, D.L. (2018) Microanatomical dissection of human intestinal 
immunity reveals site-specific changes in gut-associated lymphoid tissues over life. Mucosal 
Immunology. doi: 10.1038/s41385-018-0110-8. 
 
Defining adaptive immunity with the complex structures of the human gastrointestinal (GI) tract 
over life is essential for understanding immune responses to ingested antigens, commensal and 
pathogenic microorganisms, and dysfunctions in disease. We present here an analysis of 
lymphocyte localization and T cell subset composition across the human GI tract including 
mucosal sites (jejunum, ileum, colon), gut-associated lymphoid tissues (isolated lymphoid 
follicles (ILFs), Peyer's patches (PPs), appendix), and mesenteric lymph nodes (MLNs) from a 
total of 68 donors spanning eight decades of life. In pediatric donors, ILFs and PP containing 
naïve T cells and regulatory T cells (Tregs) are prevalent in the jejunum and ileum, respectively; 
these decline in frequency with age, contrasting stable frequencies of ILFs and T cell subsets in 
the colon. In the mucosa, tissue resident memory T cells develop during childhood, and persist in 
high frequencies into advanced ages, while T cell composition changes with age in GALT and 
MLN. These spatial and temporal features of human intestinal T cell immunity define signatures 
that can be used to train predictive machine learning algorithms. Our findings demonstrate an 
anatomic basis for age-associated alterations in immune responses, and establish a quantitative 




Kumar, B.V., Kratchmarov, R., Miron, M., Carpenter, D.J., Senda, T., Lerner, H., Friedman, A., 
Reiner, S.L., and Farber, D.L. (2018) Functional heterogeneity of human tissue-resident memory 
T cells based on dye efflux capacities. JCI Insight. doi: 10.1172/jci.insight.123568 
 
Tissue-resident memory T cells (TRMs) accelerate pathogen clearance through rapid and 
enhanced functional responses in situ. TRMs are prevalent in diverse anatomic sites throughout 
the human lifespan, yet their phenotypic and functional diversity has not been fully described. 
Here, we identify subpopulations of human TRMs based on the ability to efflux fluorescent dyes 
[efflux(+) TRMs] located within mucosal and lymphoid sites with distinct transcriptional 
profiles, turnover, and functional capacities. Compared with efflux(–) TRMs, efflux(+) TRMs 
showed transcriptional and phenotypic features of quiescence including reduced turnover, 
decreased expression of exhaustion markers, and increased proliferative capacity and signaling in 
response to homeostatic cytokines. Moreover, upon activation, efflux(+) TRMs secreted lower 
levels of inflammatory cytokines such as IFN-γ and IL-2 and underwent reduced degranulation. 
Interestingly, analysis of TRM subsets following activation revealed that both efflux(+) and 
efflux(–) TRMs undergo extensive transcriptional changes following TCR ligation but retain 
core TRM transcriptional properties including retention markers, suggesting that TRMs carry out 
effector function in situ. Overall, our results suggest a model for tissue-resident immunity 





Carpenter, D.J., Matsuoka, N., Granot, T., Kumar, B.V., Senda, T., Thome, J.J.C., Gordon, C.L., 
Miron, M., Weiner, J., Lerner, H., Friedman, A., Griesemer, A.D., Farber, D.L. (2018) Human 
immunology studies using organ donors: impact of clinical variations on immune parameters in 
tissues and circulation. Am. J. Trans.18:74-88. PMCID:PMC5740015 
 
Organ donors are sources of physiologically healthy organs and tissues for life-saving 
transplantation, and have been recently used for human immunology studies which are typically 
confined to the sampling of peripheral blood. Donors comprise a diverse population with 
different causes of death and clinical outcomes during hospitalization, and the effects of such 
variations on immune parameters in blood and tissues are not known. We present here a 
coordinate analysis of innate and adaptive immune components in blood, lymphoid (bone 
marrow, spleen, lymph nodes), and mucosal (lungs, intestines) sites from a population of brain-
dead organ donors (2 months-93 years; n = 291) across eight clinical parameters. Overall, the 
blood of donors exhibited similar monocyte and lymphocyte content and low serum levels of 
pro-inflammatory cytokines as healthy controls; however, donor blood had increased neutrophils 
and serum levels of IL-8, IL-6, and MCP-1 which varied with cause of death. In tissues, the 
frequency and composition of monocytes, neutrophils, B lymphocytes and T cell subsets in 
lymphoid or mucosal sites did not vary with clinical state, and was similar in donors independent 
of the extent of clinical complications. Our results reveal that organ donors maintain tissue 




Kumar, B.V., Ma, W. Miron, M., Granot, T., Guyer, R.S., Carpenter, D.J., Senda, T., Ho, S.-H., 
Lerner, H., Friedman, A.L., Shen, Y., and Farber, D.L. (2017) Human tissue-resident memory T 
cells are defined by core transcriptional and functional signatures in lymphoid and mucosal sites. 
Cell Reports. 20:2921-2934. PMCID:PMC5646692. 
 
Tissue-resident memory T cells (TRMs) in mice mediate optimal protective immunity to 
infection and vaccination, while in humans, the existence and properties of TRMs remain 
unclear. Here, we use a unique human tissue resource to determine whether human tissue 
memory T cells constitute a distinct subset in diverse mucosal and lymphoid tissues. We identify 
a core transcriptional profile within the CD69+ subset of memory CD4+ and CD8+ T cells in lung 
and spleen that is distinct from that of CD69- TEM cells in tissues and circulation and defines 
human TRMs based on homology to the transcriptional profile of mouse CD8+ TRMs. Human 
TRMs in diverse sites exhibit increased expression of adhesion and inhibitory molecules, 
produce both pro-inflammatory and regulatory cytokines, and have reduced turnover compared 
with circulating TEM, suggesting unique adaptations for in situ immunity. Together, our results 





Gordon, C.L., Miron, M., Thome, J.J.C., Matsuoka, N., Weiner, J., Rak, M., Igarashi, S., 
Granot, T., Lerner, H., Goodrum, F. and Farber, D.L. (2017) Tissue-reservoirs of T cell 
immunity in persistent human CMV infection. J. Exp. Med. 214:651-667. PMCID: 
PMC5339671 
 
T cell responses to viruses are initiated and maintained in tissue sites; however, 
knowledge of human antiviral T cells is largely derived from blood. Cytomegalovirus (CMV) 
persists in most humans, requires T cell immunity to control, yet tissue immune responses 
remain undefined. Here, we investigated human CMV-specific T cells, virus persistence and 
CMV-associated T cell homeostasis in blood, lymphoid, mucosal and secretory tissues of 44 
CMV seropositive and 28 seronegative donors. CMV-specific T cells were maintained in distinct 
distribution patterns, highest in blood, bone marrow (BM), or lymph nodes (LN), with the 
frequency and function in blood distinct from tissues. CMV genomes were detected 
predominantly in lung and also in spleen, BM, blood and LN. High frequencies of activated 
CMV-specific T cells were found in blood and BM samples with low virus detection, whereas in 
lung, CMV-specific T cells were present along with detectable virus. In LNs, CMV-specific T 
cells exhibited quiescent phenotypes independent of virus. Overall, T cell differentiation was 
enhanced in sites of viral persistence with age. Together, our results suggest tissue T cell 
reservoirs for CMV control shaped by both viral and tissue-intrinsic factors, with global effects 
on homeostasis of tissue T cells over the lifespan. 




Granot, T., Senda, T., Carpenter, D., Matsuoka, N., Weiner, J., Gordon, C.L., Miron, M., 
Kumar, B.V., Griesemer, A., Ho, S.-H., Lerner, H., Thome, J.J.C., Connors, T., Reizis, B., and 
Farber, D.L. (2017) Dendritic cells display subset and tissue-specific maturation dynamics over 
human life. Immunity, 46:504-515. PMCID:PMC5415308  
 
Maturation and migration to lymph nodes (LNs) constitutes a central paradigm in 
conventional dendritic cell (cDC) biology but remains poorly defined in humans. Using our 
organ donor tissue resource, we analyzed cDC subset distribution, maturation, and migration in 
mucosal tissues (lungs, intestines), associated lymph nodes (LNs), and other lymphoid sites from 
78 individuals ranging from less than 1 year to 93 years of age. The distribution of cDC1 
(CD141hiCD13hi) and cDC2 (Sirp-α+CD1c+) subsets was a function of tissue site and was 
conserved between donors. We identified cDC2 as the major mature (HLA-DRhi) subset in LNs 
with the highest frequency in lung-draining LNs. Mature cDC2 in mucosal-draining LNs 
expressed tissue-specific markers derived from the paired mucosal site, reflecting their tissue-
migratory origin. These distribution and maturation patterns were largely maintained throughout 
life, with site-specific variations. Our findings provide evidence for localized DC tissue 
surveillance and reveal a lifelong division of labor between DC subsets, with cDC2 functioning 






Zens, K.D., Chen, J.-K., Guyer, R.S., Wu, F.L., Cvetkovski, F., Miron, M. and Farber, D.L. 
(2017) Reduced generation of lung-tissue resident memory T cells during infancy. J. Exp. Med. 
214:2915- 2932. PMCID:PMC5626403  
 
Infants suffer disproportionately from respiratory infections and generate reduced vaccine 
responses compared with adults, although the underlying mechanisms remain unclear. In adult 
mice, lung-localized, tissue-resident memory T cells (TRMs) mediate optimal protection to 
respiratory pathogens, and we hypothesized that reduced protection in infancy could be due to 
impaired establishment of lung TRM. Using an infant mouse model, we demonstrate generation 
of lung-homing, virus-specific T effectors after influenza infection or live-attenuated 
vaccination, similar to adults. However, infection during infancy generated markedly fewer lung 
TRMs, and heterosubtypic protection was reduced compared with adults. Impaired TRM 
establishment was infant-T cell intrinsic, and infant effectors displayed distinct transcriptional 
profiles enriched for T-bet-regulated genes. Notably, mouse and human infant T cells exhibited 
increased T-bet expression after activation, and reduction of T-bet levels in infant mice enhanced 
lung TRM establishment. Our findings reveal that infant T cells are intrinsically programmed for 
short-term responses, and targeting key regulators could promote long-term, tissue-targeted 
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July 2015– Present   Ph.D. Graduate Student 
    Laboratory of Donna L. Farber, PhD 
    Department of Microbiology &Immunology, Columbia University 
 
Currently, I am studying mechanisms for tissue 
compartmentalization of human memory T cells. Memory T cells  
play an important role in defending against pathogens at peripheral 
sites; however, most of our knowledge about human memory T 
cells comes from studies of peripheral blood. We obtain human 
tissues through a collaboration with the organ procurement agency, 
and in my project I isolate memory T cells from different tissues 
and compare these cells to determine defining characteristics of 
human memory T cells in tissues. My data show that memory T 
cells in lymph nodes are a distinct memory T cell subset in humans 
with increased functional capacity and signs of decreased turnover 
in-vivo. In my second project, I developed a high-throughput 
sequencing technique to map T cell clones in different lymphoid 
and mucosal sites as well as blood. I discovered new insights into 
the relatedness of tissue resident and circulating T cell subsets.  
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Section in Dr. Court's lab, which has developed recombineering as 
a new way to engineer DNA in living cells. My research utilized 
recombineering in order to investigate interactions between E. coli 
and phage lambda. A large genomic region of lambda DNA was 
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in E. coli. Using genetic engineering, I mapped this phenotype to a 
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region containing a 29 amino acid open reading frame, identifying 
more precisely the genomic locus involved in a phage function. 
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I conducted research to assess the role of a transcription factor, 
KLF2, in DNA damage repair. I utilized mouse embryonic 
fibroblasts with genomic knock-out (KO) of the KLF2 gene, in 
order to compared wildtype to KO cell lines and investigate how 
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methods, I discovered alterations in cell cycle stages of WT and 
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Other Relevant Experience: 
 
2017-Present   Team Lead  
    Data Science Club, Columbia University Medical Center 
 
I am a member and team leader of the Data Science Club, a student 
led organization on campus. Club members meet weekly in order 
to conduct code review sessions, discuss literature from recent 
research, as well as complete coursework. In addition to weekly 
meetings, I participated in monthly hackathons where individuals 
brought projects to work on independently or in groups. I also 
participated in two NIH hackathons. During one, my team worked 
on integrating NIH genotype and phenotype databases with other 
sequence archives in order to facilitate easier searching. In a 
second hackathon I was the team lead to create software for 
analysis of T cell receptor sequencing data, denoted PyClonal. 
 
2017-2018   Science Alliance Leadership Training (SALT)   
    The New York Academy of Science, New York, NY 
 
I participated in a week long in person leadership, communication 
skills, and team dynamics training program help at the New York 
Academy of Sciences. I was accepted to this program through a 
selective application process with 18 other participants from 
Universities across the US, mostly from the east-coast area. I also 
participated in 40 hours of follow-up training after the week long 
in-person workshops by webcasted courses and seminars. 
 
2015-2018   Mentor 
Girls Science Day, Columbia University 
 
I led and planned experiments for three sessions of middle school 
aged girls (about 80 total students). We conducted color 
chromatography experiments, separating different dyes used in 
foods. 
